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Executive Summary 
Introduction 
Understanding the topography of this real-world data landscape is of prime interest to 
NICE (National Institute for Health and Care Excellence) in this study, as well as gaining a 
snapshot of the key areas of debate in the field. Specifically NICE seeks to understand the 
way in which different real-world data sources could help to support NICE to realise its 
strategic objectives and to this end, NICE has identified five key uses of real-world data 
that can help the organisation meet its overall strategic objectives. These are to: 
(a) Research the effectiveness of interventions or practice in real-world (UK) 
settings (e.g. through monitoring outcomes or proxy outcomes).  Data could be 
used to inform the modelling of clinical and/or cost effectiveness outcomes as part 
of guidance production. Real-world data can also help to resolve uncertainties that 
have been identified in existing NICE guidance. 
(b) Audit the implementation of guidance. For example, to assess the equity of 
implementation across different groups (including socioeconomic, geographic, 
demographic and groups differentiated by different diseases/health conditions); 
this may also form part of performance monitoring systems 
(c) Provide information on resource use and evaluate the potential impact of 
guidance. 
(d) Provide epidemiological information. For example prevalence/incidence of 
diseases, natural history, co-morbidities and information on current practice. 
(e) Provide information on current practice to inform the development of NICE 
quality standards 
 
EPPI-Centre Key Findings and Recommendations 
Key Findings 
 The real-world data landscape remains complex and heterogeneous and 
composed of sources with different purposes, structures and collection methods. 
This heterogeneity may increase with opportunities stemming from the 
incorporation of new technologies in data collection (current quality assured 
sources are limited in number) 
 Some real-world data sources are purposefully either set-up or re-developed to 
enhance their data linkages and to examine the presence/absence/effectiveness 
of integrated patient care; however, such sources are in the minority. 
Furthermore, the small number that are designed to enable the monitoring of 
care across providers, or at least have the capability to do so at a national level, 
have been utilised infrequently for this purpose in the literature. 
 Data that offer the capacity to monitor transitions between health and social 
care do not currently exist at a national level, despite the increasing recognition 
of the interdependency between these sectors.  
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 Among the data sources we included, it was clear that no one data source 
represented a panacea for NICE’s real world data needs. This does highlight the 
merits and importance of data linkage projects and is suggestive of a need to 
triangulate evidence across different data, particularly in order to understand 
the feasibility and impact of guidance.  
Key Overall Recommendation 
 There exists no overall catalogue or repository of real-world data sources for 
health, public health and social care, and previous initiatives aimed at creating 
such a resource have not been maintained. As much as there is a need for 
enhanced usage of the data, there is also a need for taking stock, integration, 
standardisation, and quality assurance of different sources. This research 
highlights a pressing need for a systematic approach to creating an inventory of 
sources with detailed meta-data and the funding to maintain this resource. This 
would represent an essential first step to support future initiatives aimed at 
enhancing the use of real-world data. 
Key Recommendations for NICE 
Increased utilisation of existing sources beyond clinical databases: 
 Making recommendations is difficult around the use of specific data sources. 
However, NICE’s current use of real-world data differs substantially from the 
landscape with respect to its low utilisation of clinical audit, disease registry and 
survey data. Several of the datasets profiled in-depth highlight the potential of 
different sources of survey, clinical database and audit data.  
 We also recommend that NICE further review its use of disease registry and audit 
data and engage in dialogue with collectors and depositors of these data to 
explore the utility of these types of data. Many sources of data available from 
disease registries and clinical audits are currently underutilised.  
Investment in capacity and partnership building 
 Use of real-world data requires substantial investment of resource that allows for 
the organisation to develop an in-depth understanding and experience of using 
different real-world sources. The extent of this undertaking should not be 
underestimated; any commitments and real-world data usage strategies should 
be matched by resources that allow for developing expertise in-house and in 
developing partnerships with data depositors and academic experts. 
 Many of the data sources profiled either have active user groups or hold regular 
consultative exercises. NICE should further investigate these opportunities and 
capitalise on these. 
Strategy and influence 
 NICE has the potential to influence the availability of real-world data sources 
and good practice around the collection and utilisation of real-world data. This 
influence could be used to develop good practice around aspects such as 
obtaining informed consent from patients or obtaining investment around the 
 5 
 
creation of data linkages. NICE should develop and publish an outward-facing 
policy around its use of real-world data which includes transparent means of 
influencing the state of the landscape, in order to ensure that sources continue 
to meet its organisational needs and to ensure alignment with national strategy. 
Exerting such influence could not only lead to benefits to NICE, but will have 
broader positive impacts across other stakeholders more widely, and could lead 
to improved patient and service user outcomes. This influence could also extend 
to developing quality standards around the way in which data are collected that 
can be shared across the sector. 
 Care.data represents an initiative that could potentially meet many of NICE’s 
real-world data needs. NICE should engage in discussions with the Health and 
Social Care Information Centre (HSCIC) to better understand and prepare for 
potentially using these data, while continuing to monitor whether and how the 
initiative overcomes challenges identified in earlier stages.  
Understanding implementation 
 Finally, while NICE is potentially able to monitor the implementation of 
guidelines using several sources, it may still lack information on the underlying 
mechanisms as to how or why guidelines succeed or fail in implementation. 
Starting its own programme of real-world data collection in the form of surveys 
of practitioners may be a way of understanding the mechanisms of un/successful 
implementation. Such an approach has been adopted elsewhere, for example by 
the Swedish Council on Healthcare Technology Assessment (SBU). 
Green shoots 
There are three key factors as to why the state of the real world data landscape should 
be regarded with some optimism for NICE and more generally. 
1. Firstly, while data linkage and the capacity to research patient journeys is not at the 
point where many would desire, there are several examples where these efforts have 
been met with success and some of these have been met with a high degree of public 
acceptance. On a national level, the care.data initiative has restarted after a pause, 
and if these efforts succeed, they could meet many of NICE’s real-world data 
requirements 
2. Secondly, while we have been critical in the study about the representation of 
sources of patient reported outcomes, there are examples featured in the main report 
where patients have become more involved and have become gatekeepers to their own 
data (e.g. Salford Integrated Record), providing a possible model for the future. In 
addition, the ubiquity of smartphone technology and apps mean that ways of patients 
providing and managing their own information are increasing at pace. 
3. Thirdly, methodological advances in the design and analysis of studies continue to 
ensure that real-world data becomes of greater utility for organisations, such as NICE, 
who wish to understand the implications of their decisions in real-world settings. These 
advances include the development of pragmatic trials using electronic health data 
which offer a balance between the methodological rigour of RCTs and the 
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generalisability of observational studies. Several UK based organisations and teams – 
some of which are represented among the expert stakeholders involved in the present 
study – are involved in driving these advances and it is likely that future studies will 
feature the results of these undertakings extensively in their findings. 
 
Study Approach
This study is focussed on identifying some of the available opportunities to NICE in terms 
of real-world data sources. To reflect the remit of NICE, in this report we consider data 
that spans clinical, public health and social care fields. To create a topographical map of 
real-world data sources we use: 
 Data from interviews with expert stakeholders  
 Data from studies discovered in the literature  
                                            
1 Pragmatic randomised controlled trials aim to mimic real life conditions and test the effectiveness of a range of 
interventions that are known to be safe. They can be instrumental in understanding the relative effectiveness where there is 
no apparent clinical advantage/disadvantage among currently accepted treatment (1. van Staa T-P, Goldacre B, Gulliford M, 
et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. Bmj 2012;344:e55.)  
What is real world data? 
The definition of real-world data can be contentious and different stakeholders have 
different views as to what constitutes ‘real-world’ data. Real world data is defined in 
this report through two key tenets: 
a. The collection of real world data reflects the usual care or treatment provided 
to populations of patients, service users or the public. This therefore excludes 
conventional Randomised Controlled Trials (RCT(s)) but could include other 
forms of RCT design, namely pragmatic RCTs1.  
b. Real world data provides enough depth to assess trends around everyday 
practice, service usage, or to assess the effectiveness of interventions and their 
outcomes. 
To meet the needs of NICE, we do not pay close attention to sources of data that have 
limited geographic representation, and prioritise those sources with national or regional 
representativeness. 
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After drawing a long-list of sources, with the aid of NICE, we then identified those data 
sources that were not in current use, or were under-utilised, but were of interest to the 
organisation, and created an in-depth profile of eleven of these data sources.   
Results - mapping of real-world datasets  
In creating the map based on the literature and on interviewees’ responses we discovered 
a total of 275 different sources of real-world data (figure 1), of which 233 are analysed 
further, being of most relevance to NICE. The remaining data sources were found to either 
have been discontinued (27) or subsumed into other studies (6 sources), were not actually 
real-world data sources (e.g. they were procedures or standards for application in the real 
world (8 sources)), or were at the protocol stage (one source). 
Figure 1: Sources of real world data discovered2 
 
How does NICE currently use real-world data? 
Internally, NICE conducted a review of its use of real-world data across different teams. 
This review asked teams to name which data source was currently being used, how these 
data were accessed, processes employed for accessing data, associated costs; and a brief 
description of how the data were used: 
The majority of data were found to be used, internally at least, to either (i) inform on the 
uptake of NICE guidance and/or explore use of medication (nine reports of usage could be 
described in this way (one represented future plans)); or (ii) for health economic 
modelling (twenty reports could be described in this way). Some of the data appear to 
                                            
2 It was also acknowledged that the HSCIC website held a great number of sources that could also be potentially 
profiled – future exercises could include a more detailed inventory of the HSCIC datasets. 
275 sources discovered
Continuing real world data sources (233)
Disease 
registry 
(88)
Clinical 
audit (50)
Surgery/ 
Technology
Registry/ 
Audit(8)
Survey 
(23)
Mortality 
register (7)
Pharmaco-
epidemiol
ogical 
database 
(8)
Clinical 
database 
(19)
Other 
types (32)
Discontinued (27)
Not real-world 
source (8)
Subsumed (6)
Not started (1)
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support the development of quality standards particularly around safe levels of staffing 
(three reports could be described in this way) and there was one reported use of data for 
monitoring epidemiological and demographic trends. One dataset was described as being 
used to establish the effectiveness of interventions. 
Evidence suggested NICE’s internal use of real-world data differs from the real-world data 
landscape in the following ways: 
 The use of clinical audit data by NICE does not match the widespread availability of 
these data 
 The use of disease registry data by NICE does not match the widespread availability 
of these data 
 Several sources of survey data are currently not being utilised internally  
 Most of the data sources/functions currently in use appear to allow for cross-
sectional analyses or repeated cross-sectional analyses only; patient-level 
longitudinal analyses appear to be conducted rarely  
 Few datasets currently in use capture Patient Reported Outcomes 
 NICE use an extensive array of different datasets to support understanding trends 
and the economic modelling of changes in prescribing trends 
 There were no reports of NICE requesting additional data to be collected alongside 
standard data in any of the real-world sources 
 Primary care data is based on The Health Improvement Network (THIN) data.  
 Few of the existing sources allow for linkage across different services which a 
patient or service user may experience; however, these types of data were also 
underrepresented in the results of the mapping exercise 
 For social care, none of the datasets described are directly sourced and explicitly 
focus on monitoring trends in private provision despite private provision being 
hugely important for the sector; these data were also underrepresented in the 
results of the mapping exercise 
It should be noted that this review did not capture the multitude of data that are being 
used in work that NICE commissions from partner organisations. 
What are some of the other broad debates and themes occurring in real-world data 
that NICE should be aware of? 
There is no standard definition of real-world data and the term can be problematic  
Often, real world data collected in primary care is viewed as a by-product of 
administrative or performance management activities. In social care, the definition of real 
world data tends to be broader from the outset and survey data was much more likely to 
be included in definitions. The breadth in the definition of real-world data was viewed as 
problematic by some and there is a need to clarify the distinction between ‘real world 
data’ and ‘just all data’. Furthermore, the term ‘real-world data’ is not a familiar one 
across all disciplines. 
Data for tracking patient and service user journeys are rare 
Obtaining data that enables the tracking of patient and service user journeys and 
trajectories is fraught with difficulty. Much of this challenge is attributed to difficulties in 
being able to link data between sources using a common identifier, although considerable 
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efforts are underway to link across some datasets. Data that enable monitoring of 
transitions between health and social care are especially underrepresented.  
Using real world data may involve using multiple datasets in addressing a single 
research question  
Real world data’s particular strength is the potential to provide the most complete picture 
available of the health and care status of the nation, and the services and interventions 
that are received in maintaining or improving health and care status2. These data are 
derived from a representative subset of the population and can provide a population-
based snapshot of (i) illness or care needs; (ii) contacts with providers that take place; (iii) 
information on treatments or care packages, and (iv) ideally provide enough information 
on the outcomes of individuals. However, the real-world data landscape remains 
fragmented and the different elements that can provide a holistic understanding of 
patient and service user trajectories are stored in different sources with no means of 
linking.  
Real-world data analysts will often encounter a trade-off between data that provides a 
depth of information on patient characteristics and data that provides a breadth of 
information on the services or interventions they receive. Real-world data projects often 
incorporate data from a number of different sources in order to overcome limitations 
within any given data source. In other real-world data projects, data from different 
sources are used in order to triangulate the findings and overcome potential concerns 
around representativeness or bias.  
 
“There is a trade-off between having more information in terms of numbers and 
information in terms of breadth and depth of indicators. So survey data such as ELSA 
[English Longitudinal Study of Ageing] will give you a lot more in terms of quality of 
characteristics – income, wealth, needs, households’ composition, service users etc. 
Certain outcomes will be much more limited on the other hand data from services; 
there will be thousands of cases in other sources - but much more limited – and the 
data and may not be of the same quality. We try to combine the data, look at patterns 
from both”. 
 
 
Real world data complements the findings from randomised controlled trials 
The main defining advantage of real-world data, besides apparent advantages in terms of 
cost, sample size and representativeness, is its (ostensibly) high external validity 1. The 
external validity reflects both the delivery of an intervention to a group that is 
representative of the general population, but more crucially in the delivery of the control, 
which usually involves an alternative treatment regimen (best available alternative) as 
opposed to a placebo. While there is an expanding literature citing studies and study 
protocols that have been conducted using real-world data, interviewees (especially those 
from clinical backgrounds) emphasised that real-world data was not a replacement 
for/superseded the findings from RCT studies. Real-world data is prone to forms of 
 10 
 
epidemiological bias unlikely to be replicated in findings from well designed and executed 
RCT studies 1 3; however, as several interviewees pointed out, RCT study data can also be 
subject to bias, and some identified that observational data was subject to greater 
scrutiny despite its superior properties in terms of transparency, than RCT data are.  
Future directions 
Two themes emerged around future potential of real-world data. The first of these is 
around the expanding potential of pragmatic clinical trials (PCTs). Unlike traditional RCTs, 
PCTs are trials that take place within real-world environments and among representative 
samples of patients, thereby placing the focus on establishing the effectiveness of 
interventions, as opposed to their efficacy. Within a PCT, patients are randomised to 
receive an intervention or control treatment but the focus on mimicking real-world 
conditions means that, among other factors: (i) the control treatment provided often 
represents the best viable alternative already in place (as opposed to a placebo as can be 
the case in some RCTs), (ii) the patients randomised reflect the normal range of patients 
in terms of disease severity, comorbidity and demographic characteristics; and (iii) the 
measures of effectiveness collected as outcomes are valid and easily understood by a 
range of stakeholders, including clinicians, patients, policy-makers, and health 
commissioners. Real-world data collected through electronic health records was viewed as 
the basis for designing and undertaking a greater number of pragmatic trials (PCTs) and a 
number of real-world sources theoretically provide the means of implementing studies and 
monitoring outcomes in real-time. Evidence from PCTs is likely to be of substantial 
interest to NICE in establishing the effectiveness of interventions in real world settings 
while maintaining randomisation, thereby eliminating or at least substantially reducing the 
occurrence of channelling bias; the proliferation of real world data sources may facilitate 
this form of evidence to become increasingly frequent in the future. 
A second theme that emerged was around new technologies stimulating new forms of real 
world data to be collected. Methods of collecting patient reported outcomes are shifting 
from paper to digital devices (smartphones and tablets): “we have a lot of interest in 
technology where people get messages on their mobile phone to fill out symptoms, 
whether these are severe and so on. Uptake is very good and this type of model can be 
utilised for trials quite easily… where you have mobile phone technology sending 
information you don’t have lots of paperwork… modern technology can help a lot with 
that. Also with ipads there is a strong movement to increases use in that.”   
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Recommended specific sources to 
consider from interviews included: 
1. Opportunities are available for assessing 
individual level service user outcomes through 
the Adult Social Care Survey (ASCS) 
2. Understanding patient journeys and experiences 
using the broad scope of data contained within 
the National Cancer Data Repository 
3. Assessing resource usage using National Minimum 
Data Set for Social Care (Skills for Care) 
4. Exploring primary care practice using three of 
the large GP datasets 
o QResearch 
o Clinical Practice Research Datalink (CPRD) 
o The Health Improvement Network (THIN) 
5. Understanding the contribution of risk factors to 
disease outcomes using the Whitehall II study 
6. Exploiting the longevity and near-universality of 
the Myocardial Ischaemia National Audit Project 
(MINAP)  
7. Examining epidemiological trends using Health 
Survey for England  
8. Examining life course experiences on patterns of 
ageing using the National Child Development 
Study 
 
9. Gaining a snapshot of social care and health 
service usage and needs of older people using 
the English Longitudinal Study of Ageing  
10. Understanding epidemiological and care trends 
among households, including ethnic minorities, 
using Understanding Society  
11. Monitoring Social and Health care trends, 
experiences and monitoring the implementation 
of standards using Care Quality Commission data 
and reports  
12. Gaining an insight into patient experiences using 
Patients Like Me  
13. Tracking data on patient journeys in integrated 
delivery networks: the potential of Scottish 
Health Informatics Programme (SHIP) 
14. Exploiting Hospital Episodes Statistics Data as a 
multipurpose dataset 
15. Exploring Epidemiological Trends using the Avon 
Longitudinal Study of Parents and Children 
(ALSPAC)  
16. Using information from an integrated learning 
system through the Salford Integrated Record 
17. Investigating the application of GP records 
18. Understanding the effectiveness of interventions 
using National Joint Registry as a registry that is 
collecting longitudinal outcomes and patient 
reported outcomes 
19. Understanding the effectiveness of interventions 
and monitoring the impact of guidance using the 
Sentinel Stroke National Audit Programme 
(SSNAP) 
20. Understanding the effectiveness of interventions 
and monitoring the impact of guidance using the 
Renal Registry 
21. Understanding the effectiveness of interventions 
and monitoring epidemiological trends using 
Adult critical care case mix programme 
(managed by ICNARC) 
22. Harnessing the potential of cardiovascular audit 
and register data to address NICE’s real world 
data needs 
23. Data from the National Diabetes Audit; “the most 
advanced for long-term conditions” 
24. Capturing genetic information on biomarkers in 
the UK Biobank  
25. Calculating cost effectiveness based on data 
from the Personal and Social Services Research 
Unit 
26. Mental Health and Learning Disabilities Data Set 
27. Understanding trends in screening rates, 
healthcare and epidemiology using Quality and 
Outcomes Framework (QoF) data 
28. Understanding epidemiological trends and 
measuring the effectiveness of interventions 
using the UK Inflammatory Bowel Disease Audit 
29. Harnessing the potential of audit data to address 
NICE’s real world data needs through clinical 
audits conducted by the Royal College of 
Surgeons Clinical Effectiveness Unit 
30. Data used to populate NICE’s Return on 
Investment Tools 
31. Data from private health providers and insurers 
Further sources that were shortlisted for 
consideration based on the literature/input from NICE 
were: (i) Care.data (ii) Prescribing observatory for 
Mental Health. It was also acknowledged that the 
HSCIC website held a great number of sources that 
could also be potentially profiled – future exercises 
could include a more detailed inventory of the HSCIC 
datasets.
Executive Summary -  
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Specific data profiled 
From the earlier long-list of 30+ datasets, a selection of eleven data sources was chosen 
for in-depth profiling based on input from the NICE steering group. Datasets were 
prioritised if they were not in current use by NICE and where they appeared to meet some 
of the broader gaps in usage or addressed any of the themes emerging from the 
interviews. A template was developed to capture the properties of different sources 
according to their suitability for NICE’s intended usage. 
Focus on the potential utility of different datasets for NICE 
All the profiled data sources are likely to have some utility to NICE dependent on the 
research question and making a specific recommendation around use is challenging as this 
is very much dependent on the context and the focus of the research question. The 
following section summarises the utility of the different sources for NICE. A full 
description of each dataset is provided in the main report. 
English Longitudinal Study of Ageing (ELSA) 
 ELSA has been used to establish the effectiveness of interventions at a population 
level using observational methods, for example in a cost-benefit analysis of 
cataract surgery among ELSA respondents 4. ELSA may be less suitable for 
establishing the effectiveness of more specialist interventions/practice, or 
establishing how interventions/practice vary among minority groups.  
 ELSA can be used to determine the implementation of guidance through examining 
broad population-level temporal changes in the receipt of common interventions or 
practice. For example ELSA data were used to examine shortfalls in care for 
chronic conditions using set quality indicators 5. Without further linkages, ELSA 
data may be less suitable for explaining the underlying mechanisms around the 
implementation of guidance, beyond patient/service-user characteristics. 
 ELSA data can be used to provide information on some aspects of resource use, for 
example how many people receive common interventions and can be used to 
establish how access may vary by individual patient characteristics.  
 ELSA data can be used to establish self-reported levels and determinants of many 
age related conditions and non-communicable diseases and more broadly 
information on lifestyle behaviours and attitudes among older people.  
 ELSA data may be less suitable for establishing the incidence/prevalence/outcomes 
of very uncommon diseases/conditions/interventions. 
 
Community Mental Health Survey (CMHS) 
 The CMHS data have been used to monitor the implementation of guidance, for 
example in monitoring the implementation of guidance aiming to strengthen 
support for service users during times of turnover in staffing 6.  The data have also 
been used to draw together guidance around expected standards of care 7. There 
may also be potential to use the data to monitor different aspects of resource 
usage.  
 The focus of the survey is on service user experiences and there is less information 
on outcomes following receipt of different forms of care, limiting the utility of the 
data with respect to establishing the effectiveness of interventions. The data are 
less suitable as a tool for monitoring epidemiological patterns in mental health. 
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Clinical Practice Research Datalink (CPRD) 
 CPRD data have utility for NICE through the flexibility in being able to collect 
additional fields. CPRD data are also available to medical researchers based 
outside UK universities potentially expanding the pool of potential partners with 
which NICE could work in using the dataset. The long established nature of CPRD 
(based on General Practice Research Database) means that several retrospective 
studies could also be potentially conducted using these data.  
 There are numerous examples where CPRD (and GPRD) data have been used in 
studies that cover all of NICE’s intended uses of real-world data. For example, 
CPRD have been used to evaluate changes in cancer diagnostic intervals following 
the introduction of NICE guidance 8. Given the potential to draw large samples, 
studies could be implemented that examine the 
epidemiology/outcomes/implementation of rare or less common conditions and 
procedures. Unlike survey-based sources, for example ELSA and HSE, and in the 
absence of further data collection, there is potential to examine only a limited 
range of patient-level intrinsic factors, although these may be sufficient for many 
studies.  
 Data linkages will expand the utility of CPRD data for NICE; current linkages 
include those with MINAP data, National Cancer Intelligence Network data and HES 
data. Area level data are also available including Index of Multiple Deprivation data 
and Townsend deprivation scores 9. Further data linkages are planned. 
 
QResearch 
 QResearch is of interest to NICE for many of the real world data uses identified by 
NICE, but access appears to be restricted to research consortiums led by academic 
institutions. Nevertheless, given the substantial potential of these data, NICE could 
consider ways of developing research projects based on QResearch data led by 
universities. 
 There is potential for QResearch data to be used in studies that cover all of NICE’s 
intended uses of real-world data. The use of QResearch data in developing risk 
prediction scores may also be of interest to NICE, potentially around forecasting 
and modelling future disease burden.  
 Given the potential to draw large samples, studies can be implemented that 
examine the epidemiology/outcomes/implementation of rare or less common 
conditions and procedures. One example is a study of peanut allergy, where a 
prevalence rate of 0.51 per 1000 patients in the UK was estimated 10. 
 The study depositors state that QResearch data are suitable for case control 
studies designed to examine risk factors for onset of disease, cross sectional 
surveys, cohort studies and sample size calculations (for non-observational studies) 
11. 
 As is the case for all three large primary care databases, there is potential to 
examine only a limited range of patient-level background characteristics, although 
these may be sufficient for many studies. 
 
The Health Improvement Network (THIN) 
 There are numerous examples where THIN data have been used in studies that 
cover all of NICE’s intended uses of real-world data. For example, THIN data have 
been used to examine equity in access to cancer screening among people with 
Intellectual Disabilities compared to those without across different types of cancer  
12. 
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 Data linkages expand the utility of THIN, and THIN data have been linked with 
Hospital Episodes Statistics (HES) data, providing potential for studying continuity 
in care between primary and secondary care. A number of patient postcode-based 
socioeconomic, ethnicity and environmental indicators are available to researchers 
including Townsend deprivation quintile scores.  
 Overall there is a wide scope for analysing data reflecting outcomes and 
experiences of morbidity and mortality at primary care level, as well as trends in 
the care and treatment provided. These data can also be linked to HES data 
allowing for potential tracking of patient journeys between primary and secondary 
care. As is the case for all three large primary care databases, there is potential to 
examine only a limited range of patient-level intrinsic factors, although these may 
be sufficient for many studies. 
 THIN data have utility for NICE through the flexibility in being able to collect 
additional fields and the potential to conduct research based on free-text fields. 
THIN data are also available to medical researchers based outside UK universities 
potentially expanding the pool of potential partners with which NICE could work 
with in utilising real world data.  
 
National Minimum Data Set for Social Care (NMDS-SC) 
 NMDS-SC is a specialist dataset suitable for monitoring trends in the social care 
workforce. This data can potentially help NICE to understand workforce 
capabilities and undertake preliminary work to understand the feasibility of 
implementing new standards and guidance in social care settings.  
 The data may be suitable to examine changes following the implementation of 
NICE guidance at a workforce level in terms of indicators such as pay, training or 
necessary skills. They may also be useful in helping to set benchmarks and develop 
quality standards around workforce capacity and skills. The data have also been 
incorporated into calculations of resource use in the literature 13. While the data 
do not provide insight into epidemiological trends per se, they do provide insight 
into the workforce preparedness for responding to epidemiological challenges, such 
as dementia 14. 
 As social care outcomes are not collected in NMDS-SC, it is unlikely that these data 
are suitable for researching the effectiveness of interventions and practice. 
 
Health Survey for England (HSE) 
 HSE was suggested in the context of monitoring epidemiological trends, although 
the potential usage extends beyond this purpose alone and potentially HSE data 
can be used to gain an understanding of trends over time in terms of resource 
utilisation, trends in social care needs and usage, trends in lifestyles and social 
determinants of health, and some trends in prescribing, service usage and attitudes 
to health. With regards to researching the effectiveness of interventions, in the 
absence of data linkages, there may be more limited potential to measure the 
effectiveness of interventions or changes in practice. Examples where data have 
been linked to explore later outcomes include an examination of fruit and 
vegetable intake and mortality 15. 
 The survey data may be of great utility for NICE in gathering contextual 
information critical in the assessing feasibility of different forms of guidance aimed 
at public health and social care challenges. The data also have the added 
advantage of being relatively easy to obtain for further secondary data analysis and 
are free to use. 
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 There is scope for auditing the implementation of guidance through examining 
change in practice at a population level; one of the strengths of HSE data in doing 
so is the ability to examine social or medical inequalities in the implementation of 
guidance. Some HSE information may be suitable in providing information for the 
development of NICE quality standards and these data may be particularly useful 
where the standard is based on meeting a certain level of patient satisfaction or 
experience. 
 
Adult Social Care Survey 
 ASCS is a survey of users’ satisfaction with the care that they receive. Such data 
can be used in forming guidance that is based on user experience and patient 
reported outcomes. There may be limited scope for undertaking secondary analysis 
of the individual service user data without further permissions being sought. 
Nevertheless, the detailed reports and tables produced may allow for gaining a 
good level of understanding of aspects of service user satisfaction with their care 
and broader aspects of wellbeing.  
 With regards to measuring the effectiveness of practice, while it may be possible 
to undertake repeated cross-sectional studies and examine the impact of changing 
practice on user experiences, fully assessing the effectiveness of interventions 
through measuring longitudinal changes at a service-user level will be challenging 
with these data. However, it may be possible to assess whether guidance is being 
implemented, particularly around service user satisfaction or service user reported 
experiences, through analysing change (for example at a Local Authority (LA) 
level). 
 With regards to using the data as an epidemiological tool, the study provides a 
snapshot of general health trends and social care needs but among a population 
who are receiving LA assistance for these health needs (the sample design 
represents a caveat around the applicability of the data). There may be scope for 
the data to be used to form quality standards around social care experiences and 
trajectories – for example around information advice and guidance received by 
older people in accessing care.  
 
Salford Integrated Record (SIR) 
 SIR was suggested as a source of data that may have the potential to overcome the 
limitations of other data source and examine patients’ integrated care pathways. 
The potential of the data for research purposes is likely to be in the process of 
being realised and there are comparatively few publications using these data in the 
literature; the data may have been used initially to mainly facilitate clinical 
decision-making and performance management. Perhaps one of the most appealing 
characteristics of the data, given the current climate around the use and ethics of 
electronic health records in medical research, is the high degree of patient 
involvement and the ability of patients to access their own records.   
 The data hold substantial potential for improving patient care. The integration of 
primary and secondary care data allows for research tracking patient outcomes 
across care providers (through examining Integrated Care Pathways (ICP)). One 
initiative using the data in this way is the Collaborative Online Care Pathway 
Investigation Tool that is being used to examine missed opportunities in patient 
care – that is where primary prevention opportunities were missed which could 
lead to adverse health outcomes. This initiative is focussed on modelling the 
circumstances and frequency of variance between idealised ICP and the actual care 
provided 16.   
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Prescribing Observatory for Mental Health (POMH-UK) 
 One of the key criteria for choosing a topic focus of the POMH-UK is that the topics 
are relevant for monitoring the implementation of NICE guidelines. This has direct 
relevance to one of the intended uses of real-world data by NICE. An example of 
study directly assessing the implementation of NICE guidance can be found in a 
study of renal and thyroid functioning among patients who are prescribed lithium 
17.  
 The utility of the data for other more research-focused or evaluative activities, for 
example in assessing the effectiveness of interventions or monitoring 
epidemiological trends, may be more limited. The data are not widely used in the 
literature and it is unclear the extent to which these data are made available for 
re-analysis, reflecting their primary function as a quality improvement tool. 
Nevertheless, there are several important questions that could be addressed for 
NICE as there may be potential to understand whether practice/outputs have 
changed over time. In addition, this source represents one of the few specialist 
sources of real-world data on mental health encountered. 
 
Care.data 
 If successfully implemented, care.data would make a substantial contribution to 
the real-world data needs of NICE and other organisations. The data could allow for 
establishing the long-term effectiveness of interventions through the capacity to 
track patient journeys through primary and into secondary care as standard, 
something that rarely occurs as standard in real-world data projects and sources. 
Uniquely, it could also potentially, allow for insight into patterns of social care and 
their relationship clinical and public health data.  
 At the time of writing it is too early to tell the extent to which care.data has been 
able to overcome the challenges encountered, particularly around consent and 
conditions around data usage. The results of the pathfinder exercise will offer 
further insight into the viability of the whole project; the majority of testing in 
pathfinder areas is due to begin later this year. 
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Section 1: Introduction, Background and Methods 
 
This report is split into five main sections: 
- The first section introduces NICE’s ambitions for the use of real-world data and 
some of the properties of real-world data that can enhance its robustness, as 
described in the literature. This section also includes details about the methods 
used to collect information in this report.  
- The second section presents the results of the map of real-world data sources and 
compares the current use of real-world data by NICE with the landscape of 
available sources. 
- The third section introduces additional information from interviews with expert 
stakeholders who provide further commentary on the state of the real-world data 
landscape including fundamental issues around what should be considered real-
world data. 
- A fourth section includes data profiles from ten selected datasets that are not 
currently being used, or are only being used in a limited way, by NICE. 
- The fifth section provides a short summary from (eleven) selected real-world data 
sources that have been profiled in-depth as well as including another organisation’s 
experiences of using real-world data. 
- The remainder of the report comprises appendices including a full list of the 275 
‘data sources’ that were initially discovered and summarily appraised. 
1.1 Introduction 
A decade ago interest in real world health and clinical data peaked with the publication of 
several systematic enquiries aimed at mapping the breadth and depth of sources of real 
world data 2 3 18 19. These reviews each had a different foci, and spanned a few years apart, 
but were consistent in highlighting that sources of real world data were plentiful and 
fragmented, having different strengths, weaknesses and idiosyncrasies; and were of 
varying utility to decision-makers at different stages of decision-making and monitoring 
processes. Previous reviews highlighted that many sources were long established: Newton 
and Garner’s review of disease registries included a description of Norway’s Leprosy 
register, set-up in 1856 and which continued until 1973, and held 8000 records including 
four from patients still alive when discontinued. Arguably other forms of real world data, 
such as the record of cholera cases developed by John Snow in 1849, have an equally long-
standing history. One of the first documented real-world health data projects might be 
found in the work of John Graunt, who analysed 2500 bills of mortality in London in 1663 
mortality and cause of deaths over 50 years in an effort to understand patterns of bubonic 
plague 20. Over 350 years later, new sources of real world data continue to be established, 
for example through the establishment of the UK’s first biobank 21 , and efforts to link and 
consolidate existing sources of real world data continue. Alongside these advances we’ve 
also seen greater investment in streamlining access points for real world data, for example 
through the establishment of the Health and Social Care Information Centre and its 
continued work. However, while there are some who laud the UK’s commitment and usage 
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of real world data in health policy 22 23, there are others who question the pace of 
advances 24. For a number of decades there have been various calls for greater systematic 
collection and utilisation of data collected routinely in healthcare. For example, in 1980 
the establishment of the Körner committee, and the recommendations made and 
implemented, ensured that greater impetus was placed on the collection of data to 
improve patient care. More recent national efforts to improve, expand and link health and 
care data have attracted a number of critiques, reflecting concerns around ethical issues, 
consent and confidentiality 25 26. The flagship care.data project was recently given a red 
flag of ‘low confidence’ by the government’s own watchdog and has been beset by 
concerns around confidentiality, privacy and data ownership 27. The widespread concerns 
around this particular project have meant that public confidence in the use of real-world 
data has been eroded, possibly leading to suboptimal clinical advancements as well as high 
levels of distress around the use of personal data 28. 
The extent to which concerns around the security and ethics of real-world data collection 
have served to limit the proliferation of real-world data sources, against a backdrop of 
expanding opportunities around the capture and analysis of real-world data, are relatively 
unknown. In addition, the type of real-world data that has attracted much recent 
controversy – linking of primary care data and its use for commercial and analytical 
purposes – is but one model of real-world data collection and real-world data use. As we 
reveal in this report, the landscape around real-world data is complex, and while different 
sources may have similar, if not identical, data collection designs, they may nevertheless 
have very different policies and be at different stages when it comes to data linkages and 
data usage. New insights and perspectives have also prioritised different aspects of 
patient care, and there is now a growing focus on collecting information seldom included 
in reporting systems in the past, for example patient reported outcomes 29, as well as 
genomic data. Therefore the extent to which the conclusions of previous reviews of data 
sources still stand, in that UK “healthcare systems, despite requiring information on 
whether they provide the right interventions well and fairly to the right people, tend to 
have poor information systems” 19; p65, are subject to debate and review. More recent 
reviews suggest that issues reflecting the lack of unity in data collection systems and 
fragmentation of sources identified in previous studies persist, hindering the potential 
contribution of real-world data 30, although new sources continue to be established that 
offer potential insights into areas of health and care where comparatively little has 
previously been known31. 
Furthermore, health care commissioning and delivery structures have changed 
dramatically in recent years, necessitating a broader scope including public health and 
social care sources of real world data in the current study, as well as clinical sources. The 
commissioning of health care has shifted to fall within the control of GPs as part of clinical 
commissioning groups. Public health surveillance and services in England now fall under 
the remit of Directors of Public Health based in Local Authorities, although with bridge 
links to health care. The planning, commissioning and delivery of social care continues to 
be based in Local Authorities, although the need for integration is recognised across the 
spectrum, and this is being reflected in new healthcare structures being developed, for 
example the recent shift to Local Authority partnership control of health care services in 
Manchester 32. NICE’s own remit since 2012 now includes all three areas (social care, 
public health, clinical healthcare). Notwithstanding the changes in demography, 
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epidemiology and care needs, attitudes and behaviours, and advances in health and social 
care technologies; these changes in health and social care delivery structures will also 
drive changes in data collection patterns and needs. The shift of services to more localised 
structures may offer opportunities for the development of networks of best practice in the 
collection of real-world data. Political support for greater utilisation of real-world data for 
research and improving patient outcomes was common across all the prospective 
candidate parties at the 2015 general election 33, indicative of substantial political will to 
strengthen and utilise real-world data. 
Unlike previous reviews in this arena, this current study takes a less systematic approach 
and adopts a broad brushed approach, not being confined to any one given particular type 
of real world data, and encompassing health, social care and public health real world 
data. To help meet the challenge of addressing the breadth, this study takes an expert-
driven approach, using semi-structured interviews with a number of experts in the field as 
a source of data, alongside creating map of the literature, the production of a case study, 
and supplementary exploration of a select number of these sources as case studies. 
Additionally, unlike previous reviews, the current study is being undertaken with the 
specific data needs of NICE driving the focus. The remainder of this chapter is focussed on 
(i) introducing the methods used to produce this report; (ii) introducing principles of good-
practice and strengths of real-world data; and (iii) introducing principles of good practice 
and strengths of real-world data that reflect NICE’s specific real-world data needs.  
 
Defining real-world data  
The definition of real-world data can be contentious and different stakeholders have 
different views as to what constitutes ‘real-world’ data. Real world data is defined in 
this report through two key tenets: 
a. The collection of real world data reflects the usual care or treatment provided to 
populations of patients, service users or the public. This therefore excludes 
conventional Randomised Controlled Trials (RCT(s)) but could include other 
forms of RCT design, namely pragmatic RCTs3.  
b. Real world data provides enough depth to assess trends around everyday 
practice, service usage, or to assess outcomes. 
 
                                            
3 Pragmatic randomised controlled trials aim to mimic real life conditions and test the effectiveness 
of a range of interventions that are known to be safe. They can be instrumental in understanding 
the relative effectiveness where there is no apparent clinical advantage/disadvantage among 
currently accepted treatment – in the case of a pragmatic RCT, instead of any one of these 
treatments being administered arbitrarily, the treatments are prescribed through random allocation 
(1. van Staa T-P, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine 
electronic health records: putting them to the test. Bmj 2012;344:e55.)  
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To meet the needs of NICE, we do not pay close attention to sources of data that have 
limited geographic representation, and prioritise those sources with national or regional 
representativeness. 
This definition therefore allows for the inclusion of clinical databases, disease and case 
registries, workforce registries, administrative records, HTA registers, surgical registers, 
surveys, clinical audits, population registries, service records and censuses to be 
included as sources of real world data (see glossary). 
1.2 Methods 
Research questions 
In order for NICE to fully capitalise on the increasing availability of data, there is a need 
to better understand the extent and relative strengths and limitations of current sources 
and how they may change in the future. Therefore in this report we address two main 
research questions: 
a. What are the main sources of clinical, health and social care data that are 
currently available that match the needs of NICE? 
b. What are the main features, strengths and limitations of some of these available 
health, clinical, social care and public health datasets for NICE? 
Two supplementary research questions include: 
c. What are the main debates around using routinely collected and other real-
world health, social care and public health data (as identified by experts and 
other sources)? 
d. What can NICE learn from another agency’s experience of using real-world 
data? 
With respect to the first question, those sources that are not in current use by NICE are 
those which are of greatest interest.  
Overall approach 
In this project we attempt to map and appraise the availability of clinical, health, social 
care and public health data sources using an expert-led approach and supplemented 
through a review of the literature and website searching. We discover and map the most 
relevant available sources of clinical, health, social care and public health data for NICE, 
mainly relying on evidence gathered from expert interviews to shortlist a number of these 
sources to profile in greater depth. This forms an expert-driven map of the most relevant 
sources of data that fit within the needs of NICE that is supplemented by explorations of 
the literature. This means that the results presented here (i) do not form and do not 
attempt to form a comprehensive map of different sources of real-world data; (ii) are 
weighted towards the real-world data needs of NICE, and therefore other health and social 
care stakeholders may prioritise these sources differently; and (iii) are focussed on those 
sources not in current use by NICE. While the research and views here are independent of 
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NICE, we received input through suggestions for expert stakeholders to interview and we 
worked collaboratively with a NICE steering group to prioritise those datasets for in-depth 
profiling. 
 
Figure 2: Process showing how different data sources were selected for in-depth profiling 
 
 
Semi-structured interviews 
The purpose of the interviews is to both ensure we are made aware of different sources of 
routine data as well as considerations in assessing its quality for use by NICE in its work. In 
the interviews we explore: 
• Knowledge of different current UK sources of clinical, health and social care data 
most relevant for use by NICE in its work (which alongside desktop research will help 
us to ensure that we are able to map out the main relevant sources) 
• Knowledge of strengths and limitations of the named sources (in the context of the 
needs of NICE).  
• Current and emerging debates around the collection, storage, analysis and 
utilisation of routine and non-routine health, clinical and social care data  
• Knowledge of examples of organisations with a similar remit to NICE that use real-
world data in a way which could be considered as best practice  
We were also interested in the way in which stakeholders perceived the overall quality 
and breadth of the landscape, their experiences of using different datasets, and the 
strategies that they used to identify the strengths and limitations of these data, and in 
some cases their future plans for using the data. Interview participants were initially 
contacted either by email or telephone and meeting times set up. The list was drawn up 
partly on the basis of exploring the existing literature and partly through input from NICE. 
Interviews were semi-structured in format, and conducted using a topic guide (which was 
modified according to area of expertise of the expert stakeholder (see Appendix 3 for an 
example). The topic guide was developed through summarily exploring the literature. The 
interview schedules were structured around considering the usefulness of data for NICE 
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and the properties and characteristics needed to assess the effectiveness of health 
technologies and practice/interventions; the quality and accessibility of data; debates 
around the availability of data, and the relative merits of real-world data for NICE. While 
a focus of the interviews was on establishing the main sources of data that could be used 
by NICE, we also probed for less well-known sources. Interviews lasted between 40-90 
minutes, although most were around 50 minutes, and were partially transcribed by a 
member of the research team. We did include verbatim quotes where appropriate to 
support some themes. Responses were analysed thematically, moving from attributing 
codes to the data to exploring themes, although maintaining a focus on mapping the real 
world data landscape.  
Literature search and case study 
We reviewed the available academic and grey literature using a structured search and 
then complemented by forward and backward citation searching. We initially conducted a 
search of PubMed using search terms reflecting geography, scope (health and social care) 
as well as terms reflecting real-world data (see box below).  
Box 1: Search string used to search for literature 
 
((((("uk"[Title/Abstract]) OR "england"[Title/Abstract]) OR "wales"[Title/Abstract]) OR 
"scotland"[Title/Abstract]) OR "northern ireland"[Title/Abstract]) AND and AND ((health) 
OR "social care") AND and AND ((((((("real world data") OR "clinical database") OR "social 
care data") OR "health data") OR "clinical audit") OR "disease registry") OR "routine data" 
OR "administrative data") in PubMed  
 
This search uncovered 743 results (700 after the removal of duplicates). To build on 
previous reviews that took place 2004-2006 2 18 19 34 and to minimise the number of 
discontinued databases that may be included in the results, a further filter was put on the 
search to exclude literature published before 2005; this reduced the number of results to 
548. All these references were imported into EPPI-Reviewer 4 and screened on title and 
abstract. In the case of 384 of these studies, the information in the title and abstract was 
sufficient to decide on whether the study included real-world data (or not) and the name 
of the real-world data source included. In 164 of the included studies, further information 
was extracted from the full text. 
From the interviews, we sought to identify a case study of an organisation that used real-
world data with a particular emphasis on identifying ‘good practice’. We sought to identify 
organisations that had used data to (i) directly assess technologies/interventions; (ii) 
address research gaps emerging from guidance; (iii) examine the extent of implementation 
of guidance; (iv) as part of economic analyses of research gaps or implementation; (v) 
measure regular performance and monitoring activities (e.g. medicine metrics). To 
produce the case study, we undertook: (a) a semi-structured interview with a 
representative of the organisation; (b) collection of/request for archival/documentary 
evidence of the (positive) impact of the use of real-world data e.g. in terms of studies 
undertaken by the organisation to address research gaps stemming from guidance or in the 
production of guidance; (c) collection of/request for evidence of the broader impact using 
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real-world data in the organisation’s activities, as well as (d) evidence on the criteria used 
to measure strengths or weaknesses of the data and strategies used to limit the impact of 
any weaknesses. Not all of these elements were populated in our case study (section 5). 
1.3 What makes for good real-world data (for NICE)? 
The following criteria/principles have been identified from the literature and the 
interviews conducted as being important; some are idealised and rarely feature in the 
available data but are nevertheless important considerations. Few data sources are likely 
to fulfil all desired properties listed. Commonly, studies will triangulate data from 
different sources in addressing research questions, such as Vinogradova and colleagues’ 35 
study, which examined data from two primary care datasets (CPRD and QResearch); this 
can be one method of minimising some of the complications of using real-world data 
sources. Using multiple sources offers wider coverage and richer information in 
combination, which can maximise the capture of information on the effectiveness of an 
interventional procedure 36-38. However, the capacity to do this is very much dependent on 
the research question/purpose of the real-world data project. 
Furthermore, even the most methodologically robust real-world data sources will have a 
complementary, as opposed to competing, role alongside other forms of evidence. This 
includes evidence from conventional experimental studies (i.e. conventional RCTs) as 
opposed to observational or pragmatic trial studies; the former remaining essential to 
establish efficacy and safety of interventional practice and the latter remaining the only 
source of evidence of effectiveness. 
Principles/Criteria for selecting/assessing sources of real-world data: 
 
Clearly defined aims: Data sources should have clearly defined aims that NICE can 
subscribe to; this appears particularly important in the present time as the purpose and 
use of real-world data is in debate. 
High levels of validity; clear case definition: Validity of constructs in real-world data 
connotes the degree to which indicators measure the conditions they purport to measure. 
This is usually achieved through implementation of standard measures/frameworks for 
measures; in registry data the problem can be framed differently in terms of clear case 
definition (and inclusion in the data), although the principles remain the same. The use of 
standard coding frames, for example ICD-104 (International Classification of Disease) as 
used in clinical databases can be one way in which validity of constructs/case definitions 
can be improved; standard measures are also implemented in social care data (e.g. 
ASCOT; ADLs; IADLs) although there may be greater variety and subjectivity in some of 
these measures.  
Clear case definition is also dependent on the diagnostic tests for the condition – e.g. even 
a common condition like asthma actually has no definitive diagnostic test but rather a set 
of symptoms and reactions to medication that provide diagnosis 39. 
                                            
4 http://apps.who.int/classifications/icd10/browse/2015/en 
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Some constructs may have good validity but through being less stable, can have lower 
levels of reliability. For example constructs such as body mass index (BMI) have lower 
levels of reliability in real-world data than more stable constructs (e.g. genetic markers) 
as they are subject to rapid change. This can be problematic for some combination of uses 
and sources of real-world data; for example if real-world data from primary care was used 
to select overweight/obese patients for a cohort study based on height and weight 
measures from the previous appointment, some of the patients included may no longer be 
classed as obese/overweight.  
Representative of populations and setting: A theoretical strength of real-world data is its 
high generalisability in comparison with data from RCT studies. This can only be achieved 
if data are representative of populations and settings 18. This can include being sectorally 
representative (e.g. representative of public and private providers)34. As a further 
condition, analytically and to enhance generalisability, real-world data should also be 
representative of ‘large’ populations or a large fraction of cases if appropriate 3. For 
example, localised registers of rare diseases may be less useful than national data for NICE 
both from an analytical (sample size) perspective and in terms of generalisability. For 
registry data in particular, different geographically-based registries may have been 
established independently originally, but may have developed a unified framework so that 
instead of representing geographic areas, they may have switched focus to a particular 
clinical or epidemiological specialism. Where fragmented data sources exist, the ability to 
combine data with other local datasets can reduce the possibility of type II statistical 
errors in particular from occurring. Data linkage in general is often problematic with real-
world health data both analytically and in terms of ethical considerations.  
Representativeness in terms of disease stages: This indicates the degree to which real-
world data include patients with different stages of a disease or condition, for example 
people with a spectrum of needs from mild to severe. In some cases, a register or 
database may only include patients with certain stages of a disease or condition, but in 
others a database/register may purport to include all cases but may in fact systematically 
underrepresent people at a certain stage or with a certain severity of a disease or 
condition for example, 40.  
Clear ethical frameworks aiming for informed consent as gold standard: Real-world 
data sources should adhere to recognised codes of ethics and as a gold standard should 
include an opt-out clause or obtain explicit consent 18. In practice this can be difficult, 
and while there are some who speculate that obtaining consent results in the introduction 
of bias; others view the lack of transparency around consent as a limiting factor on the 
extent of real-world data sources and their scope. Researchers find that most UK patients 
would allow their data to be used by the NHS for research purposes but do have concerns 
about the selling of information for commercial gain as well as in the potential misuse of 
data 41. 
Dynamic and adaptable (multipurpose): Dynamism in the goals and ambitions of real-
world data collectors can lead to innovation and investment in the data. For example a 
new database on suicide in Wales – the Suicide Information Database-Cymru is being 
developed by researchers based on routinely collected health and social care data linkage 
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42. This is the first to allow the tracking of healthcare pathways and contact with different 
providers in the UK of suicide cases. 
Flexibility to add new data and ideally to add new data on a request/trial basis: This is 
particularly important as the choice of indicators can be driven solely by the indicators 
available 43, as opposed to those addressing a research question of clinical importance. 
Consider the situation where pain is an outcome; real-world sources may not capture 
changes or improvement without additional Quality of Life indicators and Patient Reported 
Outcomes being collected.  
Flexibility to implement different study types: For example the flexibility to implement 
the different commonly occurring epidemiological study types: prospective cohort, 
retrospective cohort, case control and nested case control studies etc. Different study 
types using same data can find different results – e.g. link between statins and common 
cancers found in one nested case-ctrl study 44 but not in a retrospective cohort study 45 of 
GP data (QResearch and THIN data respectively); therefore flexibility to implement 
different designs and triangulate the results is important in real world data. 
Capable of being linked to other data (or potential) for tracking patient outcomes: A 
common identifier allowing linkage of different dataset is one of the priority 
goals/movements towards improving the potential of real-world data. Data linkage in this 
way allows for the tracking of patient journeys through health systems (or potential for) 
and is a key ingredient in forming population health systems 46 47. Some work in this area is 
underway in linking different clinical databases (HES and CPRD) and clinical databases and 
clinical registers.  
Collection of data reflective of real-world conditions (scope): One of the clear 
advantages of real-world data is the ‘real-worldness’ of it and being able to create a 
robust economic and budget impact argument is an important part of this 37. Real-world 
data presents an opportunity to understand the effectiveness of interventions and to 
collect information that provides unique insight into establishing the effectiveness of 
interventions, including a sufficient breadth of intrinsic variables and a sufficient breadth 
of prognostic variables. 
This includes considering whether the scope is broad enough to consider events beyond 
morbidity and mortality.  
Sensitivity: Due to their breadth and longitudinal nature, some sources of real-world data 
are better suited than others to enable analysts to distinguish between pre-existing 
comorbidities from complications of treatment or iatrogenic diseases 36.  
Transparent sampling frames/recruitment processes: This is an important consideration 
in order for researchers to understand and report upon potential selection effects in the 
data. Ideally, databases and registers will seek complete coverage of the cases within 
scope although this may not always be achieved 18 48, and can lead to selection effects 
(bias) where there are systematic differences between cases included in datasets and 
those who are not. Different forms of real-world data may be vulnerable differentially to 
selection effects. Some sources suggest registers are more exposed to selection bias than 
clinical databases 40 48, but participation in some of the major primary care databases is 
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also voluntary at practice and patient level 2, which can compromise representativeness. 
For NICE, the priority should be in the use of real-world data where the impact of possible 
selection effects can be ascertained – e.g. through clear study documentation – and 
potentially adjusted for where necessary. 
Where sampling frames have been used (e.g. in survey data), the construction of 
probabilistic weights and/or response weights and/or clear identification of strata and 
sampling units may be necessary to make inferences to wider populations. 
Uniformity in data collection procedures: While this may not be possible for some 
sources of real-world data, use of standard tools for measurement can be one way to 
attempt to ensure the validity of measures 1. Uniformity with other sources will aid 
comparability, including with international data 43. Within a dataset, guides and training 
around data collection and input may provide information needed to assess the uniformity 
of data collection processes. 
Steps taken/can be taken to minimise common form of bias: Due to the mainly non-
randomised nature, forms of real-world data may be accompanied by a degree of bias in 
the collection or design of the data (as well as in the analysis). While researchers may not 
be able to fully resolve these forms of bias, an ability to minimise or understand extent of 
common forms of bias specific to real-world data is important. This is particularly the case 
for those types of bias that do not ordinarily occur in RCT designs; see 49; these forms of 
bias include:  
a. Confounding by indication, channelling bias  - where the underlying risk profile 
differs for those receiving a treatment compared to those who are not 50. This is 
not insurmountable, or at least the impact can be minimised in part, e.g. use of 
instrumental variables, propensity score matching, risk stratification and other 
methods can be used to minimise impact on estimates – but all these techniques 
depend on having broad scope of data collection and the techniques themselves 
are not infallible and can introduce a degree of subjectivity 51 
b. Protopathic bias – establishing the actual sequence between diagnosis and 
treatment; establishing the sequencing and dosage of different treatments a 
patient may be receiving 
c. Additional forms of allocation bias 
d. Recall and forms of reporting bias see 36 – indicates situations where the data 
collection itself compromises the information collected for a number of possible 
reasons including respondents’ inabilities to remember or give accurate 
information, acquiescence, tendencies to give extreme or rounded values, as well 
as a tendency towards social desirability 
e. Tolerance bias (pharmacoepidemiology) see 50 – indicates whether there is scope 
for the detection of medicines for comorbidities (plus over the counter medicines) 
f. Information/detection/observer/ascertainment/assessment bias – indicates the 
possibility that those with vested interest in doing so may underreport; also 
possibility that misclassification occurs see 50 
g. Selection bias – see selection effects above 
Responsiveness: Whether the data are responsive enough to record changes in treatment 
or care package including the timing and sequencing of switching treatments. 
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Quality Assured: Robust sources of real world data will produce detailed quality assurance 
reports and quality assurance measures. These steps can adhere to common standards 
such as the National Statistics Quality Mark 34. 
A degree of data user involvement: Steering groups or user groups are one way in which 
real-world data can maintain a balance between what is pragmatically feasible and what 
data users require for research purposes 34; these can help users to influence the direction 
of real-world data sources. 
Accessible and ad hoc analyses feasible: Data should be accessible and with little 
unnecessary administrative burden. The ability to access granular data (e.g. 
patient/practitioner level data) is a clear advantage for re-analysis and addressing new 
research questions. Access should be balanced between the need to undertake clear, 
hypothesis driven research and the ability to undertake exploratory data analysis to 
explore trends, e.g. around dose response. Accessibility also includes access to clear data 
documentation and a low, or at least purposive, administrative burden for access – i.e. for 
example the process of gaining ethical approval is beneficial for researcher and data 
holder. Accessible data is also data that is low cost or free to access for research 
purposes. 
Support and training: The most useful sources of data may be those where support is 
provided in the form of manuals, helpdesks, training. The existence of a data usage library 
or archive in order to understand who is already using the data and why can also help to 
avoid duplication in studies. 
High data quality: This is an implicit aim of all real world data sources; high quality data 
can include data that include few logical inconsistencies and the ability to identify 
duplicate cases. 2 47 
Secure and confidential: Secure and confidential data protection procedures are essential 
in ensuring that the data are ethical; for NICE they can also minimise the reputational 
risks and internal risks of using real-world data 
Good levels of stability: The better the stability/longevity of the resource, the more 
expansive the research questions that can be addressed. In addition, use of a data source 
can represent an investment in itself in terms of access and training and using a data 
source with low levels of stability or likely longevity can represent a risk in itself. 
Granularity of treatment/disease data: ICD disease codes and treatment codes may not 
ordinarily capture the specificity/granularity required for some conditions; although such 
a depth of detail may be more likely to be found in registry/audit data 36 (this 
consideration is highly dependent on the research question in mind and for most types 
standard disease codes may suffice) 
Timely: Timeliness is a theoretical advantage of real-world data and a criteria in assessing 
real-world data should be its temporal relevance 23 
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1.4 What properties do NICE need of real-world data?  
The ambitions of NICE in using real-world data are summarised in five key functions. Each 
of these functions can entail different data requirements and are discussed below. 
1. Research the effectiveness of interventions or practice in real-world (UK) settings 
Real-world data would enable NICE, having first established the efficacy of interventions 
through experimental evidence, to assess the transferability of conventional RCT findings 
in real-world practice. An example of an intervention where its effectiveness has not been 
established in real-world settings is presented in Box 1, taken from NICE guidance around 
managing headaches among young people 52.  
Box 2: Example of need for researching the effectiveness of interventions in real-
world settings 
 
CG150/1: Is amitriptyline a clinically and cost effective prophylactic treatment for 
recurrent migraine? Why this is important:- Effective prevention has the potential to 
make a major impact on the burden of disability caused by recurrent migraine. There 
are few pharmacological agents that have been proven to prevent recurrent migraine. 
Amitriptyline is widely used, off-label, to treat chronic painful disorders, including 
migraine. Inadequate evidence was found in the review for this guideline for the 
effectiveness of amitriptyline in the prophylaxis of migraine. A double-blind randomised 
controlled trial (RCT) is needed to assess the clinical and cost effectiveness of 
amitriptyline compared with placebo. The definition of migraine used should be that in 
the International classification of headache disorders II or this guideline. Outcomes 
should include change in patient-reported headache days, responder rate and incidence 
of serious adverse events. If amitriptyline is shown to be effective, it will widen the 
range of therapeutic options, in particular for people in whom recommended 
medications are ineffective or not tolerated.  
 
While the recommendation states that a double-blind RCT is needed to assess the cost-
effectiveness of the drug amitriptyline, such a design would not be feasible using real-
world data, and in particular, such a design would not give a full account of the cost-
effectiveness of amitriptyline in the real-world, since patients suffering from recurrent 
migraine would unlikely be offered a placebo, but instead the best available alternative 
treatment. Investigating the effectiveness an intervention in real-world settings would 
usually require:  
i. Clear determination of the target population (who received the intervention) as 
well as a method of identifying controls (in order to establish comparative 
effectiveness) 
ii. Reliable measurement of the desired outcomes (and therefore usually requiring 
longitudinal design)  
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iii. Satisfactory range of intrinsic measures included (i.e. to control for unwanted 
sources of variability, to assess the stability of intervention effects across groups 
and to enhance generalisability) 
iv. Satisfactory range of additional prognostic variables (i.e. to control for potential 
confounding around treatment options)  
v. Given that effectiveness can refer both to clinical effectiveness as well as 
effectiveness in terms of resource use or cost, other measures around inputs and 
outputs including staffing or patient may be required 
A ‘gold-standard’ study design for measuring the effectiveness of interventions in real-
world settings might involve conducting a pragmatic RCT 1, although in practice this may 
not always be possible and the identification of a retrospective cohort may be a more 
common study design for assessing the effectiveness of interventions. Where there is a 
pre-defined outcome of interest, particularly a rarer outcome, a case-control study may 
be more appropriate. In rarer situations, a case-series design may suffice (where no 
control group is identified). Regardless of the study design, the properties identified above 
are those that are required of real-world data in order to measure the effectiveness of 
interventions. 
2. Audit the implementation of guidance  
Real-world data would enable NICE to assess the degree to which guidance is implemented 
and how this implementation may vary across different groups; for example including 
socioeconomic, geographic, demographic and groups differentiated by different 
diseases/health conditions. An example of guidance is provided below where the drug 
Naftidrofuryl oxalate was identified as the recommended option for the treatment of 
intermittent claudication in people with peripheral arterial disease, and other drugs 
(Cilostazol, pentoxifylline and inositol nicotinate) were not recommended for this 
purpose.  
Box 3: Example of need for real-world data for auditing the implementation of 
guidance 
 
TA2323: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for 
the treatment of intermittent claudication in people with peripheral arterial disease 
1.1 Naftidrofuryl oxalate is recommended as an option for the treatment of intermittent 
claudication in people with peripheral arterial disease for whom vasodilator therapy is 
considered appropriate after taking into account other treatment options. Treatment 
with naftidrofuryl oxalate should be started with the least costly licensed preparation.  
1.2 Cilostazol, pentoxifylline and inositol nicotinate are not recommended for the 
treatment of intermittent claudication in people with peripheral arterial disease.  
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1.3 People currently receiving cilostazol, pentoxifylline and inositol nicotinate should 
have the option to continue treatment until they and their clinicians consider it 
appropriate to stop. 
 
NICE identified that this guidance was being broadly implemented in a review conducted 
in 2014, and that prescriptions of naftidrofuryl oxalate had increased since 2011 and the 
evidence suggested that prescriptions for cilostazol, pentoxifylline and inositol nicotinate 
had decreased using the ePACT (Electronic Prescribing Analysis and Cost Tool) and Hospital 
Pharmacy Audit Index information 53. However, the data also showed that reductions in 
cilostazol, pentoxifylline and inositol nicotinate prescriptions had tailed off following an 
initial decline in the first quarter of 2012. ePACT data allow for the potential for 
examining some practice level characteristics although, should NICE require, alternative 
sources of real-world data may also shed light on the characteristics of prescribers and 
patients who are not using naftidrofuryl oxalate. To gain summary insight as to whether 
guidance is being implemented, at minimum the data should allow for: 
i. Clear determination of the intervention(s) (which may include implementing a 
diagnostic tool as well as ‘treatment’)  
ii. Means of establishing change over time that with relatively low levels of recall or 
other forms of bias (e.g. a repeated cross-sectional design for data capture) 
iii. Measuring outcomes is not a pre-requisite although the ability to capture 
patient/prescriber/institutional level characteristics and outcomes will enable a 
deeper understanding. As most NICE guidance provides criteria for use rather than 
a binary recommendation, then fuller scrutiny of patient records is likely necessary 
for full auditing of the implementation of guidance 54.   
Auditing the nuances of some recommendations may be particularly difficult using routine 
data. For example, Box 3 below shows that in the case of overweight and obese adults, it 
is recommended that GPs raise issues of weight loss in a respectful and non-judgemental 
way. Auditing this element of the recommendation would require subjective data from 
patients and clinicians which may not be captured in the majority of existing real-world 
data sources (although provisions could be made). Researchers who have audited the 
implementation of NICE guidelines in the past have used a number of different taxonomies 
of real world data including data from existing clinical audits, clinical databases, disease 
registries but also commonly have designed specific data collection tools (survey based 
methods that are often also included within audits) as well as undertaking interviews and 
examining locally sourced case series data 54-56. Furthermore, there is also an important 
distinction between observing trends and attributing changes to the implementation of 
NICE guidelines. In other words, while a real-world data project auditing the 
implementation of guidance may find a trend in practice, attributing this to the impact of 
the guidance itself and not to other factors (such as other developments in professional 
wisdom) is difficult. 
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Box 4: Example of need for real-world data for auditing the implementation of 
guidance 
 
PH53/6 Recommendation 6: Refer overweight and obese adults to a lifestyle weight 
management programme  
GP practices and other health or social care professionals who give advice about, or refer 
people to, lifestyle weight management programmes (see Who should take action?) 
should:  
 Raise the issue of weight loss in a respectful and non-judgemental way. Recognise 
that this may have been raised on numerous occasions and respect someone's 
choice not to discuss it further on this occasion. 
 Identify people eligible for referral to lifestyle weight management services by 
measuring their body mass index (BMI). Also measure waist circumference for 
those with a BMI less than 35 kg/m2. Consider any other locally agreed risk factors.  
 For funded referrals, note that:  
o programmes may particularly benefit adults who are obese (that is, with a 
BMI over 30 kg/m2, or lower for those from black and minority ethnic 
groups) or with other risk factors (comorbidities such as type 2 diabetes)  
o where there is capacity, access for adults who are overweight should not 
be restricted (that is, for people with a BMI between 25 to 30 kg/m2, or 
lower for those from black and minority ethnic groups) or with other risk 
factors (comorbidities such as type 2 diabetes)  
o there should be no upper BMI or upper age limit for referral.  
 Provide information on programmes available locally, where possible, taking 
people's preferences and previous experiences into account. Be clear that no 
programme holds the 'magic bullet' or can guarantee long-term success.  
 Refer people to a group rather than an individual programme if they express no 
preference because, on average, group programmes tend to be more cost 
effective.  
 Ensure people who are overweight or obese who are not referred (for whatever 
reason) have an opportunity to discuss and reconsider attending a programme in 
the future. Discuss making a follow-up appointment at an agreed date (for 
example, in 3 to 6 months). Provide them with sources of information about how to 
make gradual, long-term changes to their dietary habits and physical activity levels 
(for example, NHS Choices). 
 Give people the opportunity for a re-referral, as necessary, because weight 
management is a long-term process. Use clinical judgement, taking into account 
the person's circumstances, previous experiences of weight management and 
commitment to change.  
 
 
3. Provide information on resource use and evaluate the potential impact of 
guidance in changing resource use 
A summary examination of health or social care resource usage may include information 
on the type of health or social care resource utilised (e.g. a hospital or residential home 
stay, a GP visit or drug prescribed) as well as the amount of resource used. To gain 
summary insight for resource use at minimum the data should allow for: 
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i. Clear determination of the intervention(s) delivered and the resources employed 
(which may include implementing a diagnostic tool as well as ‘treatment’).  
ii. Means of establishing the amount of resource used. 
iii. Resource data for developing/informing guidance may need to include the data 
necessary to calculate Quality Adjusted Life Years (years lived in ‘perfect’ health).  
iv. Measuring outcomes is not a pre-requisite although the ability to capture 
epidemiological information, health outcomes (including potentially patient 
reported outcomes) and cost information may be essential for a fuller cost-
effectiveness study (as opposed to studies investigating trends in resource use).  
 
4. Provide information on epidemiological trends 
 
Box 5: Example of need for real-world data for understanding epidemiological trends 
 
CG53/3 What is the prevalence and incidence of CFS/ME in different populations? 
What is the natural course of the illness?  
Why this is important: Reliable information on the prevalence and incidence of this 
condition is needed to plan services. This will require well-constructed epidemiological 
studies across different populations to collect longitudinal data to predict outcome, and to 
calculate the economic impact of loss of work or education. We recommend that these 
questions are answered using a mixture of: 
 cross-sectional population studies, including people with different levels of disease 
severity from all ethnic groups and social classes  
 longitudinal cohorts of people with CFS/ME, and population cohorts to assess the 
incidence and prognosis of CFS/ME in a previously normal cohort 
 
Epidemiological trends may refer to summary trends (usually over time) in prevalence or 
incidence of diseases or conditions; more in-depth studies may also explore associations in 
terms of socio-demographic or socioeconomic inequalities, regional inequalities, or may 
seek to explore the impact of different exposures and their associations with the 
likelihood of developing diseases or conditions compared with staying healthy. While 
epidemiology usually refers to ill-health, the same principles may extend to social care if 
we consider the risks of developing different levels of care needs, for example. In order to 
monitor trends alone, outcome data may not necessarily be a pre-requisite, although as 
the research recommendation in box 5 outlines, there is usually a desire both to study the 
incidence/prevalence of disease as well as prognostic data.  
At minimum the data should allow for: 
i. Clear determination of the disease/condition/state through diagnostic tests OR 
standardised disease coding OR a battery of symptomology data collected with 
which to determine a (secondary level) diagnosis. This may therefore require 
information from a variety of sources, for example blood assay or radiography scan 
data. 
ii. Satisfactory range of intrinsic measures included (i.e. to assess associations across 
groups and to control for unwanted variability) 
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iii. Satisfactory range of exposure/risk variables (i.e. to assess the impact of different 
behaviours and exposures in elevating or reducing risk) 
iv. Satisfactory range of additional prognostic variables (i.e. to assess disease course)  
vi. Where relevant, reliable measurement of the desired outcomes (and therefore 
requiring longitudinal design)  
 
5. Provide information on current practice to inform the development of NICE 
quality standards 
Quality standards produced by NICE ‘describe high-priority areas for quality improvement 
in a defined care or service area. Each standard consists of a prioritised set of specific, 
concise and measurable statements’ and an example is provided in Box 6 (see 57). The use 
of real-world data for this purpose does not entail monitoring the adherence to quality 
standards, but instead involves investigating where different thresholds of practice are 
associated with measureable outcomes, be these in objective clinical or social care 
outcomes or in terms of   patient reported outcomes. The data requirements for this 
purpose are likely to mirror those for the first purpose in requiring: 
i. Clear determination of the target population (who received the intervention) as 
well as a method of identifying controls (in order to establish comparative 
effectiveness) 
ii. Clear determination of the timing, sequencing and level of inputs provided as part 
of the intervention 
iii. Reliable measurement of the desired outcomes (and therefore usually requiring 
longitudinal design)  
iv. Satisfactory range of intrinsic measures included (i.e. to control for unwanted 
sources of variability, to assess the stability of intervention effects across groups 
and to enhance generalisability) 
v. Satisfactory range of additional prognostic variables (i.e. to control for potential 
confounding around treatment options and determine other care being provided)  
Box 6: Example of quality standard 
 
NICE quality standard [QS81]: Quality statement 1 
People with suspected inflammatory bowel disease have a specialist assessment within 
4 weeks of referral. 
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1.5 Summary of data requirements based on the intended use of real-world data by NICE 
Table 1: data requirements based on NICE’s intended use of real-world data 
 Essential for basic study Desirable for more in-depth study Potential study designs for 
basic study 
Research the effectiveness of 
interventions or practice in real-
world (UK) settings 
i. Clear determination of the target population; method 
of identifying controls  
ii. Reliable measurement of the desired outcomes  
iii. Satisfactory range of intrinsic measures included  
iv. Satisfactory range of additional prognostic variables  
 
i. Given that effectiveness can refer both to clinical 
effectiveness as well as effectiveness in terms of 
resource use or cost, other measures around inputs 
and outputs including staffing or patient may be 
required 
Longitudinal data ideal e.g. 
cohort (prospective or 
retrospective cohort) 
 
Repeated cross-sectional data 
may provide indicative 
evidence of hospital/ 
unit/centre trends 
  
Audit the implementation of 
guidance 
 
i. Clear determination of the intervention(s)  
ii. Means of establishing change over time  
 
i. Ability to capture patient/prescriber/institutional 
level characteristics  
Repeated cross-sectional data 
may suffice 
Provide information on resource 
use and evaluate the potential 
impact of guidance in changing 
resource use 
 
i. Clear determination of the intervention(s) delivered 
and the resources employed 
ii. Means of establishing the amount of resource utilised 
 
i. Resource data for developing/informing guidance 
may need to include the necessary data to calculate 
Quality Adjusted Life Years (years lived in ‘perfect’ 
health) 
ii. The ability to capture epidemiological 
information, health outcomes (including potentially 
patient reported outcomes) and cost information 
may be essential for a fuller cost-effectiveness study  
Repeated cross-sectional data 
may suffice 
Provide information on 
epidemiological trends 
 
i. Clear determination of the disease/condition through 
diagnostic tests OR standardised disease coding OR a 
battery of symptomology data collected with which to 
determine a (secondary level) diagnosis. 
ii. Satisfactory range of intrinsic measures included  
iii. Satisfactory range of exposure/risk variables 
i. Where relevant, reliable measurement of the 
desired outcomes (and therefore requiring 
longitudinal design)  
 
Longitudinal data ideal e.g. 
cohort (prospective or 
retrospective cohort) or case-
control studies 
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iv. Satisfactory range of additional prognostic variables   
Cross-sectional/repeated cross-
sectional data may provide 
indicative evidence of overall 
trends 
Provide information on current 
practice to inform the 
development of NICE quality 
standards 
 
i. Clear determination of the target population (who 
received the intervention) as well as a method of 
identifying controls (in order to establish comparative 
effectiveness) 
ii. Clear determination of the timing, sequencing and 
level of inputs provided as part of the intervention 
iii. Reliable measurement of the desired outcomes  
iv. Satisfactory range of intrinsic measures included 
v. Satisfactory range of additional prognostic variables  
 Longitudinal data ideal e.g. 
cohort (prospective or 
retrospective cohort) 
 
Repeated cross-sectional data 
may provide indicative 
evidence of hospital/ 
unit/centre trends 
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Section 2: (Findings I) Mapping the topography of the real-world 
landscape and its use in NICE 
 
Real-world health, social care and public health data sources are numerous and previous 
reviews suggested that sources and access points were fragmented. A systematic search 
for all sources of real-world data was an undertaking beyond the scope of this project and 
would not directly address the research questions, which are focussed around the needs of 
NICE. Instead, three methods were used to map out the real-world data landscape with 
particular focus on those sources most relevant to NICE: 
o A review of the literature on real-world data creating a map of relevant 
sources 
o Semi-structured interviews with key stakeholders on their experiences of 
collecting or using real-world data and their broader perceptions on where 
opportunities for NICE lay 
o Supplementary desk research including website searching 
Results 
Literature review & Interview Overview 
 
Of the 548 studies published since 2005 and discovered through PubMed, 197 were 
excluded as they were either not on UK sources or were on veterinary real-world data 
(98), were not focussed on using or describing real-world data sources, provided a 
commentary about aspects of real-world data (e.g. ethics) without naming sources, or 
were duplicates. The remainder met inclusion criteria, including nine sources that were 
reviews or systematic reviews of different sources (most published close to 2005). Over a 
hundred sources (131) were coded as referring to ad hoc audits and data collection – these 
were studies that described conducting small surveys or clinical audits a single time and 
were representative only at a sub-regional geographic level; these are not named in this 
report as they are unlikely to be updated and are less generalisable in terms of geography, 
hence less relevant for NICE. The data sources named in the remaining studies were coded 
with simple descriptors (Appendix 2, analysis presented below) and were supplemented by 
those named by interviewees. Interviewees discussed a total of 55 sources of data that are 
condensed under 31 headings below, with additional information provided on each5.    
Mapping of real-world datasets  
In creating the map based on the literature and on interviewees’ responses we discovered 
a total of 275 different sources of real-world data (figure 1), of which 233 are analysed 
further, being of most relevance to NICE. The remaining data sources were found to either 
have been discontinued (26) or subsumed into other studies (6 sources), were not actually 
                                            
5 Note, we are still consolidating the results of the interviews and literature review 
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real-world data sources (e.g. they were procedures or standards for application in the real 
world (8 sources)), or were at the protocol stage (one source). 
Figure 3: Sources of real world data discovered6 
 
Sources were classified based on the name or description given on their websites, or as 
described in the literature. Disease registries comprised the greatest number of real-world 
sources uncovered (over a third); local geographic registries are represented as 
independent sources as they may have different specialisms/foci besides the geographic 
area. Clinical audits were the next more frequent type of real-world data comprising over 
a fifth of the sources uncovered (50 sources). Clinical databases and Health and Social 
Care surveys accounted for 19 and 23 sources respectively; a fuller breakdown is given 
below. 
 
 
 
 
 
 
                                            
6 It was also acknowledged that the HSCIC website held a great number of sources that could also be potentially 
profiled – future exercises could include a more detailed inventory of the HSCIC datasets. 
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Table 2: Real world data sources discovered in mapping exercises by type 
Type Number Type Number 
Disease registry 88 Donation registry 2 
Clinical audit 50 Social care database 2 
Clinical database 19 Biomarker 1 
Survey 23 Birth register 1 
Pharmacoepidemiological 
database 
8 Clinical database/ 
Disease registry 
1 
Surgery/technology register 8 GP Population List 1 
Mortality registry 7 Incident registry 1 
Screening register 5 Patient reported 
outcome database 
1 
Census 4 Population data 1 
Workforce registry 3 Other  7 
 
Real-world data on cancer were most frequent in our map of real-world sources (28 
sources) followed by those described as ‘general’ health (18 sources). The latter included 
multidisciplinary studies as well as health studies that were not focussed on a particular 
discipline or experience, and most tended to be survey based (cross-sectional and 
longitudinal); data suitable for monitoring public health trends were also well represented 
among these survey data. An array of different health topics were represented, as shown 
in Figure 4 below. Figure 5, below, shows that close to half of studies covered the UK or 
Great Britain in their scope; and in total 143 sources were representative of England. In 
contrast, less than one-in-ten of the sources had local (sub-regional) coverage (reflective 
of our selection criteria)7. 
 
 
 
 
 
 
 
                                            
7 Although this may also reflect restrictions imposed around ad hoc real world data sources. 
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Figure 4: Real world data sources discovered in mapping exercises by type 
 
 
 Figure 5: Real world data sources discovered in mapping exercises by geographic 
scope 
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An expert-driven map of real-world data opportunities 
Deriving an expert map of real-world data sources and opportunities is not without its 
limitations and caveats, and the responses received are likely aligned with the 
experiences of the interviewees who agreed to participate, extensive as this was. In 
addition, naming of specific datasets for use by NICE without a specific research question 
is challenging. All interviewees were familiar with the work of NICE, and were given the 
background on how NICE envisaged greater use of real-world data in its work, and tended 
to focus their responses on datasets that they either knew or felt were either not utilised 
or underutilised. While the datasets named were in the context of all five aims of use of 
real world data for NICE, in practice most responses were actually focussed on the way in 
which NICE could measure the effectiveness of interventions or investigate 
epidemiological and social care trends.  
Recommended sources to consider from interviews included: 
1. Understanding patient journeys and experiences using the broad scope of data 
contained within the National Cancer Data Repository 
Data collected and deposited on cancer and linked in the National Cancer Data Repository 
have been recommended for providing comprehensive data on a range of patient 
interventions and outcomes. These data have changed rapidly in recent years and the 
quality and breadth of the data have been transformed since 2008 to include core national 
outcomes data (Cancer Outcomes and Services Dataset (COSD)), radio therapy data 
(National Radiotherapy Dataset (RTDS)), cancer therapy data (Systemic Anti-Cancer 
Therapy Dataset (SACT)), and the National Cancer Patient Experience Survey; data from 
the ONS Minimum Cancer Dataset are also included to allow Repository Data to be 
reconciled with data from other sources. Three clinical audits also share data with the 
National Cancer Registries: the National Head and Neck Cancer Audit, the National Bowel 
Cancer Audit and the National Lung Cancer Audit. Efforts are made to link Repository data 
with other data including Hospital Episodes Statistics Data and data from the Clinical 
Practice Research Datalink, and linked data have been used to address a number of 
research questions aligned with NICE’s intended use of real-world data. National Cancer 
Data Repository data have been used in a number of studies and are one of the most 
comprehensive sources of data on cancer available. Repository data now falls within the 
remit of Public Health England; some more recent publications, including the 2014 Cancer 
Patient Experience Survey, have not been updated on the NCIN website. The 
recommendation around the use of National Cancer Data Repository data is also 
accompanied by an offer to help understand the data and potentially work with NICE to 
use these data (details of which have been shared).  
2. Opportunities are available for assessing individual level service user outcomes 
through the Adult Social Care Survey (ASCS) 
The ASCS is designed to capture information on social care outcomes for Local Authority-
funded social care service users, and provides unparalleled insights into social care user 
reported outcomes. Data from the survey feed into the Adult Social Care Outcomes 
Framework. The ASCS includes the items that comprise a preference-weighted measure of 
social care-related quality of life (SCRQoL) that form the Adult Social Care Outcomes 
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Toolkit (ASCOT). Apart from the ASCOT, the ASCS usually includes questions about socio-
demographics; satisfaction with social care services; physical and mental health status; 
and contextual information such as accessibility of information and advice about support, 
services and benefits; and physical accessibility 34 58. The survey is fielded as a cross-
sectional survey and results are published through the Health and Social Care Information 
Centre; the geographical granularity of these published results reaches the Local Authority 
level only. The individual user-level data are not made available through sources such as 
the UK Data Service, unlike other user experience surveys such as the Community Mental 
Health Service User Survey, although user-level data have been used in research in the 
past (based on the existence of a small number of studies; for example 58). ASCS was 
recommended on the basis of being one of the only large sources of data on social care 
user reported outcomes.  
3. Assessing resource usage using National Minimum Data Set for Social Care (Skills 
for Care) 
The National Minimum Data Set for Social Care (NMDS-SC) offers an insight into the 
characteristics of the social care workforce. It currently holds information on the 
workforce of approximately 25,000 institutions – Local Authority run as well as private 
institutions – and records on approximately 700,000 current or former social care workers 
are held 59. The data include providers who are registered with the Care Quality 
Commission as well as those who are not required to register, such as providers of day 
care services 14. These data were suggested as being potentially useful in addressing issues 
around resource usage and particularly in terms of identifying geographic differences in 
training and specialisms of the social care workforce. They have been used in a number of 
different ways including examining the characteristics of dementia care providers 14 and 
the contribution of migrant workers in providing social care 60. The data cover England 
only, are published in aggregate form on the Skills for Care website, and are also available 
for research purposes from Skills for Care8. Data are based on establishment returns and 
include information on the care workforce in terms of: establishment details qualifications 
and training, job roles, demographic characteristics (gender, age, ethnicity), employment 
details, nationality, experience, sickness, pay, recruitment and retention. 
4. Exploring primary care practice using three of the large GP datasets 
Interviewees named three main sources of GP-based real-world data that could help to 
address NICE’s real-world data needs. None of the interviewees prioritised any one source 
above another in terms of data quality, accessibility or cost; there nevertheless may be 
some differences in these characteristics as well as differences in terms of data linkage 
and size/coverage. We describe three of the sources mentioned below. All are based on 
the voluntary participation of GP surgeries; while the generalisability of these data 
sources is thought to be good, some studies have found that patients in some of these 
databases are more likely to be older and to live in more affluent areas than the 
population at large 61. Each are widely used in the literature, generating over 150 
publications combined annually 62. 
                                            
8 https://www.nmds-sc-online.org.uk/content/view.aspx?id=Accessing%20NMDS-SC%20data 
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4a. QResearch 
QResearch is a large database of GP records from around 950 GP surgeries 63 from across 
the UK. QResearch was established in 2004 64, later than other sources of GP records, 
although historical records in QResearch date back to the 1990s, making data from 
QResearch ideal for monitoring medical practice trends over time. QResearch data have 
also been used as the basis of multivariate prediction models to calculate risk of 
undiagnosed conditions among patients, such as the QCancer models 65. Across the 
literature, the data are used for a variety of purposes aligned to NICE’s intended use of 
real-world data. QResearch data are linked to deprivation data (based on patient 
postcodes) and cause of death data, and other linkage projects are underway in terms of 
linkages with registry and hospital episodes data 66; in addition QResearch data have been 
combined with European records in drug safety monitoring research 67. QResearch is a not-
for-profit organisation established primarily to meet the research needs of academic 
researchers. Costs are associated with accessing the data dependent on size and focus of 
the data, and in addition to research teams being primarily based at academic 
institutions, at least one member of the research team must be a medically qualified 
academic registered with the General Medical Council to access data. Note – QResearch 
data cannot be used for political purposes or for research that will not be published. 
4b. Clinical Practice Research Datalink (CPRD) 
The CPRD is the successor of the long-established General Practice Research Database 
(GPRD), the GPRD being established during the 1980s as a patient health information 
system for use in General Practice47. It holds the records of over 13.7 million patients 
(representing over 64 million person-years of analysis 47); estimates place the current 
number of patients currently alive at around 4.4 million and registered from 685 primary 
care practices spread throughout the UK. CPRD includes a combination of coded data, 
including on patient characteristics (some demographic information), clinical history, 
diagnoses, signs and symptoms, prescribing of drugs and devices, test results, referrals to 
secondary care and non-practice-based primary care services, immunisations and lifestyle 
factors. Free text data is also contained including the GP’s notes and annotations, as well 
as a number of communications between the GP and other providers including letters and 
emails sent to and from the GP; some of these communications are even recorded as 
scanned images47. By 2011, data from the GPRD had appeared in over 850 peer-reviewed 
papers 47; the CPRD has continued in this tradition and appears in a substantial number of 
publications. Its validity has also been tested for some conditions, being found to have 
high validity in some cases such as COPD 68 as well as many forms of chronic diseases 69. 
CPRD data are the subject of several ad-hoc data linkage projects. 
4c. The Health Improvement Network (THIN) 
The Health Improvement Network (THIN) holds data from 587 GP surgeries representative 
of the UK population, who together hold the records from over 3.6 million active patients 
(amounting to over 85 million patient observed years). THIN represents a collaboration 
between IMS and a software development company (In Practice Systems (INPS)); in 
addition a dedicated unit exists within UCL expert in using THIN data. THIN data collection 
started in 2003, although the data collectors have a more extensive experience of working 
with primary care data pre-dating THIN 70. THIN holds data on the patient (socio-
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demographic information), the patient’s medical history, practice-prescribed therapy, 
additional background health information such as smoking status, consultation episode 
data, and postcode-linked area characteristics. The data have been used extensively for 
purposes aligned with NICE’s real-world data needs, including in studies monitoring the 
impact of implementing guidance and quality standards (for example in the care given to 
smokers 71). The extent of data linkages beyond linkages based on patient postcode are 
not clear, although a number of studies have used THIN data linked with Hospital Episodes 
Statistics. As with other primary care databases, there is a cost in obtaining the data 
although support in assessing the feasibility of studies is free. 
5. Understanding the contribution of risk factors to disease outcomes using the 
Whitehall II study 
The Whitehall II study was named as a potential source of data for epidemiological 
research questions. The study recruited over 10,000 civil servants aged 35-55 working in 
London government departments in 1985. Since then there have been 11 sweeps of data 
collection with a third in progress. The study is also known as the Health and Stress study 
and has a focus on health and wellbeing that is not replicated across all the UK cohort 
studies. The narrow study design does hamper the generalisability of study findings to 
wider populations and would likely render it unsuitable for establishing prevalence or 
incidence rates representative of the wider population. However, the study has 
nevertheless been the basis for establishing associations between numerous exposures and 
patterns of health and ill-health, including health inequalities 72, and more recently in 
understanding predictors of onset of age-related diseases such dementia 73. In addition to 
a breadth of sociodemographic and socioeconomic measures, the study also collects a 
wide array of biomarkers which have been used in some studies to establish the links 
between pharmacological interventions and disease outcomes, such as the impact of 
cholesterol lowering medicines and the relationships with physical exercise and diet 74. 
The data are managed by a unit within UCL.      
6. Exploiting the longevity and near-universality of the Myocardial Ischaemia 
National Audit Project (MINAP)  
Cardiac audits were named by a number of our interviewees as a means of establishing the 
effectiveness of interventions (see also later entry). The Myocardial Ischaemia National 
Audit Project (MINAP) is a well-established audit with near-universal coverage of data on 
the management of heart attack across England and Wales (and Northern Ireland) since 
1998. The audit focusses on the management of heart attack services provided by 
hospitals and ambulance services, and aims to provide a prospective ‘census’ of all 
patients receiving care, and benchmarks the care provided against nationally and 
internationally recognised timelines for care 75. An extensive array of data are collected 
(130 fields) that capture elements of the entire patient pathway from the first call for 
help from the patient to the point of discharge. These data include demographic 
information, background medical history and clinical assessment, treatments, and a 
comprehensive array of information on drug therapy prior and during admission and at 
discharge. The audit is estimated to contain over 1.25 million records of patient 
experiences, collected by nurses and audit staff (often with the assistance of 
cardiologists) since it was established 75. MINAP data are employed extensively for a 
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variety of different purposes 76, including for research purposes (since 2006) and studies 
have addressed a number of research questions including establishing the impact of 
different interventions 77, as well as epidemiological studies addressing questions around 
the antecedents of Mycardial Ischaemia 78. 
7. Examining epidemiological trends using Health Survey for England  
Health Survey for England (HSE) data were named as a source of data for examining 
epidemiological patterns. HSE data are available in summary form from the Health and 
Social Care Information Centre as well as individual records being made available for 
analyses from the UK Data Service. HSE is cross-sectional in design, with each wave 
including a different focus on a disease, condition or population group; for example past 
waves have included a focus on renal disease, wellbeing, sexual health, the health of 
mothers and children, the health of Black and Minority Ethnic people, and respiratory 
health. Whereas other many of the datasets named in this report require contact with 
service providers for the inclusion of individuals into the data, the HSE contains 
information on a full spectrum of the UK population. Some linkage has taken place 
between HSE data and other forms of data including Hospital Episode Statistics and 
National Cancer Registry data 79. Sample sizes vary year-on-year, in part dependent on the 
study focus, but range between approximately 4,500 adult interviews in some sweeps to 
over 15,000 in others.  
8. Examining life course experiences on patterns of ageing using the National Child 
Development Study 
The National Child Development Study (NCDS) comprised a census of births occurring in a 
single week in 1958 and participants have been monitored into their 50s. The original 
18,000 strong sample has reduced to a pool of around 9,000 active participants. A wide 
range of data have been collected relevant to different points of the life course. As the 
cohort ages, data collection has become more focussed on age related transitions, 
including cognitive decline 80; the study has also recently started to collect biomarkers 
from study participants which have been used for genotyping studies 81. In 2008, 
participants were asked for consent to link their data with NHS records with 79% giving 
consent 82, although to date, records have not been linked. Individual level data are 
available to researchers through the UK Data Service. The NCDS was suggested by an 
interviewee as a potential source of data on epidemiological trends among an ageing 
population. Other research questions may also be investigated, such as health or social 
care service usage.   
 
9. Gaining a snapshot of social care and health service usage and needs of older 
people using the English Longitudinal Study of Ageing (ELSA) 
ELSA is a longitudinal study focussed on older people aged 50 and over. The study 
originally recruited around 12,000 respondents with the first full wave of data collection 
occurring in 2002; since then the panel has been replenished three times to keep 
representation at younger age groups, so that in 2012 in the sixth wave of data collection, 
data were collected from 9,169 core study members. The study has been used to monitor 
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a number of health and social care outcomes and trends in England, as well as surveillance 
of risk factors, for example correlates of falls among older people 83; some studies have 
also evaluated the impact of policy on older people’s socioeconomic outcomes 84 and a 
similar scope may exist in terms of health and social care policy. Individual level data are 
available for research purposes from the UK Data Service. Data from the English 
Longitudinal Study of Ageing were recommended for use by NICE for investigation of 
epidemiological and social care trends among older people. 
10. Understanding epidemiological and care trends among households, including 
ethnic minorities, using Understanding Society  
Data from the UK Household Longitudinal Study, also known informally as the 
Understanding Society study can be used to examine a number of health and social care 
research questions. This study has now superseded the British Household Panel Survey as 
the UK’s foremost source of longitudinal data at a household level 85. It involves data 
collection from 40,000 households that have now been tracked annually over four waves of 
data collection from 2009/10- 2012/13 among the four constituent UK countries. Further 
information on the study design is found in the study documentation 86 and weights are 
provided by the study depositors to allow analyses of the data to be representative of the 
UK population. The large sample size, boosts of ethnic minority populations, and the wide 
breadth of the study content including detailed demographic, socioeconomic, health and 
wellbeing data allow researchers to investigate a number of different questions through a 
variety of disciplines. Epidemiological research using Understanding Society has included 
studies examining behavioural risk factors for obesity through patterns of diet and physical 
activity among young people 87 and the antecedents of hypertension among adults and the 
oldest old 88. Data from Understanding Society were recommended for use by NICE for 
investigation of epidemiological and social care trends (within the context of older people, 
although the scope of the survey is broader than this). 
11. Monitoring Social and Health care trends, experiences and monitoring the 
implementation of standards using Care Quality Commission data and reports  
One interviewee, expert in social care data, described how Care Quality Commission (CQC) 
data and reports were a useful source in establishing trends and monitoring the 
implementation of guidance and standards. Another interviewee described how the CQC 
were “getting it – you don’t have to use just this administrative data that is useless in 
measuring outcomes – there’s all this data instead”, and suggested the CQC as a case 
study of an organisation that was beginning to embed real-world data into daily practice. 
The CQC itself is dependent on returns, collects a number of different forms of data 
through inspection reports, and commissions a number of user experience surveys on 
different aspects of care, including clinical care experiences as well as community health 
and social care services. Survey data collected by CQC are generally made available 
through the UK Data Service for re-analysis.  
12. Gaining an insight into patient experiences using Patients Like Me  
‘Patients Like Me’ was recommended as a source of data for understanding the 
effectiveness of interventions through analysing patient experiences (as well as potentially 
providing data for economic modelling through quality of life measures). ‘Patients Like 
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Me’ provides data on patient experiences of treatments, as well more general data on 
symptomology, captured from web-based reports. Originally, the site restricted reports to 
a selected number of long-term conditions but since 2011 the site expanded to allow 
patients living with over 2000 different conditions to submit their data 9. The self-selected 
nature of participation, its international scope, and non-standardised forms of data 
collection, do represent caveats to UK settings as well as in the broader potential of the 
data to address scientific research questions. Nevertheless, some clinicians are interested 
in the potential that data from sites ‘Patients Like Me’ can have on understanding the 
effectiveness of interventions, and more importantly in the impact that social networking 
can have on patient choice including in terms of adherence to treatment regimens and the 
impact on the patient-clinician relationships 89.    
13. Tracking data on patient journeys in integrated delivery networks: the potential 
of Scottish Health Informatics (SHIP) 
Data from Scottish Health Informatics Programme (SHIP) were named as being of interest 
for NICE in their potential capabilities to track patient journeys through different contact 
with health service providers and specifically within the context of integrated delivery 
networks. SHIP is a collaboration between academic partners and NHS Scotland, described 
as “an ambitious, Scotland-wide research platform for the collation, management, 
dissemination and analysis of Electronic Patient Records (EPRs)”, while adhering to the 
Caldicott Principles around data collection 90. This task is made easier as “compared with 
the rest of the UK, data quality is high and the centralisation of data in NHS Scotland is 
efficient”10. This is an ongoing research project, but a number of SHIP related studies have 
already been published, with many focussed on diabetes care 91 92.  
14. Exploiting Hospital Episodes Statistics Data as a multipurpose dataset 
Hospital Episodes Statistics (HES) includes data on 1.25 million hospital admitted patient, 
outpatient and accident and emergency visits annually11. The data are thought to be 
highly accurate and representative given that they form the basis for payment by the NHS 
to hospitals for the care they deliver. HES is an example of a clinical database whose 
primary function as an administrative tool has morphed to allow for research into health 
trends. Time series data can be constructed to allow examination of changing trends since 
the late 1980s. HES is routinely linked to ONS mortality data but is also linked to other 
datasets including CPRD and some registry data. Access to HES is obtained through specific 
requests from the Health and Social Care Information Centre, although some interviewees 
described access procedures as laborious. Some of the fields collected in HES include: 
Admissions; Period of Care; Augmented/critical care; Clinical data; Diagnosis; Discharges; 
Episodes and spells; Geographical data; Healthcare resource groups (HRG) data; Maternity; 
Organisation data; Patient characteristic data; Patient Pathway data; Practitioner 
characteristics; Psychiatric care data; Patient Socio-economic Data; and System data. HES 
data are already in use by NICE, although there may be greater potential to use these data 
in the five core intended uses of real-world data, particularly where data are linked. HES 
                                            
9 http://www.patientslikeme.com/about 
10 http://www.scot-ship.ac.uk/overview.html 
11 http://www.hscic.gov.uk/hes 
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data were discussed by interviewees as being suitable for use for a number of functions for 
which NICE wish to use real-world data.  
15. Exploring Epidemiological Trends using the Avon Longitudinal Study of Parents 
and Children (ALSPAC)  
The ALSPAC is a cohort study of women who were pregnant and with a due date between 
April 1991 and December 1992 living in the historic county of Avon. In total, over 13,761 
women were recruited into the study contributing information on 13,867 pregnancies 93; 
additional information from other eligible children has meant that data from a total of 
15,247 pregnancies have been included in some form 94. Information from mothers and 
children has been collected on a range of topics since then through questionnaires and 
clinical assessments; data have been linked with Mortality and Cancer registry data as well 
as CPRD and HES data 95; and by March 2014 information from ALSPAC has appeared in 
over 1,000 peer-reviewed publications. ALSPAC data were suggested in terms of exploring 
epidemiological trends; the information may also have broader uses for NICE.  
16. Using information from an integrated learning system through the Salford 
Integrated Record 
One of the most consistent themes identified by interviewees was the need to expand on 
the data linkage properties of real-world data in order to track patient journeys through 
healthcare systems and ultimately improve patient outcomes. One example of a data 
source established with this aim is the Salford Integrated Record (SIR) which combines 
primary and secondary care contacts for around 97% of the population in Salford 9612, 
representing a population of approximately 300,000. SIR data are also extracted into the 
North West EHealth linked database (NWEH-LDB) and alert system, which was recently 
assessed in terms of its properties as a platform to support the delivery of pragmatic 
clinical trials 97. NB: This is one of a range of novel real-world data projects being 
undertaken in the North West (see http://www.herc.ac.uk/research-development/) 
17. Investigating the future application of GP records 
Many interviewees named different sources of GP level data that is made available for 
research purposes (see above). However, GP data are inputted and stored on a number 
platforms and are interrogated through different software and queries – Apollo, EMIS, 
System1, Vision, MIQUEST – and these were also variously named by interviewees in 
different contexts. Not all the data collected through these systems are currently made 
available for research purposes, although the same software are used for other audit 
purposes (see HSCIC website), and further investigation may be required to investigate 
their current and potential future applications.   
18. Understanding the effectiveness of interventions using National Joint Registry 
as a registry that is collecting longitudinal outcomes and patient reported 
outcomes 
The National Joint Registry was established in 2002 to collect information on all hip, knee, 
ankle, elbow and shoulder replacement operations and to monitor the performance of 
                                            
12 http://www.salfordccg.nhs.uk/documents/Publications/SIRA5Booklet.pdf 
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joint replacement implants13. It covers all replacement operations conducted in England, 
Wales and Northern Ireland and is one of the few disease registries to collect data on 
patient reported outcomes including quality of life, and also measures some indicators 
longitudinally (six months after the procedure). The registry has an active research 
programme and data from the registry are used to explore a number of biological, 
mechanical, clinical, economic, and social factors influencing the outcome of joint 
replacement. Data from this registry are recommended for use by NICE in investigating the 
effectiveness of interventions in real-world settings.  
19. Understanding the effectiveness of interventions and monitoring the impact of 
guidance using the Sentinel Stroke National Audit Programme (SSNAP) 
Different interviewees recommended data from the Sentinel Stroke National Audit 
Programme for use by NICE for providing a comprehensive understanding of the 
effectiveness of stroke care. These data were recommended as one of the few audit 
datasets that collect data longitudinally, although in the case of SSNAP this is a recent 
development. SSNAP aims to collect a minimum dataset for every stroke patient, 
including acute care, rehabilitation, 6-month follow-up, and outcome measures in 
England, Wales and Northern Ireland14. A key feature of the SSNAP programme is 
commitment to ‘harness the power of “Big Data” to produce near real-time data 
collection, analysis and reporting’ 98. SSNAP builds on a previous 15 year history of 
collecting information on stroke outcomes. SSNAP data have been used to monitor the 
effectiveness of interventions, monitor epidemiological trends as well as monitor the 
implementation of stroke guidance. 
20. Understanding the effectiveness of interventions and monitoring the impact of 
guidance using the Renal Registry 
Data from the UK Renal Registry (UKRR) were recommended on the basis of having ‘huge 
amounts of data’ from one interviewee, and were viewed as having potential in fulfilling 
many of the ambitions NICE has for the use of real-world data. The UKRR itself views itself 
as being one of the few high quality registries that is open to requests from researchers. 
The UKRR collects data from 71 adult and 13 paediatric renal centres across the UK. In 
2014, it published its 17th report that included demographic, biochemical, treatment and 
therapy characteristics, transplant waiting list information, geographic and demographic 
inequalities in access to services, as well as a number of key outcomes for renal patients15.  
21. Understanding the effectiveness of interventions and monitoring 
epidemiological trends using Adult critical care case mix programme (managed 
by ICNARC) 
ICNARC (Intensive Care National Audit & Research Centre) run the Case Mix Programme 
(CMP), an audit of patient outcomes from adult, general critical care units (intensive care 
and combined intensive care/high dependency units) with near-universal coverage (99% of 
critical care units) and collecting units from England, Wales and Northern Ireland. 
                                            
13 http://www.njrcentre.org.uk/njrcentre/default.aspx 
14 https://www.rcplondon.ac.uk/projects/sentinel-stroke-national-audit-programme 
15 https://www.renalreg.org/wp-content/uploads/2014/12/Report2014.pdf 
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Currently, the data collectors estimate that the data from 1.5 million patients are held16. 
Data quality is likely to be high, as reports are subject to 600 validation checks. Data 
collected for the CMP include unit identifiers, demographics (e.g. age, sex, and ethnicity), 
case mix (e.g. acute severity, comorbidity, surgical status, reason for admission), outcome 
(e.g. unit/acute hospital survival) and activity (e.g. unit/acute hospital length of stay) for 
each admission to each critical care unit17. The data have been used to address a number 
of research questions around epidemiological trends, such as the antecedent 
characteristics for sepsis for example 99, and around the effectiveness of interventions and 
examining the outcomes of critical care patients for example 100. 
22. Harnessing the potential of cardiovascular audit and register data to address 
NICE’s real world data needs 
A number of interviewees gave linked responses around the potential of a number of 
different sources of real-world data on cardiovascular disease and treatment. These tend 
to fall within the remit of the National Institute of Cardiovascular Outcomes Research Unit 
(NICOR) who run six National Clinical Audits (including MINAP, which was specifically 
named and described earlier) and five Healthcare Technology Registers, which record the 
implementation of cardiac related devices. The data tend to have good geographical 
coverage across the UK. NICOR welcome applications and collaborations for research using 
the data and also supply information to the DH and the Care Quality Commission. NICOR 
are experienced in data linkage projects with Hospital Episode Statistics (HES) data and 
Clinical Practice Research Datalink data. The six clinical audits (commissioned by the 
Health Quality Improvement Partnership (HQIP) include:  
a. Adult Cardiac Surgery Audit (with the Society for Cardiothoracic Surgeons) –
collecting all data on major heart surgery in the UK 
b. Adult percutaneous interventions audit – collecting information on adults receiving 
percutaneous cardiovascular intervention 
c. Cardiac Rhythm Management Audit – collecting information on adults receiving 
interventions for cardiac rhythm disorders 
d. Congenital Heart Disorder Audit – collecting information on children who receive 
intervention 
e. Heart failure Audit – collecting information on emergency admissions of patients 
with heart failure and their outcomes 
f. MINAP 
The five technology registers include: 
(a) Left atrial appendage occlusion register – monitoring the effectiveness of this 
intervention in preventing stroke 
(b) UK Neuromodulation registry – collecting data on all spinal cord stimulator (SCS), 
intrathecal drug delivery implant for pain and spasticity (ITDD) and peripheral 
nerve stimulator (PNS) procedures  
(c) Percutaneous mitral valve leaflet repair for mitral regurgitation (register) - 
evaluating percutaneous mitral valve repair effectiveness 
                                            
16 https://www.icnarc.org/Our-Audit/Audits/Cmp/About 
17 https://www.icnarc.org/Our-Audit/Audits/Cmp/About 
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(d) Patent foramen ovale closure – monitoring the effectiveness of this intervention in 
preventing stroke 
(e) Transcatheter Aortic Valve Implantation (TAVI) (register) – measuring the 
characteristics and clinical outcomes of patients receiving TAVI 
NICOR data is widely used in the literature for all of the functions for which NICE wants to 
use real-world data. NICOR audit data were recommended on the basis of the 
comprehensiveness in terms of scope, their near-universal nature, and their potential for 
research which aligned with NICE’s ambitions around real-world data. 
The interviews also revealed that work was being undertaken at the Farr Institute to link 
cardiovascular disease data (MINAP and other sources) with CPRD data.  
All information featured on the NICOR and/or from interviews: 
http://www.ucl.ac.uk/nicor 
23. Utilising data from the National Diabetes Audit; “the most advanced for long-
term conditions” 
The National Diabetes Audit was described by one interviewee as being ‘the most 
advanced [source of audit data] for long-term conditions’ due to its breadth and longevity. 
It is described by the Health and Social Care Information Centre as being the largest 
clinical audit in the world18, and integrates data from primary and secondary care 
providers, and sets out to address four key questions revolving around the diagnosis, care 
and treatment of complications among diabetes patients in England and Wales. The audit 
is commissioned by HQIP and conducted by HSCIC and Diabetes UK. It includes (i) National 
Diabetes Core Audit (NDA); (ii) National Diabetes Inpatient Audit (NaDIA); (iii) National 
Pregnancy in Diabetes (NPID) Audit; (iv) Patient Experience of Diabetes Services Survey 
(PEDS); (v) National Diabetes Audit of Footcare (NDFA). Data from the audit are used for a 
variety of research purposes and are likely to be useful for all the functions for which NICE 
wants to use real-world data.  
24. Capturing genetic information on biomarkers in the UK Biobank 
One of our interviewees expressed the view that biological markers needed to be 
promoted in epidemiological research and cited the UK Biobank as a development in this 
field.  
25. Calculating cost effectiveness based on data from the Personal and Social 
Services Research Unit 
The Personal and Social Services Research Unit (PSSRU) calculate unit costs for different 
social care packages in a unit cost report published annually. One interviewee 
recommended these data as the basis for cost effectiveness studies. The PSSRU also has a 
much broader remit and scope, being responsible for the development of many advances 
in social care data collection and measurement instruments including the ASCOT 
measurement tool for social care-related quality of life for individuals.  
                                            
18 http://www.hscic.gov.uk/nda 
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26. Mental Health and Learning Disabilities Data Set 
The Mental Health and Learning Disabilities Data Set (MHLDDS) data were described as one 
of the few real-world data sources capturing data on mental health by one interviewee. 
Formerly known as the Mental Health Minimum Data Set, these capture data about care 
delivered to users of NHS funded secondary mental health and learning disabilities services 
for adults in England19. While the scope of the data are relatively narrow, focussing on 
service usage rather than outcomes, the data may nevertheless be useful in establishing 
broad trends and standards around mental health; for example the 2014 focus on the 
distance travelled to access mental health services may help develop and monitor the 
implementation of quality standards around accessibility. 
27. Understanding trends in screening rates, healthcare and epidemiology using 
Quality and Outcomes Framework (QoF) data 
QoF data have an advantage over the primary care databases named above in having much 
higher levels of GP surgery coverage than all three combined (over 7300 in 2013/14). QoF 
data are based on an incentive programme open to GP surgeries in England that measures 
how GP surgeries are performing against indicators in terms of their clinical performance; 
public health responsibilities (a core set and an additional set); quality and productivity; 
and patient experience (other factors taken into consideration also include surgery 
workload, local demographics and the prevalence of chronic conditions). Individual 
patient-level data however are not collected which impede the usefulness of the data for 
NICE’s intended uses of real-world data. Nevertheless, the data may provide indicative 
evidence around questions relating to the monitoring of epidemiological trends and 
understanding the impact of implementing NICE guidance through monitoring trends over 
time at the surgery level. 
28. Understanding epidemiological trends and measuring the effectiveness of 
interventions using the UK Inflammatory Bowel Disease Audit  
The UK Inflammatory Bowel Disease Audit was discussed by one interviewee in the context 
of measuring an improvement in the treatment provided to patients (suffering with bowel 
disease) and being able to examining ‘cycles of improvement’. It is managed by the Royal 
College of Physicians. In the fourth round, reporting in 2014, the audit was composed of 
five elements (i) inpatient care audit (collecting information on the first 50 patients 
admitted with ulcerative colitis in each hospital); (ii) inpatient experience questionnaire 
(each patient included in the inpatient audit provided with a satisfaction questionnaire); 
(iii) biological therapy audit (treatment, delivery, disease activity and quality of life in 
patients who are prescribed Infliximab or Adalimumab for Inflammatory Bowel Disease); 
(iv) an organisational audit; (v) quality improvement initiative (sharing best practice). 
Data from the audit have been used for a variety of purposes of relevance to NICE, 
including examining resource use and exploring staffing requirements in IBD centres 101. 
29. Harnessing the potential of audit data to address NICE’s real world data needs 
through clinical audits conducted by the Royal College of Surgeons Clinical 
Effectiveness Unit 
                                            
19 http://www.hscic.gov.uk/catalogue/PUB16421 
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The Royal College of Surgeons (RCS) Clinical Effectiveness Unit (CEU) was named as a 
source of audit data that may address NICE’s real-world data needs across a range of 
conditions. This source of real-world data was named due to the breadth of audits being 
conducted under the direction of a single organisation, which may facilitate access and 
relationships and promote uniformity in data collection methods. The audits conducted by 
the RCS-CEU include:  
- National Audit of Oesophago-gastric Cancer – monitoring the care of patients with 
Oesophago-gastric Cancer. 
- National Bowel Cancer Audit - A national clinical audit monitoring the care of bowel 
cancer patients.  
- National Prostate Cancer Audit (NPCA) – Measuring standards around the care that men 
receive following a diagnosis of prostate cancer.  
- National Vascular Registry - Collects data and reports on the process of care and 
outcomes following: (i) Repair of abdominal aortic aneurysm; (ii) Carotid interventions 
to prevent stroke; (iii) Operations of the lower limb, including angioplasty, 
infrainguinal bypass and amputation. 
- CRANE Database – A registry of all children born with cleft lips and palates in England, 
Wales and Northern Ireland 
- National Emergency Laparotomy Audit (NELA) – An audit of emergency abdominal 
surgery in England and Wales 
*All data taken from the Royal College of Surgeons website 
https://www.rcseng.ac.uk/surgeons/research/surgical-research/ceu/projects  
30. Data used to populate NICE’s Return on Investment Tools 
Several sources of data are used to populate NICE’s return on investment (ROI) tools that 
aim to inform decisions taken by Local Authorities as to the likely impacts of their 
commissioning decisions. For example, the NICE ROI tool to understand the impact of 
tobacco use strategies and interventions uses data from several nationally representative 
data sources as the basis for estimates used in the tools – including the Integrated 
Household Survey (IHS), General Lifestyle Survey, statistics from the National Centre for 
Smoking Cessation and Training, and statistics from Annual survey of hours and earnings 
among others 102. These were suggested as sources of public health real-world data. 
31. Data from private health providers 
Data from private health providers (for example Bupa) were named as a potential source 
of data where the continuity of care and treatment pathways could be examined. While 
these data would have the disadvantage of being based on a small, unrepresentative 
(socioeconomically advantaged) section of the population, they may provide some of the 
only real-world data sources that could be used to monitor the continuity of care between 
clinical care and social care. Issues of access to these data and the quality of these data 
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are unknown. However, these data were identified as overcoming the barrier around ‘NHS 
databases where patients become invisible when they move from one setting to another’. 
Overall summary of real-world sources of data recommended: 
Themes: A number of themes emerged around the data sources recommended, which are 
also explored in section 4. These include: 
- The importance of regarding clinical audit and disease registry data as important 
and overlooked forms of real-world data 
- The importance of regarding survey data as an important and overlooked form of 
real-world data, particularly in terms of social care (and public health)  
Few datasets were mentioned twice (with exception of Stroke and cardiovascular audit 
data); in contrast there was greater saturation in the themes emerging around the 
properties and challenges of working with real-world data  
Gaps in real-world data sources: Some gaps have emerged in the map of real-world data: 
- An absence of real-world mental health data. This was recognised by one 
interviewee who observed “that in Cinderella area such as mental health, we have 
not tended to do a lot of measurements; [we need to] get them up and running“.  
o From the additional mapping exercises an additional five sources of relevant 
mental health data were identified, of which the ‘Community Mental Health 
User Survey’ and the ‘Prescribing Observatory for Mental Health’ may be 
particularly relevant in addressing NICE’s real-world data needs 
- Data specifically focussed around resource use  
o In addition to the social care workforce data identified above, two data 
sources on the GP workforce and Diabetes specialist workforce were 
identified from the additional mapping exercises. 
o From the additional mapping exercise, additional real-world data sources 
that provided pharmacoepidemiological information on medication usage 
were identified: Tayside Medicines Monitoring Unit (MeMo); Prescribing 
Analysis and Cost (PACT) data; Hospital Pharmacy Audit Index; Electronic 
Prescribing Analysis and Cost Tool (ePACT); Prescription Pricing Authority 
database; IMS Health databases (Medical Data Index); IMS Health databases 
(MIDAS Prescribing Insights); Prescribing Observatory for Mental Health; 
British Society of Rheumatology Biologics Register (BSRBR); UK HIV Drug 
Resistance Database; Biologics were also represented in the Bowel Disease 
Audit  
- Data sources that incorporated patient reported outcomes and digital technologies 
as standard were in the minority; although there are efforts underway to improve 
the recording of Patient Reported Outcomes taking place across the NHS29  
- Few specific data sources from commercial delivery organisations such as data 
from private healthcare insurers were identified; no data sources on over-the-
counter medications were identified; few data sources from the voluntary sector 
were identified except where organisations were working in partnership with 
statutory organisations or Royal Colleges (e.g. in the case of Diabetes UK) or where 
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their activities were linked to quality standards. One source did state that data 
from charities were often overlooked. 
- Qualitative real-world data in health and social care virtually absent 
- Finally, the direction of real-world data is to be able to link different sections of 
patient journeys as standard. Few models emerged that were actually able to 
perform this function as standard, a notable exception being the Salford Integrated 
Record.  
How is NICE currently using real-world data? 
NICE conducted a review of its internal use of real-world data across its Impact and 
Evaluation; Costing and Commissioning; Internal Clinical Guidelines (CCP); Health and 
Social Care; Safe staffing; National Clinical Guideline Centre, National Collaborating 
Centre for Mental Health, National Collaborating Centre for Cancer and Social care teams. 
This review asked teams to name which data source was currently being used, how these 
data were accessed, processes employed for accessing data, associated costs; and a brief 
description of how the data were used. From this review, twenty-four datasets were 
identified in use (with some having multiple uses – a total of 3720 different combinations of 
datasets/uses/teams were reported across NICE; see Appendix 4 for full list): 
 The majority of data are used, internally at least, to either (i) inform on the 
uptake of NICE guidance and/or explore use of medication (nine reports could be 
described in this way (one represented future plans)); or (ii) for health economic 
modelling (twenty reports could be described in this way).  
 Some of the data appear to support the development of quality standards 
particularly around safe levels of staffing (three reports could be described in this 
way) 
 There was one reported use of data for monitoring epidemiological and 
demographic trends (ONS data was reported as being used for this purpose, 
although the precise dataset was not reported); Lifetable and mortality data was 
also used 
 One dataset was described as being used to establish the effectiveness of 
interventions (Primary Care level data using the IMS Disease Analyser; see 103 for an 
example of NICE’s use of these data) 
 There was a mixture between data that was accessed in aggregate form (pre-
constructed tables) and patient/surgery/hospital level data that was used for 
further interrogation and re-analysis 
 Clinical audit/disease registry data was reported twice: NICE is currently engaged 
in discussions to access the Systemic Anti-Cancer Therapy (SATC) dataset to gather 
data on the uptake of medicines; clinical audit data was identified as being used 
although the precise nature of use and the name of the audit was missing.  
 Two forms of survey data were reported – the Health Survey for England and the 
National Cancer Patient Experience Survey; the former was reported as beneficial 
for quality of life data and data on ethnicity 
 One Primary Care database was in current use – The Health Improvement Network 
data (on request from HSCIC); primary care data is also found through the IMS 
Disease Analyser 
                                            
20 Excludes one dataset that was not deemed to be real-world data 
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 One of the most frequently accessed datasets Hospital Episodes Statistics data 
 Licences have been purchased for three datasets for internal analyses: IMS Disease 
Analyser data, Hospital Episodes Statistics and the UK Nursing Database   
 The most common gateway for accessing health and social care data was through 
the Health and Social Care Information Centre 
How does the way in which NICE utilises data differ from the topography of the real-
world data landscape 
 
A full assessment of the way in which NICE utilises real-world data is only be possible with 
the addition of input from external agencies and partners through which NICE may 
commission work. Furthermore, other uses for data may be supported under broad 
headings in Appendix 4 such as ‘ad hoc’ enquiries or ‘ONS’. However, the evidence suggest 
NICE’s internal use of real-world data differs from the real-world data landscape in the 
following ways: 
 The use of clinical audit data by NICE does not match the widespread 
availability of these data; no specific clinical audit data were mentioned as being 
currently in use. In addition, one of our interviewees emphasised this through 
observing “So it’s National Clinical Audits that are hugely useful and 
underexploited for all the five legitimate purposes that absolutely NICE need to 
fulfil” 
 The use of disease registry data by NICE does not match the widespread 
availability of these data; no specific disease registry data were mentioned as 
being currently in use 
 Survey data are underutilised and was mentioned explicitly on two occasions 
(although may be captured under broad headings such as ‘ONS’ or ‘HSCIC’ data; 
further explication was not provided on these) 
 Most of the data sources/functions currently in use appears to allow for cross-
sectional analyses or repeated cross-sectional analyses only; patient-level 
longitudinal analyses appear to be conducted rarely  
 Few datasets used by NICE capture Patient Reported Outcomes; one exception is 
the National Cancer Patient Experience survey 
 NICE use an extensive array of different datasets to support understanding trends 
and the economic modelling of changes in prescribing trends 
 There were no reports of NICE requesting additional data to be collected alongside 
standard data in any of the real-world sources 
 Few real world data were reported as being employed to research the 
effectiveness of interventions 
 Few real world data were reported as being employed to establish epidemiological 
trends 
 Primary care data is mainly accessed through sources based on The Health 
Improvement Network data.  
 Few of the existing sources allow for linkage across different services which a 
patient or service user may experience; however, these types of data were also 
underrepresented in the results of the mapping exercise 
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 For social care, none of the datasets described are directly sourced and explicitly 
focus on monitoring trends in private provision despite private provision being 
hugely important for the sector; these data were also underrepresented in the 
results of the mapping exercise 
In-depth choices for mapping  
From this long-list of 30+ data sources, a selection of eleven was chosen for in-depth 
profiling based on input from a NICE steering group (see Section 5). Datasets were 
prioritised if they were those that were not in current use by NICE and where they 
appeared to meet some of the broader gaps in usage and the themes emerging from the 
interviews (see section 3). Although the long list of recommended datasets presented 
included a number of audit and registry data sources that NICE were not currently using, 
most of these were not selected for in-depth profiling because it was felt that there would 
be high levels of organisational familiarity with these datasets. Instead, an allied separate 
exercise was put into place to map out how NICE used registry and audit data and how this 
could be expanded in the future; the results of this exercise will be published separately 
from the present study.  
We used the template developed in Section 1 around the characteristics that make for 
good quality sources of real-world data as well as assessing the utility of the different 
sources for NICE’s intended purposes as the framework for profiling each data source. This 
framework was populated through a narrative review of the literature as well as reviewing 
any accompanying study documentation; some information on the data was also collected 
from the interviews. The exercise of profiling each data source was conducted in abstract 
without a fixed research question defined, and consequently we do not give an overall 
score or rating for any data source. Nevertheless, it is clear that all the data sources 
included for in-depth profiling could make substantial contributions to the work of NICE as 
is the case for those included in the ‘long-list’. While the profiles give a grounding in some 
of the properties of the data, such is the complexity of all of the data sources, any use of 
the data by NICE will require significant investment in terms of time and training, and in 
some cases, cost. However, as is clear from the profiles, the returns on this investment 
are potentially large when beginning to use any one of the data sources included here, or 
any of those described earlier in this chapter. Section 4 includes the detailed profiles 
while section 5 includes some analysis of the findings of these.  
The data sources selected for in-depth profiling were: 
1 QResearch 
2 THIN 
3 CPRD 
4 ELSA data 
5 NMDS-SC 
6 Salford Integrated Record  
7 Community Mental Health User Survey 
8 Prescribing Observatory for Mental Health 
9 Health Survey for England 
10 Adult Social Care Survey 
11 Care.data 
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Section 3 (Findings II): Broader cross-cutting debates and themes 
 
Cross-cutting themes 
What does real-world data mean? 
We include a discussion on the meaning of real-world data as this may help to shape the 
remit of any real-world data projects that NICE may undertake in future. 
Most of our interviewees described the tenets outlined earlier as being indicative of real-
world data and described real-world data as being ‘about types of services, people that 
use the services and how the money is spent’. This aligns closely with conceptualisations 
of Healthcare Technology Assessment itself in the literature, as the study of ‘medical, 
social, ethical and economic implications of development, diffusion, and use of health 
technology’ 104. Such alignment reinforces the role of real-world data as an essential tool 
for NICE. In describing real world data, there was a tendency among some to focus on 
routinely collected/administrative data, particularly among clinical and public health 
experts, and an emphasis on the quality of the data: “[real world data is] electronic 
pulling of data from lots of different sources with standard quality assurance processes – 
accepted in a huge range of formats and transformed. So very extreme: [at] one end hand 
written facts from doctor’s letter to a completed formatted xml structured file that has 
all data and fits a national file… you can accept anything in-between algorithms can be 
put in place that flag the quality of data”. 
This aligns with the literature where much of the data collected in primary care is viewed 
as a by-product of administrative activity. Some experts had a broader conceptualisation, 
seeing real-world data as being data that ‘provides insight on patients in the natural 
setting for that patient’. Among social care experts, the definition of real world data 
tended to be broader from the outset and survey data was much more likely to be 
included in accounts when social care expert interviewees described different forms of 
real-world data. Social care experts stated that the terminology of ‘real world data’ was 
less common in the field, although an allied term was not used in its place. This may 
reflect the findings of previous studies where inconsistent terminology was viewed as a 
barrier to mapping the availability of real-world data holistically 3. Some interviewees also 
stressed a distinction between real-world datasets which may represent amalgamations of 
multiple primary sources of data, and data sources, which were suggestive of primary or 
single sources. 
The breadth in the definition of real-world data was viewed as problematic by some; for 
example one interviewee could foresee that bringing too much breadth into a definition of 
real-world data increased the risk of diluting the quality of data under consideration: 
‘Real world data or all world data or just all data’. While most interviewees were 
comfortable with surveys and other forms of structured observational data being included 
in a definition of real-world data, newer potential sources of real-world data, particularly 
data that could be collected through apps or from unpublished sources, or views data from 
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other forms of social media, were not mentioned by interviewees. One exception was that 
one social care data expert described how blogs and other alternative sources of data, 
including Local Authority committee meeting minutes were useful sources for discovering 
the existence of other, less well known or not routinely published information, but not as 
primary sources in of themselves. Data from these sources will likely be of lower quality 
and subject to fewer robustness checks compared to larger data sources, although the 
content may nevertheless be unavailable from other sources.   
Not all interviewees were familiar with, or agreed with the terminology ‘real-world data’, 
with one interviewee observing “I don’t see any unreal data”. Some preferred referring to 
these data more transparently as ‘routinely collected data’. This may be worth noting 
when NICE are engaging in discussions about these issues externally.  
Tracking patient and service user journeys 
Two intertwined recurrent themes emerged from the fieldwork conducted, and these are 
not explicitly highlighted in these terms in the literature. Interviewees were asked about 
data that were suitable for tracking patient and service user journeys and trajectories. 
Overwhelmingly, respondents across all sectors described that this undertaking was 
fraught with difficulty. Much of this challenge was attributed to difficulties in being able 
to link data between sources using a common identifier, although among those 
respondents who were more expert in clinical health sources it was recognised that 
considerable efforts were being undertaken to link across different sets.  
 
“Two important datasets – and they just don’t talk to each other…..We have all these 
datasets not linking at the minute and [those responsible] are blocking any linkage” 
 
 
A good example of the difficulty in tracking journeys was described by an interviewee 
expert in clinical health data sources. He described a situation where an individual had 
suffered a heart attack and was diabetic. Their records should appear across multiple 
sources of data – for example in Myocardial Ischaemia National Audit Project (MINAP) data, 
National Diabetes Audit data; they should also be recorded in Hospital Episodes Statistics 
Data and in Clinical Practice Research Datalink (CPRD) data. However, the record of the 
same patient having suffered a heart attack and being diabetic appearing consistently 
across different data sources was thought to be relatively low – our interviewee gave an 
estimate of this occurring two-thirds of the time (although stressed that further 
verification was needed around this estimate). Regardless of the specific level, in common 
with other interviewees he identified that consistency across data sources hampered 
obtaining an accurate record of patient and service user journeys and trajectories. 
Inconsistencies reflected non-standardised data collection practices which led to 
differences in constructs and the type of information collected, but also in terms of the 
timeliness and updating algorithms of the data sources. 
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“So I think there is a lot of data out there which would be good for multiple purposes 
not necessarily the primary purposes it has been gathered for. But equally there is a 
total lack of joining up.” 
This theme was also present in the interviewees who spoke about social care data. Here 
the challenge was compounded by the issue of defining care packages and care 
trajectories, and the disparity between the inflexibility of data collection systems and the 
multiplicity of different care pathways and providers who would provide care: “working 
with them [real world data] trying to work our social care issues how traditional ‘care 
pathways’ work – they are problematic in social care with the multiplicity based on the 
individual person care package–environment mix”.  However, one social care interviewee 
suggested that this picture was changing as they gained access to case records directly 
from local authorities, suggesting that social care real-world data access may be highly 
dependent on establishing good relationships with individual authorities: 
 
“we are starting to use information from case records, this is in partnership with Local 
Authorities , and they are able to share some of that information for us to use” 
 
 
However, while most interviewees have been pessimistic about the capacity to trace 
patient and service user trajectories and journeys, some did express the view that this was 
a rapidly changing situation. For example one interviewee spoke of the rapid 
developments in linking different types of cancer data in forming the contents of the 
National Cancer Data Repository, and the rapidly expanding breadth of data being linked, 
including radiography and chemotherapy treatment and outcome data that enable the 
improved tracking of patient journeys. Some of these linkage exercises have taken place 
on a pilot basis where only extracts of data have been linked whereas others are now fully 
operational. Many of these developments had only taken place in the past five years, and 
clearly this is a rapidly changing field. In addition, a common theme among some of the 
interviewees was the importance of user and data community groups in helping to progress 
the breadth and usability of different datasets. Representation on such user groups can 
enable organisations and individuals to both keep pace with developments but also to 
influence how sources of real world data are enhanced to meet users’ needs. 
Nevertheless, despite these positive glimmers, the overwhelming theme in these findings 
is that tracing patient and service user trajectories and long-term outcomes is challenging, 
and where this is possible, it likely means working closely with data depositors and 
controllers to shape and customise the dataset. An example of such a collaborative 
approach is found in the Salford Integrated Record project.  
This theme does complement previous literature in this area, but is expressed differently 
in the literature through emphasis on the substantial fragmentation in sources of real-
world data 2 3 18 19 105, which presumably hampers tracking patients and service user 
journeys. For example Newton and Garner 3 had discovered up to 400 specific clinical 
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registers in England alone in their review; Raftery and colleagues discovered over 270 
sources of real world data in their comprehensive review of registries and databases 19; 
more recently Rankin and Best 105 identified approximately 20 registers with a narrow 
focus on four childhood chronic diseases. There are likely to be considerable overlaps 
between such fragmented sources of data. In our interviews the fragmentation in data 
sources was expressed in terms of the consequences of this fragmentation, and in 
particular the difficulty in tracking patient and service user journeys longitudinally. The 
absence of a common identifier between sources was identified as a prime contributory 
factor to this. 
 
“if you want to understand hospital admission for example in relation to social care 
episodes and you want to identify the same people who enter with respite care then go 
out for hospital operation then to an agency for domiciliary care you would need to 
have key I.D for this and these are not available – we have leads in terms of the health 
side but not the social care side”.   
 
 
However, new data sources are being developed and many of these are based on the 
linkage of other routinely collected health and social care data sources, including those 
intended to track healthcare pathways and contact with different providers (for example 
the Suicide Information Database-Cymru 42). Elsewhere technology and the use of routine 
data (for example through electronic health records) have been identified as critical in 
meeting new challenges, such as implementing integrated care systems 46. The literature 
and our interviews confirm that while historically there have been poor mechanisms for 
tracing patient journeys, this is an evolving picture. The question is whether this situation 
is evolving quickly enough to meet the demands of the changing health and social care 
landscape, and particularly in terms of providing evidence to support these big challenges.  
Determining treatment options and quality of data 
Real world data’s particular strength is the potential to provide the most complete picture 
available about the health and care patterns of the nation as conceivably possible 2. This 
picture is composed of data that isn’t derived from an unrepresentative subset of the 
population, but provides a population-based snapshot of contacts with providers that take 
place and information on illness or care needs, treatments or care packages, and ideally 
provides enough information on the outcomes of individuals and their use of other health 
and social care services. The quality of each data set varies greatly in content and what 
type of data has been collected. It is therefore up to the scrutiny of individual and what is 
required from the data as to where the balance lies between breadth and depth.  
 
“There is a trade-off between having more information in terms of numbers and 
information in terms of breadth and depth of indicators. So survey data such as ELSA 
[English Longitudinal Study of Ageing] will give you a lot more in terms of quality of 
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characteristics – income, wealth, needs, households’ composition, service users etc. 
Certain outcomes will be much more limited on the other hand data from services; 
there will be thousands of cases in other sources - but much more limited – and the 
data and may not be of the same quality. We try to combine the data, look at patterns 
from both”. 
 
 
Data quality has been recognised as an issue of real-world data by many in the literature 1 
and despite the population-based design, several groups are known to be 
underrepresented in these data. These include women, children, the very elderly, ethnic 
minorities and those with multiple co-morbidities 37. Some studies suggest that where 
patients are missed in real-world data sources, they may have systematically different 
characteristics. In one examination of the MASCARA (Manejo del Síndrome Coronario Agudo 
Registro Actualizado) register, a hospital-based cardiovascular register, patients who were 
‘missed’ off the register had higher risk profiles of cardiac events and received fewer 
recommended therapies than included patients; in addition mortality was almost three 
times higher 40. Furthermore, the study also found that few users of disease registry data 
acknowledged the potential selection bias in the limitations of their findings 40. 
Representativeness of data and information from hard-to-reach groups may be improved 
through obtaining multi-site data, although this can introduce further problems around 
fragmentation and diversity in administrative systems.  
Our interviewees described problems in the quality of the data around these groups and 
more often pointed to their invisibility in several real-world data sources (i.e. several 
sources do not collect information on ethnicity, sexual orientation etc.), impeding the 
ability to research inequalities in the services and treatments that different groups 
receive. More importantly numerous other fields around co-morbidities and the receipt of 
other treatment regimens may also be missing 34. Some interviewees described 
approaching or working with other organisations to obtain real-world data where possible; 
for example they described approaching bodies such as the Equalities and Human Rights 
Commission or charity or representative groups such as Stonewall. However, these data 
may have a different set of strengths and weaknesses attached to them and in particular, 
such data may not be subject to the same quality assessments as other sources of real-
world data.  
Proponents of real-world data point to its potential in achieving a ‘learning health 
system’, which help inform both patients and clinicians to improve how they make 
decisions during clinical visits 23. However, a fundamental disadvantage of real world data 
according to our interviewees is the absence of contextual information around the 
patient/service user, the provider and local practice. This was mentioned specifically 
around the ambition to ‘research the effectiveness of interventions or practice’. Missing 
contextual data means that associations observed in real world data models can be 
subject to endogeneity as the results may be compromised by omitted variables and 
unobserved factors governing selection into different treatment regimens. Such contextual 
data can explain why patients, who according to observed variables are identical in socio-
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demographic characteristics, co-morbidities, and disease progression, are prescribed 
different treatment or care packages. These unobserved variables are likely to be 
instrumental in determining patient outcomes, although are usually minimised or balanced 
across groups in randomised designs. Such unobserved factors are also a reflection that 
real-world data, and certainly those collected on a routine basis, are not collected with a 
particular underlying theme or research question in mind (this was also a recurrent theme 
in the interviews). This means that it is often the case that constructs in real world data 
(especially routinely collected data) can be outdated and data collectors can de-prioritise 
the collection of constructs or information that are of substantial value for research 
purposes.  
Interviewees did not recommend a particular source of data or statistical technique that 
could be used to minimise this form of bias and it was recognised that such bias could 
arise in multiple ways. One recommendation was that any real world data project should 
involve a clinician to discuss the potential factors around treatment options and why and 
how variations in treatment regimens arise; while this would not eliminate the issue it 
would help to understand the magnitude of potential unobserved variables. Real-world 
data projects should not be undertaken in isolation of clinical expertise; doing so risks 
ignoring potentially important sources of unobserved heterogeneity. The problem of 
unobserved confounding variables was not limited to clinical real world data projects, but 
was recognised as a limitation of social care real-world data projects where unobserved 
factors around the provision of unpaid care and the unmeasured support being provided 
represented a substantial limitation: “putting the person at the centre of package of care 
means it is sometimes difficult to record those additional elements for that package of 
care within the statistics that are recorded and measurable… other elements of the 
package not normally delivered uniquely by local authority: the carer, friends, family all 
of the non-recordable effects in an individual life”.  
Proof of concept: how should we measure the robustness of real world data? 
The main defining advantage of real-world data, besides apparent advantages in terms of 
cost, sample size and representativeness, is its (ostensibly) high external validity 1. The 
external validity reflects both the delivery of an intervention (to a group that is 
representative of the general population), but more crucially in the delivery of the 
control, which usually involves an alternative treatment regimen (best available 
alternative) as opposed to a placebo. While there is an expanding literature citing studies 
and study protocols that have been conducted using real-world data, interviewees (those 
from clinical backgrounds) emphasised that real-world data was not a replacement for/did 
not supersede the findings from RCT studies. Real-world data is prone to forms of 
epidemiological bias unlikely to be replicated in findings from well designed and executed 
RCT studies 1 3; however, as several interviewees pointed out, RCT study data can also be 
subject to bias, and some felt that observational data was subject to greater scrutiny 
despite its often superior properties in terms of transparency, than RCT data are. Others 
highlighted that there was a need for undertaking activities and developing methods 
aimed at bridging the divide between RCT and non-RCT studies; pragmatic trials may be 
one way; recruitment of patients who have a greater resemblance to ‘real patients’ may 
be another.  
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While there are examples of studies that have considered undertaking RCTs studies using 
routinely collected real-world data as a basis for sample selection or otherwise informing 
the design of the study 1, some of our interviewees felt that more should be done to 
evaluate the properties of real-world data and to understand the magnitude of potential 
bias within real-world data studies. Specifically, some viewed that a true mark of the 
robustness of observational data is the ability to replicate the findings of RCT studies in 
carefully matched real-world data studies. While other interviewees felt that this notion 
was an underlying motive behind many real-world data validation studies for example 69 
106, for some this avenue of enquiry, and particularly moving beyond construct validation 
studies, was an important ‘proof of concept’ for real-world data studies. However, there 
are also several reasons why results of RCT and observational data may not be concordant, 
and separating out the influence of bias from the influence of measuring effectiveness vs 
efficacy and explaining the ‘real-worldness’ is difficult. A lack of replication of results of 
real world data can both symbolise the strength or real-world data, as well as its 
limitation. 
Future directions 
Two themes emerged around future potential of real-world data. The first of these is 
around the expanding potential of pragmatic clinical trials (PCTs). Unlike traditional RCTs, 
PCTs are trials that take place within real-world environments and among representative 
samples of patients, thereby placing the focus on establishing the effectiveness of 
interventions, as opposed to their efficacy. Within a PCT, patients are randomised to 
receive an intervention or control treatment but the focus on mimicking real-world 
conditions means that, among other factors: (i) the control treatment provided often 
represents the best viable alternative already in place (as opposed to a placebo as can be 
the case in some RCTs), (ii) the patients randomised have reflect the normal range of 
patients in terms of disease severity, comorbidity and demographic characteristics; and 
(iii) the measures of effectiveness collected as outcomes are valid and easily understood 
by a range of stakeholders, including clinicians, patients, policy-makers, and health 
commissioners. Real-world data collected through electronic health records was viewed as 
the basis for designing and undertaking a greater number of pragmatic trials (PCTs) and a 
number of real-world sources theoretically provide the means of implementing studies and 
monitoring outcomes in real-time. Evidence from PCTs is likely to be of substantial 
interest to NICE in establishing the effectiveness of interventions in real world settings 
while maintaining randomisation, thereby eliminating or at least substantially reducing the 
occurrence of channelling bias; the proliferation of real world data sources may facilitate 
this form of evidence to become increasingly frequent in the future. 
 
In practice the trial has been useful as it utilises routinely collected health records to run 
trials to observe patient’s responses to drugs…pragmatic trials where you randomise 
patients and everything is closely monitored in the real world unlike a randomised trial. 
Pragmatic trials are very different as they represent a broad sample of clinicians and 
patients. There is a wide range of data collection … whole purpose is in keeping it simple 
and keeping it real. 
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A second theme that emerged was around new technologies stimulating new forms of real 
world data to be collected. Methods of collecting patient reported outcomes were thought 
to be shifting from paper to digital devices (smartphones and tablets): “we have a lot of 
interest in technology where people get messages on their mobile phone to fill out 
symptoms, whether these are severe and so on. Uptake is very good and this type of 
model can be utilised for trials quite easily… where you have mobile phone technology 
sending information you don’t have lots of paperwork… modern technology can help a lot 
with that. Also with ipads there is a strong movement to increases use in that.”   
 
For me a survey could be sending a message to a patient on a regular basis surveying their 
experiences. The old model of surveys will be disappearing, keeping it simple. For me in 
that sense is simple data collection can be collection such as using disease registry 
 
 
Patient and service user views are underrepresented in most real-world data sources 
There are substantial disjoints in the translation processes between establishing the 
efficacy and safety of new medical interventions through experimental studies and the 
implementation of such technologies into everyday practice 37. Key in establishing the 
effectiveness of new technologies is establishing that the voice and views of patients and 
service users are represented. All interviewees felt that this was a weakness of routinely 
collected real-world data. However, some respondents did report that there were 
increasing efforts underway to secure the linkage of data that more broadly reflects 
patient wellbeing to existing real-world datasets. For example the National Cancer Data 
Repository has considered information on quality of life 107. There are also programs of 
NHS surveys (some described in this report) measuring patient satisfaction if not 
‘outcomes’ per se. Additionally, this situation is likely to change rapidly over the next few 
years as the data and the ability to link different forms of data are enhanced. As one 
interviewee reported: “Eventually we would like to link [our data on cancer] with mental 
health, cardiovascular disease; we would love to pull social security records to know how 
cancer can impact on going back to work or not; it would be wonderful to know.” 
At the moment, survey data usually provide indications of public views and attitudes, and 
these can reflect experiences of the services provided (e.g. satisfaction with the NHS has 
been collected as part of the British Social Attitudes survey), although these data rarely 
have the depth of information necessary to measure how views and quality of life varies 
across different patient trajectories and the necessary sample size to study how these 
vary across different treatments or care packages. None of our interviewees mentioned 
sources of qualitative information that were collected routinely as part of real-world data 
projects.    
The lack of patient voices in real world data as they stand does serve as an impediment on 
the ambition of NICE to holistically research the effectiveness of interventions or practice 
or to establish quality guidance since this type of data does form an important component 
for these assessments. The lack of data on patient views and experiences is also at odds 
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with the potential capacity of real-world data to establish the effectiveness of treatments 
and care packages. 
Patient Consent and Awareness 
Some of the experts interviewed discussed issues of consent and in particular viewed the 
ambiguities around where consent has been gained and patient and service user 
expectations around how data were used. In relation to how consent is obtained through 
hospital and GP surgeries it seems at times could be problematic. One interviewee shared 
the awkwardness felt by some GPs’ when asking for consent: “when patients don’t give 
consent, GP’s are nervous and it puts them in an imposition to get consent... when there 
is uncertainty the easiest thing to do is not to do anything.” A further interviewee 
highlighted the contrast between public acceptance for data on shopping behaviours to be 
collected and analysed by large supermarkets to personalise shopping experiences, but 
comparative reluctance for medical researchers to conduct a similar undertaking. Some 
experts also felt that the publicity surrounding care.data had also (temporarily) 
disadvantaged the position of real-world data depositors. Concern around consent is 
echoed in the literature where in 2004, Black and colleagues found that only a fifth of 
databases had collected any form of consent or included an opt-out clause 18. Elsewhere, 
consent has been described as ‘gold standard yet problematic’ 3  
The current consensus is that while issues around patient consent in the collection of 
many sources of real-world data are unlikely to breach the constraints of the Data 
Protection Act, the ambiguity and lack of patient and service user awareness of where 
data is collected and how it is analysed does restrict the expanded use of real world data. 
In particular, one interviewee expressed concern that patient data was being sold and 
managed by commercial organisations, and much of the public would be unaware of this 
commercial arrangement. Where patient consent was raised as an issue, it was also felt 
that this would also be reflected in the quality and breadth of the data: “there are 
differences in nature of the studies in terms of consent which are reflected in a way of 
the quality of the data”. 
 
“The public doesn’t like the sounds of real-world data but if the information is 
communicated that it is used to improve care and that is what is happening it will not 
put people off. But the sound of big databases farming it [patient data] out puts 
people off” 
 
 
Data for epidemiological purposes   
Examples of survey data were usually cited when considering the type of real-world data 
that may be suitable for establishing epidemiological trends. However, for rare or genetic 
conditions some viewed registry data as holding potential. One expert gave the example of 
Familial hypercholesterolemia, a genetic disorder, and the way in which registry data 
could be used as a surveillance system for monitoring trends and identifying potentially 
high risk patients. Some of the certain markers of the disorder are high levels of 
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cholesterol and heart failure occurring among younger people aged 45 years and under. 
Heart failure registry data could be used to identify these cases where there was a high 
likelihood of the disorder among individuals and procedures around cascade testing from 
these individuals could be used then to identify other family members likely to be 
susceptible.  
Specific issues in social care data 
Real world data in social care  
The interviewees who were expert in social care data sources reported that ‘real world’ 
data was a less frequently used term within social care circles. In the literature, some 
have claimed that in the case of social care real world data, the data are limited due to 
the difficulty in identifying meaningful outcomes for social care service users 108, and that 
this has led to data collection being focussed on information on outputs and costs more so 
than the type of data needed to fully assess and understand the effectiveness of different 
social care models.  Social care real world data sources were more likely to include survey 
data, although even these were perceived as having disadvantages in the breadth of the 
additional contextual data that was included and that they were: “able to offer some 
level of baseline information…but there are restrictions on what information they can 
give; real world data are good at giving statistical elements but not good giving the 
things that aren’t recorded…more of the social side and we’re obviously more interested 
in this in the social care sector”. Therefore the multiplicity of care sources, particularly 
unpaid care sources, that are usually part of an individual’s care package are difficult to 
assess and measure and “makes it difficult to assess ‘real worldness’ of the data.”; in 
addition, this limited the extent to which new and emerging problems in social care 
delivery could be investigated, such as the increased risk of financial abuse following 
moves towards personalised budgets.  
Aggregate vs individual level data 
For social care in particular, our interviewees reported that there are substantial 
challenges in obtaining individual level data (as opposed to aggregate data) that allow for 
re-analysis and full secondary data analysis. While the data are initially collected in 
individual form, they can only be deposited into national repositories in aggregate form 
(which is viewed as an unnecessary burden on Local Authorities who input the data, and a 
hindrance to researchers who want to use the data). Large-scale survey data provides 
complementary information but provides only small sample sizes of health and social care 
service users. Data sharing arrangements with individual Local Authorities are one way of 
overcoming the challenge of obtaining service-user level data, although establishing these 
arrangements are time consuming: 
 
“Social care services – 152 Local Authorities! They’re happy to set agreements and we 
can get their data if we help them to understand the advantages – but it’s very time 
consuming and complicated!”  
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A patchwork quilt of social care data 
Interviewees described that real world social care data was like a patchwork quilt. Unlike 
clinical data where many broad research questions are addressed using a single source of 
data, some of our interviewees reported a mosaic of different sources was necessary to 
address social care research questions. One interviewee described the process of finding 
social care real world data akin to ‘detective work’ and would consult with a variety of 
secondary sources in order to uncover new or alternative sources of real-world data. 
Another interviewee described that this situation was unlikely to change in the near future 
as there was a lack of strategic coordination and leadership in coordination issues around 
social care data in the sector: “social care is underrepresented in real-world data per se; 
we have HSCIC but there are differences in between what is collected and how we 
measure effectiveness ….Historically far more money was put into pharmaceuticals 
research – and interest in health research than health and social care, and this is 
reflected in the availability and quality of data.”  However, a new strategy around care 
information that has been developed by HSCIC may go some way in addressing this gap21. 
Private sector sources of data do exist and are used but have limitations that are not 
always shared with public sector data 
Expert interviewees did not express consensus in the availability and representativeness of 
data. While some claimed that “you can get just as much private sector information as 
public you need to know where to look”, others were more sceptical about the 
representativeness of social care data in terms of private providers. In particular, many of 
the real-world data sources that were named did not provide, and in many cases collect, 
individual level data and focussed instead on aggregated data (e.g. residential care home 
returns may have been available but data needed to track individual level transitions may 
be unavailable). However, there are cases in the literature where real-world data 
collected routinely on an individual basis from private providers have been used, for 
example in comparing health and social care outcomes between domiciliary care 
recipients and outcomes for residents of housing with care 109. These alternative sources 
may also be subject to different data collection protocols and are likely to differ 
substantially in terms of quality.  
Overall, sources of individual level data were identified as being more prone to being 
unrepresentative of the experiences of privately funded social care service users. For 
example, while the Adult Social Care Survey collects data on social care users’ and carers’ 
experiences from a large-sample, this does not include those who self-fund, who account 
for up to 45% of those in residential care 110.  
 
“The social care system in England is means tested and there are a substantial number 
of older people who are excluded on the grounds of income and wealth. There are very 
few data sources, ELSA being one of them, that tell us anything about what is 
happening to those people” 
                                            
21 See 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/443353/HSCIC-
Strategy-2015-2020-FINAL-310315.pdf  
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One interviewee contrasted the situation in the UK regarding real-world data with that of 
Norway and Scandinavia where data were obtained through “Statistics Norway across a 
group of sectors; you can pay a small fee for individual level data” and concluded that in 
the UK “while the real world data offers potential opportunities for studying real world 
practice, in reality a lot of this is unobserved in the data.” 
 
Specific issues in clinical data 
Recommendations around disease registry and clinical audit data 
When asked how NICE should research and evaluate the effectiveness of interventions, 
responses tended towards recommending data collected through registries and collected 
for the purposes of clinical audits as holding untapped potential in considering how the 
effectiveness of interventions should be measured. These data were identified as holding 
more detailed accounts of treatment regimens. However, where these data were thought 
to be particularly useful was when they were linked to clinical database data, such as HES 
or CPRD, for the longer-term monitoring of serious adverse events. Some also viewed audit 
data as being well utilised in monitoring the implementation of guidelines around 
treatment and care, but underutilised in the development of guidelines. Registry and 
clinical audit data for relatively common conditions such as heart failure or diabetes were 
viewed by interviewees as useful sources of real world data.  
This contrasts with some views expressed in the literature which suggest that disease 
registers are only useful for rarer conditions. In particular, the depth of measures and the 
direct remit of audits in improving patient outcomes and clinician performance made 
audit data particularly useful in the mind of one interviewee. 
 
“clinical audit data is special as we measure what is useful to measure, not what is 
easy to measure” 
 
 
Some therefore described that register and audit data was more akin to a real-world data 
set that was designed with a specific set of research questions in mind; they also 
described their usefulness in monitoring new or less common treatment options. However, 
even within registry data, there may be variations in the quality of the data available; for 
example: “with lung cancer because we have the audit early on data on lung cancer, it is 
very good... if you go to some other cancers – at the moment some data is not so good at 
a population level.” 
Registry and audit data are also not immune to the critiques around the difficulties in 
linking data, and some interviewees viewed that different registries were particularly 
weak at communicating with one another. Nevertheless some did not view challenges in 
linking data as being insurmountable and described steps that were being taken to enable 
the data to be linked: “If you have a particular question you can pay to link these systems 
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and pull out data [GP data]. These things are all in this ‘Black Box’ of data [which can be 
linked to specific registry data]. At the moment two systems sit on top of it - one for the 
analyst and the other is meant for more general user – all in development - not publically 
available and the quality of data varies. … In time will all be linked once quality 
assurance is more secure… say in a year or 18 months it will be literally one very large 
spreadsheet 11 half million or 12 million people in there with 10’s of millions of records. 
[It] will be spectacular; nowhere in the world will there be anything like this.”   
Disease coding frames and accuracy 
Standard disease coding frames are often used to highlight the virtues of real-world data. 
They can help researchers to distinguish co-morbidities from complications in real-world 
data and the next iterations may be rolled out with greater ability to examine healthcare 
related injury (iatrogenic diseases) 36. However, while some interviewees did see the value 
of standard disease coding frames, the level of granularity of these was questioned. For 
example ICD-10 codes (International Classification of Disease codes) are used across 
several datasets and were perceived as an aid for national comparison studies. However, 
because they are used in developing and developed world contexts, some interviewees 
questioned the level of granularity that these codes could achieve in terms of many non-
communicable/age-related/chronic diseases and their interventions. Registry data, 
because of their specialised nature, were said to be less sensitive and collected greater 
information on the disease which could help to overcome this limitation. Other studies 
have questioned the granularity of information on treatment options 36. 
A reliance on CPRD data? 
Interviewees described that GP data was held by a number of different companies and 
organisations, with their estimates ranging from 6-9% to 15% of their market share. CPRD 
was described as being one of the first organisations to establish itself as a provider of GP 
level data for research purposes. Interviewees did mention a number of other sources 
including – QResearch, Apollo, Systm1, EMIS and others – some of which represent the data 
collection or extraction software and some of which, e.g. QResearch represent 
organisations with a similar remit to CPRD and may represent alternative suppliers for 
NICE. In addition, different providers may have different quality systems – for example the 
patient lists that GPs hold can have errors: patients frequently change address without 
notifying their GP and sometimes patients on the list may no longer be present in the area 
creating variations and duplications, and lead to inaccuracies in establishing denominators 
and calculating rates. In inner city areas where there is a higher level of population churn 
this problem can lead to substantial levels of inaccuracies 2; different providers may have 
different systems and algorithms in place to deal with these. Similarly, different providers 
may have different systems in place to deal with selection effects of GP surgeries opting in 
or out of data capture systems. When asked whether any one provider (e.g. CPRD) held 
advantages over another, interviewees did not specify this to be the case.  
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“There are differences in how the data are captured and collected – e.g. in terms of 
free text data rather than coded data….but I can’t say one system is better than 
another.”  
 
 
Unless specifically linked, all GP level data such as CPRD and QResearch data are likely to 
have little information on hospital contacts and services provided beyond the limited 
information contained in discharge letters.  
Specific issues in public health data 
Difficulties in obtaining data with sufficient granularity at a Local Authority level 
One interviewee highlighted difficulties in obtaining data on public health issues at a local 
authority level. Given that most public health functions are now devolved, difficulties 
were identified in obtaining data that could help local policy-makers to make informed 
commissioning decisions that reflected local health trends. From NICE’s perspective, this 
lack of data could hamper its ambitions to measure, for example, the implementation of 
its guidance, as different Local Authorities can exercise different policies with regards to 
which services are commissioned and the foci of these services.   
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Section 4: Selected in-depth data profiles 
 
The English Longitudinal Study of Ageing 
Aims and description: The English Longitudinal Study of Ageing (ELSA) is a 
multidisciplinary study of older people aged 50 and above who are living in private 
households in England at the time of recruitment. It aims to “measure outcomes across a 
wide range of domains and to provide high-quality multidisciplinary data that can shed 
light on the causes and consequences of outcomes of interest”22. It collects a wide range 
of data on socioeconomic position, finances and pensions; social exclusion and 
participation; health, wellbeing and social care needs and service usage; living 
arrangements and housing; and retirement processes. In addition to self-reported 
measures, selected sweeps collected data through a nurse visit which can involve the 
collection of a number of measures of physical health including lung function tests, grip 
strength and blood assay measures. While multidisciplinary in nature, ELSA is likely to be 
of greatest value as a tool for monitoring population health trends among a cohort aged 50 
and over and in terms of examining the effectiveness of some clinical, public health and 
social care interventions. 
Background, history and study design: ELSA was developed as a companion study to the 
US Health and Retirement Study to document the ageing process and the 
interconnectedness between life domains including health and wellbeing, socioeconomic 
status, working life and retirement, social and personal relationships, and numerous other 
domains 111. Sample participants were originally recruited from the Health Survey for 
England and data were first collected in 2002/3; since then a further five sweeps of data 
have been collected from the same participants with a seventh wave collected in 
20014/15. The original sample has also been replenished four times (including at the latest 
sweep) to ensure that the data continue to represent the ageing process among those aged 
50/55 years and over. Data from study members’ partners has also been collected as part 
of the study. 
Validity of measures (e.g. construct, content, criterion validity) and case definitions: 
ELSA is a multipurpose study which has included a number of different scales (sometimes 
only subscales) and validated measures as part of its core set of measures that are fielded 
at each sweep, as well as validated measures that have been used at irregular intervals. 
These validated measures cross a number of domains including wellbeing (for example 
CASP Quality of Life Scale 112), mental health (for example CES-D measures of depression 
113) and clinical measures, for example the Rose Angina Questionnaire and the MRC 
Questionnaire. There have been a number of exercises aimed at validating some of the 
self-reported measures collected; for example validating self-reported levels of physical 
exercise through accelerometer data 114, while others have used evidence from different 
longitudinal studies, for example to understand the validity of self-reported coronary 
heart disease status (CHD) 115. Validation of measures can also take place within the study 
                                            
22 http://www.elsa-project.ac.uk/about 
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– for example in validating report of self-declared diabetes and diabetes diagnosed 
through blood glucose tests 116. Objective measures are also collected through nurse visits 
and efforts are made to improve the accuracy of the data collected: for example waist 
circumference is measured twice, and even a third time when the two first measures 
differ by over 3 cm 117 and similar procedures are also undertaken for other measures such 
as the use of spirometers that detect whether technically acceptable measures are 
collected 118. Some measures may need to be interpreted differently to reflect the way in 
which they are collected when undertaking comparative work between surveys, although 
this doesn’t compromise validity per se; for example cortisol levels are collected through 
hair samples provided during nurse visits in ELSA and tend to reflect chronic levels of 
stress, but are collected through salivary measures in some other studies, including the 
National Child Development Study (NCDS) and as such need different interpretation. 
Clear case definition is likely to be possible using a number of (mainly self-reported) 
measures that correspond with validated scales, although may be considered more reliable 
where the data have been linked with others (see below). Clear case definition for some 
constructs such as social care needs is also possible through the use of measures such as 
Activities of Daily Living Measures and Instrumental Activities of Daily Living measures, 
which may correspond with measures across other surveys 119; while these latter measures 
will hold less relevance compared to Local Authority measures of social care need, these 
data nevertheless lend themselves to summarily exploring levels of unmet social care 
needs and geographic variations. 
All case definitions are subject to a similar limitation regarding the length between 
sweeps of data collection, which at two years is less than some other major sources of 
longitudinal data, but nevertheless may hold implications for creating population-level 
epidemiological estimates. This may be especially relevant for unstable constructs 
expected to change relatively rapidly over time, as well as for domains that can be 
influenced by changes in policy (such as changes in social care eligibility) or other 
contextual influencers. 
Representative of populations and settings: ELSA is intended to represent residents living 
in private households in England. New sweeps of data have included new cohorts of 
participants to ensure that the sample remains broadly representative of people aged 
50/55. Sample weights are provided to ensure that analysts can generate estimates that 
remain broadly representative accounting for attrition and differential response rates to 
different elements of the study – for example different weights are provided for main self-
completion survey, the self-completed sexual behaviour questionnaire, the blood test, the 
nurse visit and the main survey 118. In addition, different weights are constructed for 
longitudinal and cross-sectional analyses. Typically, these weights are constructed to 
ensure that estimates reflect either the longitudinal sample or broader populations in 
terms of age, region of residence, household composition, presence of a long-term illness, 
ethnicity (measured as white vs non-white) and self-reported health. 
There are limitations to the study design. One of the main limitations to using ELSA is that 
it is representative only of those in private households, and the aim of the study does not 
include representing the experience of residents in community establishments. ELSA did 
not seek to oversample groups that are traditionally either underrepresented or 
Section 4: Selected in-depth data profiles - The English Longitudinal Study of Ageing 
73 
 
underpowered in surveys, for example Black and Minority Ethnic groups or Lesbian, Gay, 
Bisexual or Transgender people. Where analyses have attempted to examine differences 
using such groups, they have been accompanied by a number of caveats and have resorted 
to analysis that overlooks the heterogeneity across diverse groupings (see, for example 
120). There are also some issues with examining heterogeneity in ageing experiences among 
the oldest old population due to the grouping of those aged 85+ to ensure confidentiality.  
Representativeness of different disease stages: This is a multipurpose study and its aim 
is not to provide detailed case histories of disease trajectories, although some the data do 
lend themselves to study longitudinal changes and variations in disease/condition status 
and manifestations. The data have also been used to monitor the quality of care received 
by study members across a range of indicators (see 121). Due to the study design (survey of 
private households), it could be possible to speculate that some experiences of severe 
illness and cognitive decline may be underrepresented in estimates. Some studies have 
found indicative evidence of underrepresentation (through increased risk of attrition) of 
older people with cognitive decline 122. 
Clear ethical frameworks: Full consent is obtained from participants and different forms 
of consent are obtained for different forms of data collection and linkage. Ethical approval 
for all the ELSA waves was granted from the National Research and Ethics Committee 123. 
Funding for the study is obtained from the National Institute of Aging (USA), Department 
of Health, Department for Work and Pensions, Office for National Statistics, Department 
for Transport, HM Revenue and Customs, Department for Communities and Local 
Government.  
Dynamic and adaptable: ELSA is a multipurpose study and has responded to the changing 
needs of users, researchers and policy-makers through collecting an increasing breadth of 
information including blood assays, self-reported sexual behaviour and sleep patterns as 
well as responding to policy changes such as the changes to the state pension age and 
contextual effects such as the recession. ELSA’s principle investigators are based at 
NatCen, UCL (Epidemiology and Population Health) and the Institute for Fiscal Studies and 
are supported by a number of other academics and an advisory group consisting of policy-
makers and academics.  
Data Linkages: Permissions have been sought to link the data from ELSA respondents with 
Her Majesty’s Revenue and Customs (HMRC) / Department for Work (DWP) records on 
National Insurance contributions, benefits, tax records and pension; permissions have also 
been sought to link with Hospital Episode Statistics data and NHS Central Register 
(mortality) and cancer registration data 111 124. ELSA shares a similar design with other 
studies of ageing in Europe and the US allowing for international comparisons; efforts have 
also been undertaken to harmonise the data with a Korean study 121.  
Collection of data reflective of real-world conditions (scope): ELSA collects a broad 
range of data that includes older people’s usage of social care and clinical services, the 
perception of the quality of their experiences, and their outcomes. Previous studies have 
included those with a focus on measuring limited health literacy as a barrier to colorectal 
cancer screening 125, perceptions of age and other forms of discrimination in accessing 
health services 126, and geographic and socioeconomic-based inequalities in access to full 
joint replacement across England 127.  
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Sensitivity: Not applicable with respect to detecting iatrogenic diseases. ELSA has 
collected detailed life history data which could facilitate establishing the sequence of 
certain events and diseases.   
Understanding or reporting of selection/sample composition: There exists detailed 
documentation across a number of reports that outline the sample selection and 
replenishment procedures; these also give an indication as to potential issues with 
selection and representativeness see 128. As with survey data, analysts can encounter 
problems with item or module non-response and, reflective of being a longitudinal study, 
analysts can encounter issues with wave non-response or attrition. Weights are 
constructed that can be implemented to help correct for the effects of some of these but 
not fully and not for all types of missingness.  
Uniformity in data collection procedures: ELSA developed as a ‘companion study’ to the 
Health and Retirement Survey in the US and the data from both sources have been 
harmonised 121. ELSA collects data through a blend of Computer Assisted Personal 
Interviewing (CAPI) and self-completed questionnaires, in addition to Nurse Visit data (not 
collected at every sweep) and telephone interviews in certain cases.  
Steps taken to minimise common forms of bias: Methods are employed by analysts to 
correct statistically for many forms of bias. Modifications to the questionnaire design have 
been tested to explore the impact of bias induced through self-reported bias such as 
optimism bias in self-reported health 129. The collection and harmonisation of repeated 
measures collected in the same sweep (described earlier) also reduced the risk of bias in 
the collection of bias. Nevertheless, ELSA data is subject to many of the caveats arising in 
working with survey data.  
Scope: As described earlier, there is a wide scope for analysing data reflecting outcomes 
and experiences beyond morbidity and mortality, particularly with respect to measures of 
mental wellbeing and quality of life and patterns of social care need and usage. 
Granularity of treatment/disease data: ICD-10 codes are used to classify primary cause of 
death but not for morbidity. Otherwise, high levels of granularity exist for many clinical 
and social care measures allowing for investigations to take place across different scales 
and sub-scales. 
Other considerations/information: ELSA is a prospective cohort of older people which 
gives an indication of patterns of ageing in England. A number of different study designs 
have been implemented within the study, and the data are widely used in cross-sectional 
and longitudinal formats. The survey content does change at sweeps suggesting a good 
degree or responsiveness and new concerns are reflected, for example an end of life 
telephone survey was fielded at the latest sweep. News and updates can be found on the 
ELSA webpage (http://www.elsa-project.ac.uk/) while the anonymised individual-level 
data are available (free of charge) for non-profit purposes and subject to agreement with 
other conditions to registered users of the UK Data Archive (http://www.data-
archive.ac.uk/); alongside the data a full inventory of study documentation including 
technical guides and questionnaires can also be found. An eighth wave of data collection is 
planned in 2016/17 following the latest sweep in 2014/15.  
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ELSA in numbers: Core data: Wave 1 (2002/3): 12,100 cases. Wave 2: 9,433 cases. Wave 
3: 9,771 cases. Wave 4: 11,050 cases. Wave 5: 10,274 cases. Wave 6 (2012/13): 10,601 
cases. 
Summary and Utility for NICE: ELSA was originally proposed as a potential useful source 
of data on social care. In the latest wave, the data included data on a range of social care 
and health topics including the occurrence, data of occurrence, impact and medication 
taken for a number of chronic mental and physical health conditions, adverse health 
events, health service usage, social care usage, social care needs, care and the provision 
of care, quality of life and mental wellbeing, all of which are domains highly pertinent to 
the work of NICE. 
   
Desired use by NICE Potential suitability23 
Research the effectiveness 
of interventions or 
practice in real-world (UK) 
settings 
Determination of population of interest; reliability of 
measures; range of intrinsic measures and additional 
prognostic measures all satisfied with ELSA. Sample size 
and the non-purposive sampling of healthy and unhealthy 
subjects means that researching potential practice impacts 
may be restricted to widespread practices only. 
 
Example study and abridged abstract: 
A cost-benefit analysis of cataract surgery based on the 
English Longitudinal Survey of Ageing: This paper uses 
the English Longitudinal Survey of Ageing to explore the 
self-reported effect of cataract operations on eye-sight. A 
non-parametric analysis shows clearly that most cataract 
patients report improved eye-sight after surgery and a 
parametric analysis provides further information: it shows 
that the beneficial effect is larger the worse was self-
reported eye-sight preceding surgery so that those with 
very good or excellent eye-sight do not derive immediate 
benefit. Nevertheless, the long-run effect is suggested to 
be beneficial. Calibrating the results to existing studies of 
the effect of imperfect eye-sight on quality of life, the 
impact of cataract operations on Quality Adjusted Life 
Years is found to be similar to that established in previous 
studies and well above the costs of cataract operations in 
most circumstances 4. 
 
                                            
23 Potential suitability here is something of a subjective construct in the absence of a clear research 
question to be addressed. However,  
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Audit the implementation 
of guidance.  
 
Determination of changes in practice may be challenging in 
the absence of linked data; in addition the gap in data 
collection may be problematic for some analyses of change 
over time; the data will give an overall picture and may be 
particularly informative in terms of detecting long-term 
changes in practice around social care.  
 
Example study and abridged abstract: 
Limited health literacy is a barrier to colorectal cancer 
screening in England: To determine the association 
between health literacy and participation in publicly 
available colorectal cancer (CRC) screening in England 
using data from the English Longitudinal Study of Ageing 
(ELSA). 73% of participants had adequate health literacy 
skills. Screening uptake was 58% among those with 
adequate and 48% among those with limited health literacy 
skills. Limited health literacy is a barrier to participation in 
England's national, publicly available CRC screening 
programme. Interventions should include appropriate 
design of information materials, provision of alternative 
support, and increased one-on-one interaction with health 
care professionals. 125 
 
Provide information on 
resource use and evaluate 
the potential impact of 
guidance in changing 
resource use 
 
Determination of inputs/resource use may be patchy and 
may differ according to the condition. Some studies 
possible. 
 
Example study and abridged abstract: 
Self reported receipt of care consistent with 32 quality 
indicators: national population survey of adults aged 
50 or more in England: Objective: To assess the receipt of 
effective healthcare interventions in England by adults 
aged 50 or more with serious health conditions. Main 
outcome measures: Percentage of indicated interventions 
received by eligible participants for 32 clinical indicators 
and seven questions on patient centred care, and 
aggregate scores. 
Receipt of indicated care varied substantially by condition. 
Substantially more indicated care was received for general 
medical (74%, 73% to 76%) than for geriatric conditions 
(57%, 55% to 58%), and for conditions included in the 
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general practice pay for performance contract (75%, 73% to 
76%) than excluded from it (58%, 56% to 59%). Conclusions: 
Shortfalls in receipt of basic recommended care by adults 
aged 50 or more with common health conditions in England 
were most noticeable in areas associated with disability 
and frailty, but few areas were exempt 5.  
Provide information on 
epidemiological trends 
 
Determination of several conditions possible – the data 
have also been used to determine the levels of 
undiagnosed conditions in populations. 
 
Example study and abridged abstract: 
Prevalence of frailty and disability: findings from the 
English Longitudinal Study of Ageing: Objective: to 
examine the prevalence of frailty and disability in people 
aged 60 and over and the proportion of those with 
disabilities who receive help or use assistive devices. 
Results: the overall weighted prevalence of frailty was 
14%. Prevalence rose with increasing age, from 6.5% in 
those aged 60–69 years to 65% in those aged 90 or over. 
Among frail individuals, difficulties in performing activities 
or instrumental activities of daily living were reported by 
57 or 64%, respectively, versus 13 or 15%, respectively, 
among the non-frail individuals. Conclusions: frailty 
becomes increasingly common in older age groups and is 
associated with a sizeable burden as regards difficulties 
with mobility and other everyday activities 130. 
Provide information on 
current practice to inform 
the development of NICE 
quality standards 
 
Determination of inputs/resource use may be patchy and 
may differ according to the condition. Depth of 
information on the components of practice needed to 
establish quality standards may be patchy. 
 
Example study and abridged abstract: 
The impact of primary care supply on quality of care in 
England: The aim of this study is to assess the relationship 
between primary care supply and the quality of primary 
care in England. We use data from the English Longitudinal 
Study of Aging (ELSA) which provides a panel of individuals 
aged 50 and over living in England. Wave 2 to 4 (2004 to 
2009) include data on a number of indicators developed for 
assessing the quality of care of the consultations. The 
survey data are linked to Primary Care Trusts (PCT) level 
data on primary care supply measured by the number of 
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GPs in the area of residence and the average distance to 
the general practice. In the pooled analysis across all 35 
indicators, our findings suggest that, after controlling for 
individual demographic characteristics, socioeconomic 
factors, perceived health, and area level factors, a larger 
number of GPs in the area has a statistically significant and 
positive impact on quality of care, and distance from GP 
practice has a statistically significant and negative impact 
131.   
 
Key References:  
Bridges, S., D. Hussey, et al. (2015). The dynamics of ageing: The 2012 English 
Longitudinal Study of Ageing (Wave 6) Techincal Report. London, NatCen. 
Steptoe, A., E. Breeze, et al. (2013). "Cohort profile: the English longitudinal study of 
ageing." International journal of epidemiology 42(6): 1640–1648. 
 
 
Community Mental Health Service User Survey/Community Mental Health Survey 
Aims and description: The Community Mental Health Service User Survey (CMHSUS)24 is a 
cross-sectional survey of adult mental health service users carried out by the Picker 
Institute Europe on behalf of the Care Quality Commission (CQC). It is part of the National 
Patient Survey programme that was established by the Department of Health in 2002 and 
transferred to the CQC in 2009 132. The aim of the survey is collect information from users 
of community mental health services – service users whose needs cannot be ordinarily met 
in primary care settings – and to understand their views on the care they received and 
whether/how this care needs to be improved. The results of the survey can be used by 
NHS trusts to understand their performance and benchmark their performance against 
other trusts; a scoring system has been developed to facilitate comparisons between NHS 
trusts.    
Background, history and study design:  
The CMHSUS is part of the broader programme of work now under the auspices of the CQC 
that collects information from service users across a range of clinical services and areas. 
The mental health survey represents a simple (non-stratified) random sample of users. The 
latest sweep of available data collected in 2014 surveyed adults (18+) in receipt of 
specialist care or treatment for a mental health condition and had been seen by a 
participating NHS trust within a set window 625. This includes people who were receiving 
treatment through Care Programme Approach (CPA) and those who were not. The 2015 
                                            
24 Surveys of patient experiences have also been known as Community Mental Health Service Survey 
and Community Mental Health Survey in previous years. 
25 http://ukdataservice.ac.uk/ 
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survey, currently underway, adopted a similar approach. Notable exclusions from the 
survey include people who were only seen once for an assessment, current inpatients 
receiving treatment for mental health conditions, and people receiving treatment for a 
specific area such as drug and alcohol abuse, learning difficulties and specialist forensic 
services 6. While there may be similarities in the design of survey, the content changed 
substantially in 2014 to reflect changes in policy, service delivery patterns and best 
practice, and this hinders comparability for studies seeking to implement a repeated 
cross-sectional design. 
NHS trusts are responsible for implementing the survey in their areas and are given 
detailed instructions on how to administer the survey 133. In 2014, the data are weighted 
by age and gender to account for differences in the composition of responses between NHS 
trusts; the data are not adjusted to account for any potential differences between 
responders and non-responders 133, and the weights do not necessarily enable inferences to 
be made for the whole population in receipt of mental health services. Detailed 
information on the steps taken to correct for other factors that may compromise 
representativeness particularly when comparing scores at a trust level, are given in the 
data documentation. The 2014 sweep achieved a response rate of 29% with responses 
obtained from 13,787 individuals.  
The 2014 survey asked respondents to complete a total of 49 questions ranging from: their 
history of contact with mental health services, their experience and satisfaction with the 
contact and service they received at their last contact, questions on how their care is 
organised, planned and reviewed and their experiences of these interactions, questions 
about medication they receive and their feeling of involvement in directing their care, 
broader questions about the support and information people received, overall perceptions 
of being treated with respect and dignity; and information about service users’ 
demographics (age, gender, religion, ethnicity and others). Not all of these fields are 
available for researchers to reanalyse, and only age and gender are available to examine 
trends by demographic characteristics.  
Validity of measures (e.g. construct, content, criterion validity) and case definitions:  
The survey has a high level of face validity and asks about service user satisfaction and 
perceptions, and does not contain tools or measures that are diagnostic in nature. The 
2014 redevelopment was intended to improve the accessibility of the survey for users 
through using more collaborative language, included changes to the language ensure 
applicability across different NHS trusts, and addressed gaps in knowledge through 
including new questions such as on service users’ relationships with staff. These changes in 
language, while improving validity, do hinder comparisons between 2014 data and data 
collected in earlier sweeps.   
Representative of populations and settings:   
The data are a simple random sample of service users. NHS trusts are asked to compile a 
list of all service users accessing services over a set period and to select around 900 users 
randomly from this list using Excel. The intended sample size is around 850 per trust but a 
sample of 900 is drawn to account for any missingness due to incorrect address details, 
service users now living outside the UK or death. The aim is to obtain a response rate of 40 
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per cent; overall 29 per cent was achieved. The survey is administered as a postal survey, 
and those with mobility issues, other physical and sensory impairments, and those with 
literacy issues may experience difficulty in completing/returning the survey. 
The weighting strategy is intended to correct for compositional differences between trusts 
in terms of their age and gender, as younger people and women are said to be more 
critical in their responses than men and older people 133. However, the impact of non-
response on the representativeness of the data is unclear and is a caveat. There are also 
exclusion criteria imposed on who should complete the survey (outlined earlier) which 
further constrict the generalisability of the results. 
Representativeness of different disease stages: As the data are drawn from a sample in 
receipt of mental health services, to whom a postal survey is administered, it is unclear 
the extent to which the responses represent the full spectrum of mental health issues and 
their severity of users of community mental health services. However, linkage of mental 
health cluster codes has been approved26. 
Clear ethical frameworks: Research Ethics Committee (REC) approval has been obtained 
for the survey and trusts must not deviate from the guidance provided  133 in order to 
comply with the ethical approval granted. Service users are assumed to opt-in to being 
contacted as part of the survey unless they explicitly opt out. 
Dynamic and adaptable: The survey has collected different data across sweeps and the 
2014 sweep represented a substantial overhaul of the questions used in order to adapt to 
the needs of users and decision-makers and to reflect changes in policy and service 
provision.  
The study does not have a longitudinal design in of itself, which does limit the potential 
research designs that can be implemented - time-series/repeated cross-sectional study 
designs can be implemented where there are limited changes to the questionnaire.  
Data Linkages:  
Some linkages have recently been granted to expand the scope of the survey (including 
providing information on mental health cluster codes)27. 
Collection of data reflective of real-world conditions (scope): A broad scope of data is 
collected that reflect service user experiences. These can be used to understand how 
service delivery varies between NHS trusts. The data only allow for a limited 
understanding of how these vary by the characteristics of the service user e.g. 
demographics and clinical histories. Nevertheless, the data do allow for examining how 
real-world practice may deviate from guidelines and expected standards. For example, all 
service users who are eligible for a Care Programme Approach (CPA) should have out-of-
hours contingency care plans in place and all service users regardless of CPA status should 
                                            
26 http://www.nhssurveys.org/Filestore/CAG_9-
07%28b%29_2014_Community_Mental_Health_Survey_inclusion_of_mental_health_care_cluster_fina
l_approval.pdf  
27 http://www.nhssurveys.org/Filestore/CAG_9-
07%28b%29_2014_Community_Mental_Health_Survey_inclusion_of_mental_health_care_cluster_fina
l_approval.pdf 
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be aware of out-of-hours emergency contacts. However, the 2014 report showed that a 
fifth (21%) of CPA designated service users and almost two-fifths (38%) of other service 
users reported not knowing who to contact in the event of a crisis occurring outside office 
hours 6. 
Sensitivity: N/A: the data do not allow for the identification of outcomes or conditions. 
Understanding or reporting of selection/sample composition: Some potential limitations 
around the sample are outlined earlier in the description provided on representativeness. 
There is little information available to develop an understanding of how respondent 
characteristics vary from those of the target sample.  
Uniformity in data collection procedures: There may be some synergies between the 
Community Mental Health Survey data and other patient satisfaction data; however the 
validity of such comparisons is unclear. Furthermore, as the questions do change between 
sweeps, there is also a constricted ability to examine change over time through repeated 
cross-sectional studies.  
Steps taken to minimise common forms of bias: The data may be subject to bias in terms 
of systematic differences between responders and non-responders. Other forms of bias 
may be applicable, for example social desirability bias or extreme responding. The study 
collectors do attempt to minimise possible errors occurring in the sample design including 
ensuring that trusts implement the same procedures and limits when drawing a sample 
(including restrictions of age/services used etc) as well as in implementing opt-out clauses 
and providing information to respondents 134. 
Scope and flexibility in research design: In the absence of data linkage, these data are 
mainly suited to cross-sectional and repeated cross-sectional/time-series designs.  
Granularity of treatment/disease data: N/A – no information is provided on the nature of 
service users’ mental health condition. Information is however provided as to whether 
service users are provided with a Care Programme Approach (CPA), which provides greater 
integrated support to users who need it28. 
Other considerations/access information: Raw data are available free of charge to 
registered users of the UK Data Archive for re-analysis, although do not contain the full 
range of data collected in the interests of confidentiality. Detailed reports of findings are 
also available from the CQC website and other sources.    
CMHSUS in numbers: Extent of sweeps: 2002-present; Sample size in 2014: 13,787 service 
users; 57 NHS trusts 
Summary and utility for NICE: These data are potentially very useful for NICE in being 
able to monitor changes in practice since the issuing of guidance and in helping to 
understand current practice in order to inform on the development of quality standards. 
The data have been used for a similar purpose within NICE and NICE collaborating centres 
in the past in order to help develop guidance around improving patient experiences 7. 
However, there are limitations around the breadth of respondent characteristics and 
                                            
28 Information on CPA status has not been provided in the data deposited on the UK Data Archive 
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issues – for example there may be limited scope for exploring how standards vary by the 
needs and characteristics of the client group. The availability of the data on the UK Data 
Archive also mean that NICE are able to directly access the data and conduct its own 
analysis. If this is not already the case, NICE should seek to develop dialogue with CQC in 
order to better understand the potential around this and other NHS surveys of user 
experiences. This survey was selected to be profiled in-depth because of the paucity of 
other datasets identified during the course of this review that had an explicit focus on 
mental health. Some caveats may exist around the sample composition; the data also 
appear to be rarely utilised within the peer-reviewed literature. 
Desire use by NICE Potential suitability29 
Research the effectiveness 
of interventions or 
practice in real-world (UK) 
settings 
N/A – the focus of this survey is on service user experiences 
more than outcomes 
Audit the implementation 
of guidance.  
 
Yes, these data are particularly effective for this purpose 
and many of the fields included in the survey can be 
directly measured against NICE guidance. 
 
Example study: Changes in who people see: 
“NICE guidance (CG136) states that changes in staffing can 
be disruptive to care and it is therefore important that 
services maintain continuity of individual therapeutic 
relationships wherever possible. Where changes are 
necessary, people should be provided with appropriate and 
accessible information about what is happening. Just over 
two fifths of respondents (41%) said that in the last 12 
months, the people they see for their care or services had 
changed. When asked what impact this had on the care 
they receive, just under half (46%) of this group said that it 
‘stayed the same’. Equal proportions (27%) said that ‘it got 
better’ or that it ‘got worse’. However, 37% of respondents 
on CPA and 50% of respondents not on CPA said that they 
did not know who was in charge of organising their care 
whilst this change was taking place 6. 
 
Provide information on 
resource use and evaluate 
the potential impact of 
The data can potentially provide a snapshot of resource 
use based on service users’ reports; repeat cross-sectional 
                                            
29 Potential suitability here is something of a subjective construct in the absence of a clear research 
question to be addressed. However,  
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guidance in changing 
resource use 
 
studies may provide information on the impact of changing 
guidance on resource use. 
 
Provide information on 
epidemiological trends 
 
N/A – in its current form the data are not suitable for this 
purpose  
Provide information on 
current practice to inform 
the development of NICE 
quality standards 
 
There are examples from existing guidance where 
information from past surveys have been used to form 
guidance (and around minimum standards). 
 
Example: 
“The guidance is the first to focus on improving service 
users’experience of mental health services rather than on 
increasing the effectiveness or safety of the interventions 
they should be offered. Recent UK surveys of service users 
showed inconsistent practice and sometimes wide variation 
in performance among trusts, which were two of the 
factors prompting the development of the guidance. The 
surveys showed that a large proportion of service users 
were not given an out of hours telephone number to use 
and that during assessment many service users were not 
involved in decision making about their care and treatment 
and did not have their preferences taken into account. 
Almost half reported that they were not given a copy of 
their care plan. Many users of community mental health 
services reported that they were not given adequate 
information about medication and care coordination, and 
many said that they were not getting effective treatment 
from trusted professionals; a large proportion said they did 
not have a care review meeting or their physical health 
needs met.” 7 
 
Key References:  
CQC. National Summary of the Results for the 2014 Community Mental Health Survey. 
London: Care Quality Commission, 2014. 
Picker Institute Europe. Guidance Manual for the NHS Community Mental Health Service 
Users Survey 2014  Oxford: Picker Institute Europe, 2014. 
Kendall T, Crawford MJ, Taylor C, Whittington C, Rose D. Improving the experience of care 
for adults using NHS mental health services: summary of NICE guidance. Bmj 
2012;344. 
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Clinical Practice Research Datalink (CPRD) 
Aims and description: The Clinical Practice Research Datalink (CPRD) refers both to the 
eponymous organisation which is described as the ‘English NHS observational data and 
interventional research service’ 30 as well as the shorthand description for CPRD-Gold, 
which describes a specific dataset. CPRD is jointly funded by the National Institute for 
Health Research (NIHR) and the Medicines and Healthcare Products Regulatory Agency 
(MHRA). CPRD-Gold (referred to as CPRD from hereon in) is the primary care dataset that 
can be considered as the successor to the General Practice Research Database. The new 
designation reflects the CPRD’s ambition to link greater number of datasets in order to 
understand the entire journey of clinical care. 
Background, history and study design:  
The GPRD started in 1987 (under the guise of the Value Added Medical Products (VAMP) 
dataset) as GP practices were beginning to adopt computer software as a means of storing 
data about their patients, although some practices will have uploaded records predating 
1987 135. In 2012, GPRD was rebranded as CPRD and currently, 674 practices are estimated 
to be contributing to the CPRD database 9, making the number of currently participating 
practices larger than THIN but smaller than QResearch. CPRD holds records on the medical 
histories of 11.3 million patients, 4.4 million who are currently registered31. As with both 
other large primary care databases, CPRD holds a wide breadth of data on the primary 
care interactions of patients including demographic information, clinical events such as 
symptomology and diagnosis, immunisation, tests and test results, specialist referrals, 
referrals to secondary care, hospital admissions and major outcomes, circumstances 
relating to patients’ death 9. Free text information is not usually part of the data made 
available to researchers 9, although CPRD can make these available in certain cases 136. 
The CPRD can also facilitate the recruitment of practices and patients to take part in 
studies requiring the additional collection of biosample data or to take part in trials 9. In 
addition, CPRD can facilitate the collection of patient reported outcome data from 
specific cohorts of patients. Furthermore, additional data can be collected on a practice 
level, and studies have used this latter approach to assess the validity of case definition in 
CPRD 68. 
CPRD and THIN collect data from practices that use Vision software and both are said to 
have comparable data structures, differing to QResearch which uses EMIS 137 138. Small 
differences do exist based on operating systems and there are indications that Vision may 
enable faster coding of items (except prescribing information) and therefore a greater 
number of items are likely to be coded and that practices using Vision may have slightly 
higher achievement rates for QoF indicators 138; however, the effect of these small 
differences on actual usability, breadth of the data, and data quality is not clear in the 
literature and may be marginal. Given the close history between CPRD and THIN, there are 
substantial overlaps between CPRD and THIN data, and practices can participate in both 
databases. A 2012 study that examined 781 practices that were participating in either 
CPRD (GPRD at the time) or THIN found that 327 (41.9%) were common to both datasets; 
286 (36.6%) were included in CPRD only and 168 (21.5%) were included in THIN only.  
                                            
30 http://www.nihr.ac.uk/about/clinical-practice-research-datalink 
31 Email communication dated 27th March 2015 
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Validity of measures (e.g. construct, content, criterion validity) and case definitions: 
As is the case for both of the other two major sources of primary care data, THIN uses 
Read code system to record medical information and there are approximately 250,000 
read codes used to record patient diagnoses, symptoms and the care that patients receive; 
previously CPRD had used OMIS (Oxford Medical Information Systems)  139. Read codes have 
been in use in the NHS since 1985, although have been variously updated and different 
versions do exist; the successor to read codes are Systematized Nomenclature of Medicine 
Clinical Terms (SNOMED-CT); read codes and SNOMED-CT can be cross-mapped to ICD-10 
codes 140. CPRD uses additional codes (OPCS4 and BNF) and will include ATC drug coding 
and MedDRA coding for adverse event reporting in future 136.  
As with other large GP-level clinical datasets it is possible to undertake validation studies 
and explore levels of consensus of CPRD data using data from an alternative clinical 
databases (THIN and QResearch) as well as from other (linked and unlinked) data sources. 
For studies comparing CPRD and THIN data, there are potential for additional validation 
studies based around the overlaps and between datasets examining potential discrepancies 
between these records at a practice level. Systematic reviews have been undertaken to 
explore levels of diagnostic validity in the GPRD (CPRD’s predecessor). Herrett and 
colleagues 106 examined the results of 212 validation studies (1987-2008) of GPRD 
diagnostic validity while Khan and colleagues 69 examined 47 studies. Both reviews 
concluded that diagnostic validity in the GPRD was high and the potential for 
misclassification was low. The included studies used a variety of methods to assess 
diagnostic accuracy, although a gold standard was considered to be those studies that 
assess validity through re-examination of medical records, hospital records or GP 
questionnaires 69. While the overall level of validity was considered good, there were some 
specific disease areas where the potential for misclassification was higher mainly involving 
acute conditions 69, and while Herrett and colleagues 106 found that the median value for 
confirmed cases stood at 89%, some studies reported values as low as 24%. Since both 
reviews were undertaken and after GPRD became known as CPRD, there has been 
continued interest in the quality of the data, and these studies have confirmed lower 
levels of diagnostic validity for less stable constructs, aspects of previous medical history, 
or prevalence acute conditions. For example, previous smoking status is thought to be 
underrepresented 141, as is current BMI status 142. 
Of particular note and likely relevant to all clinical databases and more widely are the 
conclusions of a second study of validity and (mis)classification by Herret and colleagues 
which compared the cases of acute myocardial infarction in the CPRD, HES and MINAP. 
While positive predictive values were high, relying on data from any one data source led 
to underestimates of between 25-50% of events compared to using data from all three 
sources 141.  
Representative of populations and settings: Overall, CPRD data is thought to be 
nationally representative and on average contains data from around 4.4 million active 
participants. There are some geographic disparities in the data; for example, while 1.5% 
and 9.1% of patient records in the database come from the North East and Wales 
respectively 9, these areas account for 4.1% and 4.8% of the national population. By virtue 
of the sample design there are also some populations that are not represented such as 
prisoners and those receiving private primary care 9. Low data quality for some items 
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prevents full assessment of representativeness of the data; ethnicity for example is 
present for around a quarter of records which is comparable with the other two clinical 
databases, although analyses of CPRD suggests that despite low levels of completion, the 
ethnic profile mirrors that of census data, and the quality of the data has increased 
substantially among more recent registrants 143. Data quality is also an issue with other 
items such as BMI 142.  
Nevertheless, the small disparities in composition are not thought to compromise the 
overall representativeness of the sample, and most studies using the data regard CPRD as 
being broadly representative of national primary care trends and practice. This is further 
reinforced by studies comparing prevalence rates of major conditions which find 
consistency in rates  144. Most studies therefore use CPRD data as being representative of 
national trends and outcomes in primary care.  
Representativeness of different disease stages: CPRD is a primary care clinical database 
that allows researchers to monitor the treatment of disease in primary care settings. In 
this respect, it shares many of the limitations of the other two major sources of primary 
care data in that the possibility of monitoring different stages of disease beyond primary 
across different care providers is only possible through data linkages based on common 
identifiers (see below). However, part of the justification for rebranding GPRD to CPRD 
was specifically because of the enhanced data linkages that were expected to take place 
within the dataset.  
Data are used to monitor disease stages in the literature and the factors predicting 
transitions to different stages and conditions; for example Fleming and colleagues mapped 
trends in the progression of cirrhosis in primary care using data from the GPRD; the utility 
of the data for mapping disease stages is likely to be highly dependent on the research 
question being asked. As CPRD is not designed for examining a single disease or condition, 
monitoring disease progression from a patient perspective may be challenging; however, 
there may be scope for including patient reported outcome data through fielding 
additional tools for capturing patient reported outcomes 136 , although there are few 
examples of such studies occurring in the published literature. 
Clear ethical frameworks: CPRD has approval from the National Research Ethics Service 
Committee (NRES) for all purely observational research using anonymised CPRD data. 
Researchers wishing to undertake studies using CPRD data are required to submit their 
proposal to an Independent Scientific Advisory Committee to gain approval; those who 
wish to collect additional data from patients will likely need to seek further Research 
Ethics Committee approval. Patients of participating practices are given notice that their 
practice is a contributing member of CPRD, and notice that they can opt-out if they wish, 
although the procedures and number of patients withdrawing consent are unclear 145.  
Dynamic and adaptable: Adaptation/dynamism in the actual collection of data will be a 
reflection of development either in the extent/depth of read codes available, the extent 
of data linkages and changes in the Vision platform and extraction algorithms. The 
potential for additional instruments to be fielded among patients means that data that 
better meets the data requirements of the research question can be collected 
purposefully; in particular this means that data on Patient Reported Outcomes could be 
collected alongside other clinical measures. Studies that have exploited this adaptability 
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include O’Meara and colleagues’ study of the pharmacoepidemiology of statins that 
implemented additional blood tests among patients 146.  CPRD data have been used for a 
number of epidemiological study designs (see below). 
Data Linkages: CPRD data are notable in the extensive data linkages that are available, 
potentially offering a broad resource for examining patient transitions. Data linkage 
projects can be completed on request from researchers, although established linkages 
exist with registry and audit data as well as other clinical and social databases. CPRD 
existing data linkages include those with MINAP data, National Cancer Intelligence 
Network data and HES data. Area level data are also available including Index of Multiple 
Deprivation data and Townsend deprivation scores 9. Further data linkages are planned. 
Several studies have exploited the data linkages based on CPRD data; these include, for 
example, McDonald and colleagues’ study of community acquired infections among older 
diabetics in primary care (CPRD) and the consequent utilisation of secondary care (HES) 
147. Not all practices that contribute to CPRD also agree to further data linkage. In 
addition, these linked data also have their limitations – for example linked HES data will 
not provide information on hospital prescribing or testing. 
Collection of data reflective of real-world conditions (scope): A broad scope of data 
reflecting primary care interactions between patient and GP are collected in CPRD, and 
the extensive data linkages allow for further analysis of patient journeys across primary 
into secondary care. There exist several published studies that examine a broad range of 
research questions around the frequency, quality, treatment of regimes and outcomes of 
these, and the broad scope of data is considered a strength of CPRD 9. Of particular 
interest to NICE may be those studies that offer insights into resource utilisation in and 
beyond primary care: such studies include calculations of incidence of hospitalisations and 
referrals among people with diagnosed chronic lymphocytic leukaemia 148, and calculating 
the incidence of consultations, prescriptions, referrals, and diagnostic testing among 
people living with fibromyalgia 149. In the latter study, the ‘real-worldness’ of the data 
meant that researchers were able to comment on GPs’ ability and willingness to classify 
cases as fibromyalgia. 
Sensitivity: There are a number of studies that utilise data from CPRD to assess iatrogenic 
disease or complications arising from therapy. The degree of sensitivity in this respect will 
be highly dependent on the disease/condition itself. 
Understanding or reporting of selection/sample composition: Consultation with study 
depositors is likely to inform on the impact and procedures for surgeries opting in/out of 
the study. There is little evidence of any difference in the profile of participating 
surgeries in CPRD compared to those who do not participate (beyond the data on 
representativeness presented above). No literature was found that described differences 
in CPRD participating surgeries that consented to data linkage (e.g. with HES data) 
compared to surgeries that did not. 
Uniformity in data collection procedures: No purposeful data collection method per se – 
dependent on GP entry as part of consultation and patient care. As described above, 
uniformity in coding systems used makes CPRD data highly comparable with QResearch and 
THIN data.  
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Steps taken to minimise common forms of bias: Sample selection bias (as opposed to 
selection bias across the database) can occur in studies but can be minimised through 
utilising a number of analytical techniques including implementing more sophisticated 
matching procedures see, for example, 150.  Confounding by indication is a risk in using 
CPRD data for effectiveness studies, although use of appropriate analytical techniques 
likely to offset the risk in part. Studies using CPRD data have also undertaken forms of 
sensitivity analysis by different treatment regimes or stratified analyses by risk profile to 
examine whether their conclusions hold in order to examine potential impacts of 
confounding by indication for example 151. However, these strategies are unlikely to fully 
remove the possibility of this form of bias 152. Misclassification bias may be minimised 
through standardised data entry and the use of read codes, although validation studies 
suggest that there exist potential differences and discrepancies in the classification of 
disease. Modifications to the sample drawn can help offset the potential impact of other 
forms of potential bias such as protopathic bias see, for example 153. Selection effects at 
the practice level (and potentially the patient level) are also possible, although the risk is 
likely equivalent to other clinical databases. As is common across clinical datasets, the 
influence of unobserved confounders including over-the-counter medications will be 
unquantifiable as will levels of compliance with reported treatment regimes.  
Scope and flexibility in research design: As described earlier, there is a wide scope for 
analysing data reflecting outcomes and experiences of morbidity and mortality at primary 
care level, as well as trends in the care and treatment provided. These data can also be 
linked to many other data sources allowing for potential tracking of patient journeys 
between primary and secondary care as well as greater detail of the nature of these 
experiences. There are also examples of studies that have implemented additional data 
collection through CPRD in order to address specific research questions.  
Granularity of treatment/disease data: Given that read codes form the basis for the entry 
of data into CPRD, and that over 250,000 codes exist, a high level of granularity of data 
can be incorporated into studies. This granularity has been exploited in many studies to 
better distinguish between certain forms of condition. 
Other considerations/access information: Training is available from CPRD. Costs are 
associated with accessing CPRD data and vary by the size of the dataset and the nature of 
the linkages. However, standard extracts approximate at around £15,000 for a dataset of 
1,000 patients to over £60,000 for a dataset of over 300,000 patients. An annual license is 
also available costing between £125,000-£255,000 depending on the nature of the 
subscribing organisation. The data are supported by a Knowledge Centre who can address 
most researchers’ queries (kc@cprd.com).  
CPRD in numbers: 685 GP Practices; 13.7 million patient records; 4.4 million active 
patients; 85.8 million patient years of data; 8.9% of the population; 75% of contributing 
practices in England in CPRD with linked data. 
Summary and utility for NICE: CPRD data have utility for NICE through the flexibility in 
being able to collect additional fields and the potential to conduct research based on free-
text fields. CPRD data are also available to medical researchers based outside UK 
universities potentially expanding the pool of potential partners with which NICE could 
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work in using the dataset. The long established nature of CPRD (based on GPRD) means 
that several retrospective studies could also be potentially conducted using these data.  
Desire use by NICE Potential suitability32 
Research the effectiveness 
of interventions or 
practice in real-world (UK) 
settings 
Determination of population of interest and reliability of 
measures are satisfied with CPRD; range of intrinsic 
measures and additional prognostic measures (although 
data quality may be problematic for some measures in 
common with other similar sources of primary care data). 
Additional scope for collecting patient reported outcomes 
is possible. 
 
Example study and abridged abstract: 
“Effectiveness of maternal pertussis vaccination in 
England: an observational study:  Background 
In October, 2012, a pertussis vaccination programme for 
pregnant women was introduced in response to an 
outbreak across England. We aimed to assess the vaccine 
effectiveness and the overall effect of the vaccine 
programme in preventing pertussis in infants. We 
undertook an analysis of laboratory-confirmed cases and 
hospital admissions for pertussis in infants between Jan 1, 
2008, and Sept 30, 2013, using data submitted to Public 
Health England as part of its enhanced surveillance of 
pertussis in England, to investigate the effect of the 
vaccination programme. We calculated vaccine 
effectiveness by comparing vaccination status for mothers 
in confirmed cases with estimates of vaccine coverage for 
the national population of pregnant women, based on data 
from the Clinical Practice Research Datalink. 
Findings: The monthly total of confirmed cases peaked in 
October, 2012 (1565 cases), and subsequently fell across all 
age groups. 26 684 women included in the Clinical Practice 
Research Datalink had a livebirth between Oct 1, 2012 and 
Sept 3, 2013; the average vaccine coverage before delivery 
based on this cohort was 64%. Vaccine effectiveness based 
on 82 confirmed cases in infants born from Oct 1, 2012, 
and younger than 3 months at onset was 91% (95% CI 84 to 
95). Vaccine effectiveness was 90% (95% CI 82 to 95) when 
the analysis was restricted to cases in children younger 
than 2 months. Interpretation: Our assessment of the 
                                            
32 Potential suitability here is something of a subjective construct in the absence of a clear research 
question to be addressed. However,  
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programme of pertussis vaccination in pregnancy in 
England is consistent with high vaccine effectiveness. This 
effectiveness probably results from protection of infants by 
both passive antibodies and reduced maternal exposure, 
and will provide valuable information to international 
policy makers 154. 
Audit the implementation 
of guidance.  
 
Determination of changes in primary care practice possible 
using CPRD data; such studies have included studies based 
on the introduction of NICE guidance.  
 
Example study and abridged abstract: 
“Comparison of cancer diagnostic intervals before and 
after implementation of NICE guidelines: analysis of 
data from the UK General Practice Research Database:  
Background: The primary aim was to use routine data to 
compare cancer diagnostic intervals before and after 
implementation of the 2005 NICE Referral Guidelines for 
Suspected Cancer. The secondary aim was to compare 
change in diagnostic intervals across different categories of 
presenting symptoms. Methods: Using data from the 
General Practice Research Database, we analysed patients 
with one of 15 cancers diagnosed in either 2001–2002 or 
2007–2008. Putative symptom lists for each cancer were 
classified into whether or not they qualified for urgent 
referral under NICE guidelines. Diagnostic interval 
(duration from first presented symptom to date of 
diagnosis in primary care records) was compared between 
the two cohorts. Results: Patients who presented with 
NICE-qualifying symptoms had shorter diagnostic intervals 
than those who did not (all cancers in both cohorts). For 
the 2007–2008 cohort, the cancers with the shortest 
median diagnostic intervals were breast (26 days) and 
testicular (44 days); the highest were myeloma (156 days) 
and lung (112 days). The values for the 90th centiles of the 
distributions remain very high for some cancers. Tests of 
interaction provided little evidence of differences in 
change in mean diagnostic intervals between those who did 
and did not present with symptoms specifically cited in the 
NICE Guideline as requiring urgent referral. Conclusion:  
We suggest that the implementation of the 2005 NICE 
Guidelines may have contributed to this reduction in 
diagnostic intervals between 2001–2002 and 2007–2008. 
There remains considerable scope to achieve more timely 
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cancer diagnosis, with the ultimate aim of improving 
cancer outcomes 8. 
 
Provide information on 
resource use and evaluate 
the potential impact of 
guidance in changing 
resource use 
 
Determination of inputs/resource use is possible at primary 
care level as well as linkages into secondary care.  
 
Example study and abridged abstract: 
“The prevalence and incidence, resource use and 
financial costs of treating people with attention 
deficit/hyperactivity disorder (ADHD) in the United 
Kingdom (1998 to 2010): The aims of this study were to 
characterise the epidemiology of diagnosed ADHD in the UK 
and determine the resource use and financial costs of care. 
Methods For this retrospective, observational cohort study, 
patients newly diagnosed with ADHD between 1998 and 
2010 were identified from the UK Clinical Practice 
Research Datalink (CPRD) and matched to a randomly 
drawn control group without a diagnosis of ADHD. The 
prevalence and incidence of diagnosed ADHD were 
calculated. Resource utilisation and corresponding financial 
costs post-diagnosis were estimated for general practice 
contacts, investigations, prescriptions, outpatient 
appointments, and inpatient admissions. Mean annual total 
healthcare costs were higher for ADHD cases than controls 
(e.g. £1,327 versus £328 for year 1). Conclusions: The 
prevalence of diagnosed ADHD in routine practice in the UK 
was notably lower than in previous reports, and both 
prevalence and incidence of diagnosed ADHD in primary 
care have fallen since 2007. Financial costs were more 
than four times higher in those with ADHD than in those 
without ADHD155. 
 
Provide information on 
epidemiological trends 
 
Determination of several conditions possible. Large 
population samples of patients with rare conditions are 
possible using these data (although not in all cases). 
 
Example study and abridged abstract: 
“The incidence of pneumonia using data from a 
computerized general practice database: Despite being 
widely recognized as a significant public health problem 
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there are surprisingly few contemporary data available on 
the incidence of pneumonia in the UK. We conducted a 
general population-based cohort study to determine the 
incidence of pneumonia in general practice in the United 
Kingdom. Data were obtained from The Health 
Improvement Network (THIN) – a computerized, 
longitudinal, general practice database. Recorded 
diagnoses of pneumonia between 1991 and 2003 were used 
to calculate the incidence of pneumonia stratified by year, 
sex, age group and deprivation score. The overall incidence 
of pneumonia was 233/100 000 person-years [95% 
confidence interval (CI) 231–235] and this rate was stable 
between 1991 and 2003. In conclusion, pneumonia is an 
important public health problem and the incidence of 
pneumonia is higher in people at the extremes of age, men 
and people living in socially deprived areas.” 156 
 
Provide information on 
current practice to inform 
the development of NICE 
quality standards 
 
Determination of inputs/resource use and components of 
practice likely to be sufficient. 
 
Example study and abridged abstract: 
Regional and temporal variation in the treatment of 
rheumatoid arthritis across the UK: a descriptive 
register-based cohort study: Objectives To describe 
current disease-modifying antirheumatic drugs (DMARDs) 
prescription in rheumatoid arthritis (RA) with reference to 
best practice and to identify temporal and regional trends 
in the UK. Participants with RA were identified through 
screening of all patients in the General Practice Research 
Database (GPRD) with a clinical or referral record for RA 
and at least 1 day of follow-up. 
Results Of the 35 911 patients in the full RA cohort, 15 259 
patients (42%) had incident RA. Analysis of prescribing in 
incident RA patients demonstrated that between 1995 
(baseline) and 2010 there was a substantial increase in 
DMARD, and specifically methotrexate, prescribing across 
all regions with a less marked increase in combination 
DMARD prescribing. Conclusions There has been a 
substantial increase in prescribing of DMARDs for RA since 
1995; however, regional variation persists across the UK 
with relative undertreatment, according to established 
best practice. Improved implementation of evidence-based 
best clinical practice to facilitate removal of treatment 
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variation is warranted. This may occur as a result of the 
implementation of published national guidance157. 
 
Key References:  
Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data 
Resource Profile: Clinical Practice Research Datalink (CPRD). International journal of 
epidemiology 2015:dyv098. 
 
QResearch 
Aims and description: QResearch is a collaboration between Nottingham University and 
EMIS (software developers) which provides access to anonymised primary care patient-
level data to academic researchers based in UK universities. The aims of this collaboration 
are stated on the QResearch website as being ‘to develop and maintain a high quality 
database of general practice derived data for use in ethical medical research’33. A second 
aim is to make health morbidity statistics available to the health community at large (at 
aggregate level) 158. QResearch is profiled here along with THIN and CPRD as one of the 
three major clinical databases in the UK. 
Background, history and study design: The data collected in QResearch are based on 
patient interactions with their GP and include information on patients’ demographics, 
lifestyle and physical characteristics (height, weight, smoking status), symptoms, clinical 
diagnoses, consultations, referrals, prescribed medication and results of investigations; 
data linkages also offer a broader set of potential data for analyses 159. Only coded data 
are available from QResearch - excluding free text data and attachments – which 
decreases the possibility of breaches of confidentiality of patients 66. 
EMIS (Egton Medical Information Systems) is one of the largest providers of integrated 
software for clinicians in the UK and was designed in the 1980s as software written by 
doctors for doctors with the ultimate aim of improving patient care34. EMIS provides 
software for GPs and other clinicians to store and interrogate patient-level records. The 
facility to use anonymised patient records for academic research became functional over 
2004-2006 although patient records date back much further to the 1990s when the 
practices involved in QResearch began adopting EMIS systems 158 160. Practices benefit in 
two ways from taking part in QResearch: firstly through the wider findings of research 
based on QResearch and secondly through feedback on their data quality35.  The latest 
publications using QResearch data suggest that over 700 GP practices now contribute data 
161, although this number may now stand at 950 practices 11 and the data are thought to 
represent the medical histories of over thirteen million patients 11 137. QResearch is alone 
in collecting data from GP practices using EMIS; CPRD and THIN collect data from practices 
that use Vision software 137 138. Small differences do exist based on operating systems and 
there are indications that Vision may enable faster coding of items (except prescribing 
                                            
33 http://www.qresearch.org/SitePages/What%20Is%20QResearch.aspx 
34 http://www.emis-online.com/company-profile 
35 Not all practices who use EMIS are included in QResearch 
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information) and therefore a greater number of items are likely to be coded and that 
practices using Vision may have slightly higher achievement rates for QoF indicators 138; 
however, the effect of these small differences on actual usability, breadth of the data, 
and data quality is not clear in the literature and may be marginal. 
Validity of measures (e.g. construct, content, criterion validity) and case definitions: 
QResearch uses standard codes: As is the case for both of the other two major sources 
of primary care data, QResearch uses Read code system to record medical information and 
there are approximately 250,000 read codes used to record patient diagnoses, symptoms 
and the care that patients receive 139. Read codes have been in use in the NHS since 1985, 
although have been variously updated and different versions do exist; the successor to 
read codes are Systematized Nomenclature of Medicine Clinical Terms (SNOMED-CT); read 
codes and SNOMED-CT can be cross-mapped to ICD-10 codes 140.  
As is the case with other large GP-level clinical datasets it is possible to undertake 
validation studies and explore levels of consensus of QResearch data using data from an 
alternative clinical databases (CPRD and THIN) as well as from other (linked and unlinked) 
data sources. One such study examined the impact of statins in reducing mortality from 
ischaemic heart disease, finding ‘remarkable consistency’ between CPRD and QResearch 
data in terms of statistical analyses 138. Studies on other health concerns, including 
cancer, also suggest a high degree of concurrence between CPRD and QResearch data 35. 
Studies on smoking prevalence also suggest that the data closely follow trends in the 
Health Survey for England 162; although overall QResearch data has not been validated as 
extensively as CPRD data. Furthermore, the data may share some of the limitations found 
in CPRD and THIN based around the nature in which data are collected and the stability of 
constructs. There is also potential to undertake validation studies against linked data (see 
later section), and studies that have examined the levels of valid NHS number through 
which to undertake such linkages have revealed high levels of completeness to facilitate 
this work 163. Where a number of QResearch validation studies have focussed is on 
validating risk prediction scores that are based on simulation models using QResearch data 
against actual observed events for example 164. 
Representative of populations and settings: QResearch is broadly representative of GP 
practices in the UK. Three forms of selection effect potentially compromise the 
representativeness of the data. Firstly, although EMIS is the largest provider of 
information systems to GP practices not all GP surgeries are represented. Secondly, not all 
GP surgeries who use EMIS are included in QResearch data. Thirdly, not all patients 
belonging to included surgeries will consent to having their data included: included 
practices are asked to display notices in their surgeries to inform patients about their 
participation in QResearch, and patients who do not wish their anonymised data to be 
included are able to opt out 158. These potential limitations are likely to be shared across 
all three major primary care databases. Some (minor) demographic differences may exist 
between the three large clinical databases. For example, some differences have been 
uncovered between samples of THIN and QResearch patients, with QResearch patients 
having a more even representative socioeconomic profile according to patients’ postcodes 
than THIN 165. Low data quality for some items prevents full assessment of 
representativeness of the data; ethnicity for example is present for around a third of 
records which is comparable with the other two clinical databases and analyses of CPRD 
Section 4: Selected in-depth data profiles - QResearch 
95 
 
suggests that despite low levels of completion, the ethnic profile mirrors that of census 
data, and this may also be the case for QResearch data 143. The largest differences are 
likely to lie in the size of the clinical databases, with THIN being the smallest and 
QResearch the largest. 
Representativeness of different disease stages: QResearch is a primary care clinical 
database that allows researchers to monitor the treatment of disease in primary care 
settings. In this respect, it shares many of the limitations of the other two major sources 
of primary care data in that the possibility of monitoring different stages of disease 
beyond primary across different care providers is only possible through data linkages based 
on common identifiers (see below). As discussed earlier, QResearch has high data quality 
for NHS number, a common identifier across several databases. As QResearch is not 
designed for examining a single disease or condition, monitoring disease progression from 
a patient perspective may be challenging and there are no studies that describe QResearch 
data being used to examine patient reported outcomes. 
Clear ethical frameworks: QResearch has full ongoing approval from the Trent 
Multicentre Research Ethics Committee and research studies which utilise QResearch data 
need to obtain ethical approval from this committee. Patients of participating practices 
are given notice of the facility of opting out of the study.  
Dynamic and adaptable: There are numerous examples of QResearch data being used for 
innovative studies; there are several opportunities for improved patient care being 
exploited through the development and use of risk scores in primary care which have been 
found to outperform traditional frameworks. Adaptation/dynamism in the actual 
collection of data will be a reflection of development either in the extent/depth of read 
codes available, the extent of data linkages and changes in the EMIS platform and 
extraction algorithms from EMIS for QResearch.  
Data Linkages: QResearch data are routinely linked to socioeconomic data (based on 
patients’ postcodes) and cause of death data (based on Office for National Statistics death 
certificate) 66. Further data linkage projects have enabled data linkage between 
QResearch and cancer registry data 163. There is also work underway to link QResearch 
data with hospital episode data (inpatient data, outpatient data, maternity data, critical 
care data) 66. 
Collection of data reflective of real-world conditions (scope): A broad scope of data 
reflecting primary care interactions between patient and GP are collected in QResearch 
and studies have included: epidemiological studies around the incidence and correlates of 
smoking cessation 162; studies investigating potential iatrogenic complications following 
prescriptions of statins 166; and studies examining resource use through trends in 
consultation rates in GP practice 167.  
Sensitivity: The data have been used to examine potential iatrogenic complications 
following statin prescriptions (see above). Triangulation of findings between different data 
sources may be necessary to confirm findings. The data may allow for and establishing 
states before administering treatment. 
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Understanding or reporting of selection/sample composition: Further contact with study 
depositors is likely to inform on the impact and procedures for surgeries opting in/out of 
the study. The impact is likely to be similar across all three primary care databases. 
Uniformity in data collection procedures: No purposeful data collection method per se – 
dependent on GP entry as part of consultation and patient care. As described above, 
uniformity in coding systems used makes QResearch data highly comparable with THIN and 
CPRD data.  
Steps taken to minimise common forms of bias: Confounding by indication a risk in using 
QResearch data for effectiveness studies, although use of appropriate analytical technique 
likely to offset the risk in part, and studies using QResearch data have explored the 
potential extent and impact of indication bias using different methods see, for example, 
166. Modifications to the sample and to the range of data included can reduce the impact 
of other forms of potential bias, for example protopathic and recall bias see, for example, 
35. Selection effects at patient and practice level are also possible, although the risk is 
likely equivalent to other primary care databases.  
Scope and flexibility in research design: As described earlier, there is a wide scope for 
analysing data reflecting outcomes and experiences of morbidity and mortality at primary 
care level, as well as trends in the care and treatment provided. The study depositors 
state that QResearch data are suitable for case control studies designed to examine risk 
factors for onset of disease, cross sectional surveys, cohort studies and sample size 
calculations (for non-observational studies) 11. 
Granularity of treatment/disease data: Given that read codes form the basis for the entry 
of data into QResearch, and that over 250,000 codes exist, a high level of granularity of 
data can be incorporated into studies. The data depositors/gatekeepers can also provide 
advice on the level of granularity  
Other considerations/information: QResearch is one of the newest sources of primary 
care information but is rapidly emerging as the largest source with new practices 
becoming involved and EMIS being the most common form of information management 
system in use. Further data linkage projects are likely to enhance the potential for 
tracking patient journeys in future. However, the data have a number of stipulations: 
firstly while QResearch is being run as a not-for-profit collaboration, some costs are 
associated with extracting the data (which are dependent on the study itself). Secondly, 
to access QResearch, a stringent ethics process needs to be undertaken to ensure that the 
purposes for which the data are to be used adhere to the underlying principles of 
QResearch. Finally, and most fundamentally for NICE, data for QResearch are available 
only to researchers based in UK universities, which compromises its potential for internal 
use.  
QResearch in numbers: 950 GP Practices; 13 million patient records; Largest sample 
available: 100,000. 
Summary and Utility for NICE: QResearch is of interest to NICE for many of the real world 
data uses identified by NICE, but it appears the data cannot be directly accessed by NICE. 
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Nevertheless, given the substantial potential of these data, NICE should consider ways of 
developing research projects based on QResearch data in partnership with universities.  
Desire use by NICE Potential suitability36 
Research the effectiveness 
of interventions or 
practice in real-world (UK) 
settings 
Determination of population of interest and reliability of 
measures are satisfied with QResearch; satisfactory range 
of intrinsic measures and additional prognostic measures 
(although data quality may be problematic for some 
measures in common with other primary care data).  
 
Example study and abridged abstract: 
“Unintended effects of statins in men and women in 
England and Wales: population based cohort study using 
the QResearch database: Objective: To quantify the 
unintended effects of statins according to type, dose, and 
duration of use. Design: Prospective open cohort study 
using routinely collected data. Setting: 368 general 
practices in England and Wales supplying data to the 
QResearch database. Results: Individual statins were not 
significantly associated with risk of Parkinson’s disease, 
rheumatoid arthritis, venous thromboembolism, dementia, 
osteoporotic fracture, gastric cancer, colon cancer, lung 
cancer, melanoma, renal cancer, breast cancer, or 
prostate cancer. Statin use was associated with decreased 
risks of oesophageal cancer but increased risks of moderate 
or serious liver dysfunction, acute renal failure, moderate 
or serious myopathy, and cataract. Adverse effects were 
similar across statin types for each outcome except liver 
dysfunction where risks were highest for fluvastatin. A 
dose-response effect was apparent for acute renal failure 
and liver dysfunction. All increased risks persisted during 
treatment and were highest in the first year. Conclusions 
Claims of unintended benefits of statins, except for 
oesophageal cancer, remain unsubstantiated, although 
potential adverse effects at population level were 
confirmed and quantified.  
Audit the implementation 
of guidance.  
 
Determination of changes in primary care practice possible 
using QResearch data. An example of a study examining 
current and changes in diagnostic practice (not guidelines 
per se) is given below. 
                                            
36 Potential suitability here is something of a subjective construct in the absence of a clear research 
question to be addressed. However,  
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Example study and abridged abstract: 
“Incidence, prevalence, and trends of general 
practitioner–recorded diagnosis of peanut allergy in 
England, 2001 to 2005: Previous descriptions of the 
epidemiology of peanut allergy have mainly been derived 
from small cross-sectional studies. Objective: To 
interrogate a large national research database to provide 
estimates for the incidence, prevalence, and trends of 
general practitioner (GP)–recorded diagnosis of peanut 
allergy in the English population. Methods: Version 10 of 
the QRESEARCH database was used with data from 
2,958,366 patients who were registered with 422 United 
Kingdom general practices in the years 2001 to 2005. The 
primary outcome was a recording of clinician-diagnosed 
peanut allergy. Results: The age-sex standardized 
incidence rate of peanut allergy in 2005 was 0.08 per 1000 
person-years (95% CI, 0.07-0.08), and the prevalence rate 
was 0.51 per 1000 patients (95% CI, 0.49-0.54). A 
significant inverse relationship between prevalence and 
socioeconomic status was found. Conclusion: These data on 
GP-recorded diagnosis of peanut allergy from a large 
general practice database suggest a much lower prevalence 
in peanut allergy than has hitherto been found. This 
difference may in part be explained by underrecording of 
peanut allergy in general practice. Further research is 
needed to assess the true frequency of peanut allergy in 
the population and whether there has been a true increase 
in recent years10. 
 
Provide information on 
resource use and evaluate 
the potential impact of 
guidance in changing 
resource use 
 
Determination of inputs/resource use is possible at primary 
care level. Studies on prescribing trends have been 
undertaken as well as studies examining other forms of 
resource use. 
 
Example study and abridged abstract: 
Trends in Consultation Rates in General Practice 1995 
to 2008: Analysis of the QResearch® database: This 
report presents the largest longitudinal study of trends in 
consultations undertaken in primary care and is part of an 
ongoing series of analyses using the QResearch® database  
(http://www.qresearch.org)168.  
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Provide information on 
epidemiological trends 
 
Determination of several conditions possible. Large 
population samples of patients with rare conditions are 
possible using these data. 
 
Example study and abridged abstract: 
Trends in the epidemiology of chronic obstructive 
pulmonary disease in England: a national study of 51 
804 patients: Aim: To investigate the epidemiology of 
physician-diagnosed COPD in general practice. Cross-
sectional study of 422 general practices in England 
contributing to the QRESEARCH database. Data were 
extracted on 2.8 million patients, including age, sex, 
socioeconomic status, and geographical area. Trends over 
time for recorded physician diagnosis of COPD were 
analysed (2001–2005). There was little change over time in 
the incidence rate of COPD (2005: 2.0 per 1000 patient-
years, 95% confidence interval [CI] = 2.0 to 2.1), but a 
significant increase in lifetime prevalence rate (2001: 13.5 
per 1000 patients [95% CI = 13.4 to 13.7]; 2005: 16.8 [95% 
CI = 16.7 to 17.0]; P<0.001). Conclusion Given the peak in 
the incidence rate of COPD, we may be approaching the 
summit of COPD incidence and prevalence in England. 
However, the number of people affected remains high and 
poses a major challenge for health services, particularly 
those in the north east of the country and in the most 
deprived communities in England. 169 
Provide information on 
current practice to inform 
the development of NICE 
quality standards 
 
Determination of inputs/resource use and components of 
practice likely to be sufficient. 
 
Key References:  
Hippisley-Cox, J., D. Stables, et al. (2004). "QRESEARCH: a new general practice database 
for research." Journal of Innovation in Health Informatics 12(1): 49-50 
Hippisley-Cox, J. (2014). QResearch. Primary Health Care Specialist Group Conference. 
Stratford-upon-Avon, Warwickshire. 
QResearch. (2012). "What is QResearch?" from 
http://www.qresearch.org/SitePages/What%20Is%20QResearch.aspx. 
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The Health Improvement Network (THIN) 
Aims and description: The Health Improvement Network (THIN) is a collection of 
anonymised electronic health records collected unobtrusively that are based on GP-patient 
interactions from over 550 GP practices. THIN is a collaboration between ‘In Practice 
Systems (INPS)’ who developed Vision software used by general practitioners (GPs) in the 
UK to manage patient data (the underlying software used to populate both CPRD and 
THIN), and IMS Health who then provide access to the data for use in medical research37. 
IMS is part of a global company which is described as serving ‘the world’s leading 
pharmaceutical companies and medical research organisations, providing electronic 
pseudonymised primary care patient data’, and were the company leading on the 
development of the GPRD (the predecessor of CPRD) 170. As is common across the primary 
care clinical databases, the ultimate aim of THIN is to improve patient care38.  
Background, history and study design:  
Prospective data collection for THIN began in 2002 although data are available for some 
practices dating as far back as 1987 171. THIN data currently account for around 5.7% of the 
UK population and comprise one of the large medical datasets alongside QResearch and 
CPRD. Furthermore, although the records of over 3.5 million current patients are held in 
THIN, these represent around 35 per cent of all records held, the remainder being patients 
who have withdrawn consent, moved practice or died 172. Patient characteristics including 
registration details and the patients’ age and gender; medical history around diagnoses, 
treatments and referrals including information for pharamcoepidemiological studies; 
background and lifestyle related health characteristics including vaccination status, 
physical characteristics (height and weight) and smoking status; laboratory results; and 
detailed information around the patient-physician interactions, are collected in THIN; 
these are held in four distinct databases (practice, patient, therapy and clinical datasets) 
173. Additionally, unlike QResearch, THIN data do include free-text based information 174; 
estimates from 2015 suggest that 35 per cent of all comments in medical records have 
been coded or anonymised and can potentially be used in research. Additional information 
may also be available including anonymised questionnaires completed by the patient or 
GP; copies of patient-based correspondence; a specified intervention (e.g. a laboratory 
test to confirm diagnosis); and death certificates 174.  
CPRD and THIN collect data from practices that use Vision software and both are said to 
have comparable data structures, differing to QResearch which uses EMIS 137 138. Small 
differences do exist based on operating systems and there are indications that Vision may 
enable faster coding of items (except prescribing information) and therefore a greater 
number of items are likely to be coded and that practices using Vision may have slightly 
higher achievement rates for QoF indicators 138; however, the effect of these small 
differences on actual usability, breadth of the data, and data quality is not clear in the 
literature and may be marginal. Given the close history between CPRD and THIN, there are 
substantial overlaps between CPRD and THIN data, and practices can participate in both 
databases. A 2012 study that examined 781 practices that were participating in either 
                                            
37 https://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database 
38 http://www.thin-uk.net/gps/ 
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CPRD (GPRD at the time) or THIN found that 327 (41.9%) were common to both datasets; 
286 (36.6%) were included in CPRD only and 168 (21.5%) were included in THIN only.  
Validity of measures (e.g. construct, content, criterion validity) and case definitions: 
As is the case for both of the other two major sources of primary care data, THIN uses 
Read code system to record medical information and there are approximately 250,000 
read codes used to record patient diagnoses, symptoms and the care that patients receive 
139. Read codes have been in use in the NHS since 1985, although have been variously 
updated and different versions do exist; the successor to read codes are Systematized 
Nomenclature of Medicine Clinical Terms (SNOMED-CT); read codes and SNOMED-CT can be 
cross-mapped to ICD-10 codes 140.  
As with other large GP-level clinical datasets it is possible to undertake validation studies 
and explore levels of consensus of THIN data using data from an alternative clinical 
databases (CPRD and QResearch) as well as from other (linked and unlinked) data sources. 
For studies comparing CPRD and THIN data, there are potential for additional validation 
studies based around the overlaps and between datasets examining potential discrepancies 
between these records at a practice level. For example, Lewis and colleagues 171 examined 
whether well-established epidemiological associations were reproducible in THIN data, 
finding that they were, with the exception of a known association between aspirin and 
myocardial infarction (which itself may be a reflection of the ‘real-worldness’ of the data 
and the influence of over-the-counter self-medication). They also established that there 
were no systematic differences between the results of CPRD and THIN participating 
practices. 
Several disease-specific validation studies have been undertaken employing a variety of 
different methods to establish the validity of these THIN data including examining free-
text information, information from additional physician questionnaires, and examining of 
alternative read codes. Several have reported high levels of validity across a variety of 
conditions and treatments including Psoriasis, Chronic Kidney Disease, smoking cessation 
medication prescriptions, Hepatitis C incidence and ischemic cerebrovascular diagnoses 175-
179, although with some caveats 177. Instances of misclassification are more likely to occur 
with less stable constructs, such as smoking status 180. No systematic reviews of validation 
studies of THIN data were identified.   
Representative of populations and settings: Some (minor) demographic differences may 
exist between the three large clinical databases. For example, some differences have 
been uncovered between samples of THIN and QResearch patients, with QResearch 
patients having a more even socioeconomic profile based to patients’ addresses than THIN 
165; similar conclusions are also drawn in other studies of representativeness which find 
that 23.5% of THIN patients live in the most affluent quintile 172. THIN patients are also 
thought to be slightly older and the data also have minor differences in geographic 
distribution across UK regions and countries 172. Nevertheless, these small disparities are 
not thought to compromise the overall representativeness of the sample, and most studies 
using the data regard THIN as being broadly representative of national primary care trends 
and practice. 
Low data quality for some items prevents full assessment of representativeness of the 
data; ethnicity for example is present for around a quarter of records which is comparable 
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with the other two clinical databases, although analyses of CPRD suggests that despite low 
levels of completion, the ethnic profile mirrors that of census data 143. The largest 
differences are likely to lie in the size of the clinical databases, with THIN being the 
smallest and QResearch the largest. 
Representativeness of different disease stages: THIN is a primary care clinical database 
that allows researchers to monitor the treatment of disease in primary care settings. In 
this respect, it shares many of the limitations of the other two major sources of primary 
care data in that the possibility of monitoring different stages of disease beyond primary 
across different care providers is only possible through data linkages based on common 
identifiers (see below). However, the data are used to monitor disease stages in the 
literature and the factors predicting transitions to different stages and conditions 181; the 
utility of the data for doing so are likely to be highly dependent on the research question 
being asked. As THIN is not designed for examining a single disease or condition, 
monitoring disease progression from a patient perspective may be challenging; however 
there may be scope for including patient reported outcome data through fielding 
additional anonymised questionnaires 174 although there are few examples of such studies 
occurring in the published literature. 
Clear ethical frameworks: THIN has full ongoing approval from the South East Multicentre 
Research Ethics Committee and research studies. Researchers wishing to undertake studies 
using THIN data are required to submit their proposal to a Scientific Review Committee to 
gain approval; those who wish to collect additional data from patients will need to seek 
further Research Ethics Committee approval39. Patients of participating practices are given 
notice that their practice is a contributing member of THIN 182, although the procedures 
and number of patients withdrawing consent are unclear.  
Dynamic and adaptable: Adaptation/dynamism in the actual collection of data will be a 
reflection of development either in the extent/depth of read codes available, the extent 
of data linkages and changes in the Vision platform and extraction algorithms. However, 
the potential for additional instruments to be fielded among patients means that data that 
better meets the data requirements of the research question can be collected 
purposefully; in particular this means that data on Patient Reported Outcomes could be 
collected alongside other clinical measures. THIN data are suitable for a number of 
epidemiological study designs included cohort, case-control and case-series40. 
Data Linkages: Recent developments have seen THIN data being linked with Hospital 
Episodes Statistics (HES) data, providing potential for studying continuity in care between 
primary and secondary care. A number of patient postcode-based socioeconomic, ethnicity 
and environmental indicators are available to researchers including Townsend deprivation 
quintile scores.  
Collection of data reflective of real-world conditions (scope): A broad scope of data 
reflecting primary care interactions between patient and GP are collected in THIN and 
there are several published studies that examine a broad range of research questions 
around the frequency, quality, treatment regimes and outcomes of these. These include: 
                                            
39 http://www.csdmruk.imshealth.com/our-data/ethics.shtml 
40 http://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database/pros-cons 
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studies that examine the equity of services provided in real-world settings, for example 
disparities in cancer screening services provided to people with learning difficulties 12; 
studies that examine the levels of and factors related to the discontinuation of anti-
depressant medication in primary care practice 183; and studies that examine the impact of 
policy changes in the diagnosis of Chronic Obstructive Pulmonary Disease 184.  
Sensitivity: The data have been used to examine complications of iatrogenic disease in 
some studies; for example the incidence of cardiovascular complications following 
iatrogenic Cushing’s syndrome 185. Other studies, have relied mainly on the breadth of 
data collected on chronic conditions and the sequencing of events and diagnoses to 
distinguish between complications and co-morbidities for example 186. The degree of 
sensitivity in this respect will be highly dependent on the disease/condition itself. 
Understanding or reporting of selection/sample composition: Consultation with study 
depositors is likely to inform on the impact and procedures for surgeries opting in/out of 
the study. There is little evidence of any difference in the profile of participating 
surgeries in THIN compared to those who do not participate. Surgeries whose levels of 
data quality do not meet agreed standards are not allowed to participate in THIN, 
although the impact of excluding these practices is relatively unknown. 
Uniformity in data collection procedures: No purposeful data collection method per se – 
dependent on GP entry as part of consultation and patient care. As described above, 
uniformity in coding systems used makes THIN data highly comparable with QResearch and 
CPRD data.  
Steps taken to minimise common forms of bias: Confounding by indication is a risk in 
using THIN data for effectiveness studies, although use of appropriate analytical 
techniques likely to offset the risk in part. Studies using THIN data have also undertaken 
forms of sensitivity analysis and stratified analyses by risk categories to examine whether 
their conclusions hold, in order to examine potential impacts of confounding by indication 
187. Misclassification bias is thought to have minimal influence on the conclusions drawn 
from studies using the data 171. Modifications to the sample drawn can help offset the 
potential impact of other forms of potential bias such as protopathic bias 188. Selection 
effects at the practice level (and potentially the patient level) are also possible, although 
the risk is likely equivalent to other clinical databases. As is common across clinical 
datasets, the influence of unobserved confounders including over-the-counter medications 
will be unquantifiable as will levels of compliance with reported treatment regimes.  
Scope and flexibility in research design: As described earlier, there is a wide scope for 
analysing data reflecting outcomes and experiences of morbidity and mortality at primary 
care level, as well as trends in the care and treatment provided. These data can also be 
linked to HES data allowing for potential tracking of patient journeys between primary and 
secondary care.  
Granularity of treatment/disease data: Given that read codes form the basis for the entry 
of data into THIN, and that over 250,000 codes exist, a high level of granularity of data 
can be incorporated into studies. This granularity has been exploited in many studies to 
better distinguish between certain forms of condition – for example in distinguishing 
between iatrogenic and endogenous forms of Cushing’s syndrome see 185. 
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Other considerations/information: Training is available from IMS. There exists a 
dedicated research team within UCL – the THIN Database Research Team – who conduct 
research into cardiovascular disease, mental health, pharmacoepidemiology and other 
fields of primary care research using THIN data.  
THIN in numbers: 587 GP Practices; 12.4 million patient records; 3.7 million active 
patients; 85.8 million patient years of data. 
Summary and Utility for NICE: THIN data hold potential for much of NICE’s intended use 
of real-world data. THIN data have utility for NICE through the flexibility in being able to 
collect additional fields and the potential to conduct research based on free-text fields. 
THIN data are also available to medical researchers based outside UK universities 
potentially expanding the pool of potential partners with which NICE could work in using 
the dataset. 
Key References:  
Lewis, J. D., Schinnar, R., Bilker, W. B., Wang, X., & Strom, B. L. (2007). Validation 
studies of the health improvement network (THIN) database for pharmacoepidemiology 
research. Pharmacoepidemiology and drug safety, 16(4), 393-401. 
 
Blak, B. T., Thompson, M., Dattani, H., & Bourke, A. (2011). Generalisability of The Health 
Improvement Network (THIN) database: demographics, chronic disease prevalence and 
mortality rates. Informatics in primary care, 19(4), 251-255. 
 
UCL THIN Research. The THIN database: UCL, 2015. 
https://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database 
 
Desire use by NICE Potential suitability41 
Research the effectiveness 
of interventions or 
practice in real-world (UK) 
settings 
Determination of population of interest and reliability of 
measures are satisfied with THIN; range of intrinsic 
measures and additional prognostic measures (although 
data quality may be problematic for some measures in 
common with other primary care data). Additional scope 
for collecting patient reported outcomes is possible. 
 
Example study and abridged abstract: 
“Clinical Outcomes and Cost-effectiveness of 
Continuous Positive Airway Pressure to Manage 
Obstructive Sleep Apnea in Patients With Type 2 
Diabetes in the U.K:  To assess clinical outcomes and cost-
effectiveness of using continuous positive airway pressure 
(CPAP) to manage obstructive sleep apnea (OSA) in 
                                            
41 Potential suitability here is something of a subjective construct in the absence of a clear research 
question to be addressed. However,  
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patients with type 2 diabetes (T2D) from the perspective of 
the U.K.’s National Health Service (NHS). Using a case-
control design, 150 CPAP-treated patients with OSA and 
T2D were randomly selected from The Health Improvement 
Network (THIN) database (a nationally representative 
database of patients registered with general practitioners 
in the U.K.) and matched with 150 OSA and T2D patients 
from the same database who were not treated with CPAP. 
The total NHS cost and outcomes of patient management in 
both groups over 5 years and the cost-effectiveness of 
CPAP compared with no CPAP treatment were estimated. 
Initiating treatment with CPAP in OSA patients with T2D 
leads to significantly lower blood pressure and better 
controlled diabetes and affords a cost-effective use of NHS 
resources. These observations have the potential for 
treatment modification if confirmed in a prospective 
study” 189 
Audit the implementation 
of guidance.  
 
Determination of changes in primary care practice possible 
using THIN data; such studies have included studies based 
on the introduction of NICE guidance 184.  
 
Example study and abridged abstract: 
“The impact of the 2004 NICE guideline and 2003 
General Medical Services contract on COPD in primary 
care in the UK:  The introduction of the NICE guideline on 
COPD and the inclusion of COPD in the new Quality and 
Outcomes Framework (QOF) were designed to improve the 
care of people with COPD in primary care in the UK. We 
have investigated whether these initiatives have had an 
impact on the prevalence of COPD, the recording of 
spirometry data and the use of combined inhaled 
corticosteroid/long-acting beta-agonist inhalers. We 
analysed data from The Health Improvement Network for 
the year before and after the introduction of the NICE 
guideline. Following the introduction of the NICE guideline 
for COPD and the new QOF, there has been an increase in 
the prevalence of COPD in general practice and a large 
increase in spirometry data and prescriptions for 
combination inhalers.” 184  
 
Provide information on 
resource use and evaluate 
the potential impact of 
Determination of inputs/resource use is possible at primary 
care level as well as linkages into secondary care.  
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guidance in changing 
resource use 
 
 
Example study and abridged abstract: 
“Trends in depression and antidepressant prescribing in 
children and adolescents: a cohort study in The Health 
Improvement Network (THIN): In 2003, the Committee on 
Safety of Medicines (CSM) advised against treatment with 
selective serotonin reuptake inhibitors (SSRIs) other than 
fluoxetine in children, due to a possible increased risk of 
suicidal behaviour. This study examined the effects of this 
safety warning on general practitioners' depression 
diagnosing and prescription behaviour in children. The 
study identified a cohort of 1,502,753 children (<18 y; 
registered with GP for >6 m) in The Health Improvement 
Network (THIN) UK primary care database. Trends in 
incidence of depression diagnoses, symptoms and 
antidepressant prescribing were examined 1995–2009, 
accounting for deprivation, age and gender” 190 
 
Provide information on 
epidemiological trends 
 
Determination of several conditions possible. Large 
population samples of patients with rare conditions are 
possible using these data (although not in all cases). 
 
Example study and abridged abstract: 
“The incidence of pneumonia using data from a 
computerized general practice database: Despite being 
widely recognized as a significant public health problem 
there are surprisingly few contemporary data available on 
the incidence of pneumonia in the UK. We conducted a 
general population-based cohort study to determine the 
incidence of pneumonia in general practice in the United 
Kingdom. Data were obtained from The Health 
Improvement Network (THIN) – a computerized, 
longitudinal, general practice database. Recorded 
diagnoses of pneumonia between 1991 and 2003 were used 
to calculate the incidence of pneumonia stratified by year, 
sex, age group and deprivation score. The overall incidence 
of pneumonia was 233/100 000 person-years [95% 
confidence interval (CI) 231–235] and this rate was stable 
between 1991 and 2003. In conclusion, pneumonia is an 
important public health problem and the incidence of 
pneumonia is higher in people at the extremes of age, men 
and people living in socially deprived areas.” 156 
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Provide information on 
current practice to inform 
the development of NICE 
quality standards 
 
Determination of inputs/resource use and components of 
practice likely to be sufficient. 
 
Example study and abridged abstract: 
Access to Cancer Screening in People with Learning 
Disabilities in the UK: Cohort Study in the Health 
Improvement Network, a Primary Care Research 
Database To assess whether people with learning disability 
in the UK have poorer access to cancer screening. Four 
cohort studies comparing people with and without learning 
disability, within the recommended age ranges for cancer 
screening in the UK. We used Poisson regression to 
determine relative incidence rates of cancer screening. 
Setting: The Health Improvement Network, a UK primary 
care database with over 450 General practices 12 
 
Key References:  
Lewis, J. D., Schinnar, R., Bilker, W. B., Wang, X., & Strom, B. L. (2007). Validation 
studies of the health improvement network (THIN) database for pharmacoepidemiology 
research. Pharmacoepidemiology and drug safety, 16(4), 393-401. 
 
 
National Minimum Data Set for Social Care (NMDS-SC) 
Aims and description: The National Minimum Data Set for Social Care (NMDS-SC) is a 
database that collects information on the profile of the social care workforce in England. 
The data collection is organised by Skills for Care and the data hold information on 
700,000 care workers (current and former) working in adult social care across 25,000 
establishments42. Underlying the collection of the data is an ambition to ensure that the 
adult social care sector has a ‘confident, capable and skilled workforce’ to ensure the 
delivery of excellent quality care43.  
Background, history and study design:  
Established in 2005, the data are described as the first attempt at implementing a 
standardised approach to collecting information on employees working across social care 
establishments 14. While there has traditionally been a focus on the adult social care 
workforce, the data also contain information on the workforce providing care in almost 
1,600 children’s establishments and approximately 1,000 family establishments social 
                                            
42 https://www.nmds-sc-online.org.uk/content/About.aspx 
43 https://vimeo.com/121886971 
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care. In May 2015, data from 24,621 establishments were included in England; these 
represented a mixture of private establishments (30.1%), voluntary sector (18.6%), Local 
Authority/statutory controlled establishments (47.3%) and those that did not fit within any 
particular class (4.0%) 191. This allows for comparisons to be drawn between the workforce 
mix across sectors. In addition, data are collected on approximately 220 variables 
reflecting details around the social care establishment (including size, location, primary 
client group, sector), the highest qualifications of workers, induction status, job grade and 
title of workers; gender, disability status, ethnicity and age of workers; contract type and 
hours; nationality and country of birth; sectoral experience; sickness; pay; and 
establishment records around recruitment, retention and destination of leavers192. These 
data are uploaded monthly by employers who provide aggregate estimates or provide 
individual level data for some or all of their employees193. Until 2012, participation in the 
NMDS-SC was optional, although despite being a voluntary levels of participation were 
high; after this point completion of NMDS-SC has become the ‘mandatory workforce data 
collection tool for the English adult social care sector’193, although this may not fully apply 
to all privately registered establishments194. Employers submit details of their workforce 
and in return are able to benchmark their workforce mix according to national trends 
using a dashboard of indicators. In addition, they are also able to access e-learning 
modules on pertinent issues such as dementia care and can apply for workforce 
development funding. Employers also have an option of sharing their data with NHS 
Choices and the Care Quality Commission44.   
Validity of measures (e.g. construct, content, criterion validity) and case definitions:  
Many of the indicators included in NMDS-SC have high levels of construct validity and are 
not intended to capture complex diagnoses or constructs, therefore validation studies are 
in the minority. However, there are indications that some of the measures that are 
included in NMDS-SC do have low data quality – for example Hussein and colleague’s study 
found that around 55% of records in a 2011 extract held valid information on both 
ethnicity and nationality 195. Furthermore, explorations of the validity and quality of some 
of the data are possible through implementing consistency checks196. Overall, there remain 
some differences in data quality for certain domains, including in turnover rates, and data 
quality can vary systematically by Local Authority197. Nevertheless, previous issues around 
data quality identified in early reviews 198 are thought to be improving over time34. The 
data depositors (Skills for Care) are also making adaptations to improve data quality with 
regards to measuring the increasing plurality of ways in which social care is planned, 
purchased and delivered, including improving data capture around non-CQC registered 
employees and capturing information on the arrangements of direct payment recipients 
who purchase their social care directly 199. 
Representative of populations and settings:   
The data are thought to be representative of statutory/Local Authority run care, as all 
Local Authorities are required to provide data to NMDS-SC. Skills for Care estimate that 
there are 38,000 Care Quality Commission (CQC) registered providers and employers of 
adult social care in England and as of December 2014 it was estimated that 55% of these 
contribute data to NMDS-SC 200. In total there are thought to be 1.3 million jobs in the 
                                            
44 https://vimeo.com/121886971 
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social care sector 200, and 663,000 workers are represented in the NMDS-SC data 191. Those 
purchasing their own care directly – i.e. single person employers who are also the care 
recipient – are known to be underrepresented in the data195. 
Representativeness of different disease stages: NMDS-SC does not capture information 
on the care trajectories of social care recipients. It may be possible to trace longitudinal 
progression in terms of gaining qualifications and professional development in the data. 
Clear ethical frameworks: Data are most commonly provided at an aggregate level to 
maintain the anonymity of individuals and establishments. Anonymised individual level 
data are available although subject to approval from Skills for Care who ‘will make 
individual judgments on the supply of raw data taking into consideration the nature of the 
person / organisation requesting the data and the intended use of the data’45.   
Dynamic and adaptable: The NMDS-SC data user group are responsible for considering 
changes to the core dataset to ensure that necessary fields are captured (see 201 for recent 
adaptations that the group has considered). 
Data Linkages: While data linkages are not specifically mentioned in much of the 
literature around NMDS-SC, there are examples of studies where NMDS-SC data have been 
linked to other datasets. Hussein and Manthorpe’s 202 study provides an example where 
NMDS-SC data were linked with Index of Multiple Deprivation data in order to understand 
antecedent characteristics of patterns of volunteering in social care settings. 
Collection of data reflective of real-world conditions (scope): NMDS-SC is a specialist 
dataset that can provide unique information on the composition, skill mix and 
development needs of the adult social care workforce. It does not, currently, contain 
information on the outcomes of social care recipients. 
Sensitivity: This is not applicable for NMDS-SC. 
Understanding or reporting of selection/sample composition: An outline of the 
representativeness (provided above); beside underrepresentation of direct payment 
recipients, there is little evidence that the NMDS-SC data differs systematically from the 
total care workforce population.  
Uniformity in data collection procedures: There is uniformity within the system as all 
contributing employers are asked to submit their using a standardised portal, although 
there are irregularities in intervals for data collection 203. There may be differences as to 
whether employers provide granular information on some or all of their employees, as 
opposed to aggregate data193.  
Steps taken to minimise common forms of bias:  
Due to the more narrow focus of NMDS-SC, forms of bias discussed elsewhere, such as 
protopathic bias of confounding by indication, are not relevant considerations in these 
data. Some bias may occur as employers essentially collect data ‘on behalf’ of the 
workforce. This could mean that an employer may make a ‘best guess’ as to the ethnicity 
or age of an employee. Further bias may occur in this process as employers may express 
                                            
45 https://www.nmds-sc-online.org.uk/content/view.aspx?id=Accessing%20NMDS-SC%20data 
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digit preference or informed guesses with respect to other fields in the absence of 
accurate information204. The extent to which this occurs has not been studied in-depth in 
the literature, although is a recognised caveat of using the data.  
Appropriate recognition of the hierarchical nature can be found in some studies, for 
example Hussein’s 2010 investigation into pay across the sector 205; recognition of which 
can reduce levels of bias in model estimates. Undertaking longitudinal and event history 
analyses in these data can be difficult due to left and right censoring occurring 203.  
Scope and flexibility in research design: Due to the nature of the data, in 
epidemiological terms these data are better suited to cross-sectional, time-series and 
cohort studies as opposed to case-control studies.  
Granularity of treatment/disease data: The level of granularity of the data is appropriate 
for the scope of the data. Detailed information is collected on job roles, experience and 
the characteristics of the establishment. 
Other considerations/access information: Raw data are available on request from Skills 
for Care (Analysis@skillsforcare.org.uk); preference is given to projects that are funded by 
the Department of Health; conditions of use are attached to these data around use for 
intended projects and sharing with third parties.     
CPRD in numbers: 24,621 social care establishments; 55% of CQC registered providers of 
adult social care; 663,000 social care workers represented in the data. 
Summary and Utility for NICE: NMDS-SC is a specialist dataset suitable for monitoring 
trends in the social care workforce. This data can potentially help NICE to understand 
workforce capabilities and undertake preliminary work to understand the feasibility of 
implementing new standards and guidance in social care settings.   
Desire use by NICE Potential suitability46 
Research the effectiveness 
of interventions or 
practice in real-world (UK) 
settings 
As social care outcomes are not collected in NMDS-SC, it is 
unlikely that these data are suitable for this purpose. 
Audit the implementation 
of guidance.  
 
The data may be suitable to examine changes following 
guidance at a workforce level in terms of indicators such as 
pay, training or necessary skills. 
  
 
Provide information on 
resource use and evaluate 
the potential impact of 
Data from NMDS-SC form the basis for the calculation of 
some unit costs for social care. Such data could form the 
basis of studies that examine inequities in resource use by 
                                            
46 Potential suitability here is something of a subjective construct in the absence of a clear research 
question to be addressed. However,  
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guidance in changing 
resource use 
 
geographic area, for example. Resource use is not linked to 
individual social care user data.  
 
Example study: 
Unit costs of health and social care. University of Kent, 
2009.13 
 
Provide information on 
epidemiological trends 
 
Determination of epidemiological trends is not possible 
using these data. However, determination of workforce 
data to respond to epidemiological challenges is a key 
strength. 
 
Example study and abridged abstract: 
“The dementia social care workforce in England: 
Secondary analysis of a national workforce dataset14: 
Objective: Little is known about the social care workforce 
supporting people with dementia in England. This article 
seeks to compare the characteristics of people employed in 
the social care sector supporting people with dementia 
with other members of the social care workforce. This 
article reports on the secondary analysis of a new national 
workforce dataset from England covering social care 
employees. Secondary analysis of this dataset was 
undertaken using 457,031 unique workers’ records. There 
are some important differences between the dementia 
care workforce and other parts of the social care 
workforce in respect of the dementia care workforce being 
more likely to be female, to work part-time, to be 
employed by agencies and to be less qualified. Many work 
for medium-sized care businesses and in people’s own 
homes. The findings are set in the context of efforts to 
increase training and skills. Knowledge of the social care 
workforce is relevant to care quality and should be borne 
in mind when planning interventions and commissioning 
services. 
 
Provide information on 
current practice to inform 
the development of NICE 
quality standards 
Determination of potential inputs/resource use likely to be 
sufficient to form quality standards in terms of staffing 
although these are unlinked to patient outcomes. 
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Key References:  
Hussein S. Longitudinal Workforce Analysis using Routinely Collected Data: Challenges and 
Possibilities. London: King's College London, 2012. 
Skills for Care. The state of the adult social care sector and workforce in England 2015. 
Leeds: Skills for Care, 2015. 
 
Health Survey for England (HSE) 
Aims and description: The Health Survey for England is an annual cross-sectional survey 
profiling the physical and mental health status of the English population residing in private 
residences. As well as headline trends, the breadth of data collected allows the 
relationships between health status and socioeconomic, sociodemographic and lifestyle 
factors to be collected. Each annual survey includes a different theme around a particular 
disease, lifestyle factor or demographic group, as well as including an extensive range of 
core questions. The survey is carried out by the National Centre for Social Research 
(NatCen) (with the involvement of UCL, see below) on behalf of the Health and Social Care 
Information Centre47.    
Background, history and study design:  
The first Health Survey for England (HSE) was carried out in 1991 and was conducted by 
the Office for Population Censuses and Surveys (later the Office for National Statistics). 
Since then, responsibility for carrying out the survey has transferred to NatCen and the 
Research Department of Epidemiology and Public Health, UCL 206.  
The survey has a broad remit, with a focus that changes annually that can also involve the 
collection of data through different instruments, and has a complex sampling frame to 
ensure representativeness (and in some cases sample power) across England. Waves of 
data collection have focussed on adults aged 16 and over, but since 1995 the study has 
also included children living in households, although the sampling frame remains focussed 
on obtaining nationally representative samples of adults aged 16 and over. To obtain 
nationally representative estimates, a stratified random probability sample design is 
implemented where postcode sectors are first randomly sampled, followed by addresses 
within those postcodes. Postcode sectors contain an average of 3,000 addresses and small 
sectors (<500 addresses) are combined with neighbouring sectors; further stratification is 
implemented on the basis of socioeconomic status, local authority, and with additional 
modifications to account for seasonality for further details see, 206. Where an address is 
found to contain multiple dwellings, one dwelling is selected at random and where a 
dwelling has multiple households in occupation, one household is randomly selected 207. 
Weights are constructed for analysts using the data that can account for both probabilistic 
selection and for non-response 207. 
                                            
47 http://www.hscic.gov.uk/healthsurveyengland 
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Core data collected at each sweep since 1994 include general health and longstanding 
illness; alcohol consumption; smoking; height and weight; and many individual 
socioeconomic and sociodemographic characteristics 206. Other data that have been 
collected with some interruptions include reports of acute disease, accidents, dietary 
patterns, cardiovascular disease, contraception, use of cycle helmets, lung function, 
cotinine, blood pressure, and a number of other fields collected periodically as well as 
data to support particular survey foci. Data are collected by trained interviewers initially 
and in a second interview by nurses (dependent on the sweep) using computer assisted 
interviewing; in 2013 a typical interview lasted for 50 minutes for a single person and 60-
65 minutes for a couple household and a nurse interview lasted for 30 minutes 208. 
Validity of measures (e.g. construct, content, criterion validity) and case definitions:  
The HSE includes complex measures, indicators and scales that have been validated 
through pilot work, are validated against other instruments in the survey, are 
benchmarked against other data, or whose validity has been established elsewhere. 
Examples of the internal validation of measures include the Physical Activity and 
Sedentary Behaviour Assessment Questionnaire (PASBAQ) , which has been validated 
against accelerometer data collected from a random subsample of patients and was found 
to have good levels of validity 209. However there is also evidence that caution needs to be 
exercised for some data collected; for example parental reports of their children’s 
physical activity levels using HSE instruments are found to have low levels of validity for 
estimating moderate to vigorous physical activity levels 210. Such self-reported lifestyle 
data may be prone to forms of reporting bias (see later sections). Other studies have 
relied on instruments known to have high levels of validity and reliability; for example 
Tiffin and colleagues’ 211 used the well-established Strength and Difficulties Questionnaire 
as a measure of mental health to examine the relationship between mental health and 
obesity. 
Additional checks are implemented before the data are released and not all data collected 
in interviews are considered valid for analysis purposes 212 
Representative of populations and settings:   
The data are representative of private households in England. This has limitations in 
understanding the health of people living in communal establishments (e.g. residential 
homes) as well as other populations, for example the prison population. In terms of the 
impact of this on health estimates, given that people living in establishments are more 
likely to be older and socioeconomically disadvantaged, this could mean that HSE data 
under represent levels of ill health compared to a population-wide sample 212. Other 
studies have found that the (unweighted) data may over-represent women and under-
represent men 213. Nevertheless, studies using HSE data treat the data as being 
representative of national trends. Study weights and information on sampling units 
provided with the data enable analysts to account for the design of the survey and for 
non-response and to produce nationally representative estimates in their studies. 
While the data itself may be broadly representative of the population, there may be some 
difficulty in obtaining sufficient sample size (and statistical power) in order to conduct 
analysis on smaller groups occurring in the population including, for example, ethnic 
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minorities. The 2013 sweep of data contained information from 8,795 adults and 2,185 
children meaning that analysis by several smaller demographic or geographic groupings are 
limited and are more likely to be reliant on aggregations of smaller groupings, losing 
granularity of data. Some previous HSE surveys have been designed to oversample some 
groups; in the case of ethnicity, the 1999 and the 2004 surveys focussed on the health of 
ethnic minorities with corresponding boosts to samples of Irish, Black Caribbean, Indian, 
Pakistani, Bangladeshi and Chinese respondents and these sweeps can be combined to 
further boost sample sizes 214. Other sweep-specific foci can, in some cases, also enable 
similar analyses to be undertaken for other groups. For example, while communal 
establishments are usually excluded from the data, the 2000 focus on older people 
collected data from 2,493 residents in care homes 215. 
Representativeness of different disease stages: The HSE is an annual cross-sectional 
survey. It does not allow for longitudinal analysis of individuals across sweeps. However, 
some forms of longitudinal analyses are possible based on data linkages which could 
enable the monitoring of progression to different disease stages (see below). Furthermore, 
the data give cross-sectional information on the prevalence of diseases stages and stages 
of needs. For example, recent foci on chronic kidney disease allowed for the estimation of 
different stages of renal disease stage by health authority characteristics 216. The latest 
available sweep (2013, at the time of writing) had a focus on social care, and allowed for 
the examination of different social care needs and provision across the population 
(Activities of Daily Living and Instrumental Activities of Daily Living) 217.  
Clear ethical frameworks: The latest sweep was granted ethical approval from Oxford A 
Research Ethics Committee 212. Individual level data are released, although identifiers are 
removed from the records so that the anonymity of respondents is preserved.  
Dynamic and adaptable: The survey is carried out by two partner organisations on behalf 
of the Health and Social Care Information Centre (HSCIC). The HSIC has consulted on 
different aspects of the survey, including content and foci in future sweeps which does 
allow user input into the survey content; the latest sweep highlighted user interest in the 
inclusion of wellbeing measures 218.  
The study does not have a longitudinal design in of itself, which does limit the potential 
research designs that can be implemented (time-series/repeated cross-sectional study 
designs can be easily implemented). However, the potential for data linkages does expand 
on the number of possible study designs 206. 
Data Linkages:  
HSE data can be linked (for respondents who consent) to the National Health Service 
Central Register allowing cancer and mortality data to be linked. Respondents are also 
asked  for permission to link HSE data with Hospital Episodes Statistics data; just under 
four-fifths consented to these linkages in 2009 (78% and 77% respectively) 206. Additional 
neighbourhood level data have also been linked based on respondents’ residence. 
Studies that have used linked data include a study of socioeconomic deprivation and air 
pollution on the consequent impacts on lung function; this used data linked based on ward 
residence to conclude that lower social class and poor air quality were independently 
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associated with decreased lung function 219. Another example study comes from Oyebode 
and colleagues 15, who pooled data from sweeps 2001-2008 to obtain a sample of 65,226 
records which were linked to mortality records. Cause of death was categorised and the 
study examined the impact of fruit and vegetable consumption on the risk of death by any 
cause, death from cancer, and death from cardiovascular events, finding that eating 7+ 
portions of fruit or vegetables daily reduced the hazard of death by approximately 33 per 
cent in any given period.   
While the HSE raw data are available on the UK Data Archive; special permission is needed 
to use these linked data which can be granted by NatCen/HSCIC. 
Collection of data reflective of real-world conditions (scope): HSE provides 
comprehensive information on the health of the population in England. This includes 
collecting a broad set of indicators reflective of real-world conditions in terms of 
epidemiological conditions, social and socioeconomic determinants of health, health 
service usage and, since 2011, biannual estimates around social care needs and usage 
among those aged 65 and over. The data can also be used to investigate how any of these 
factors vary by social groupings; for example, Nazroo and colleagues’ 214 study examined 
whether inequalities based on ethnicity that occur in the US in health service access and 
usage were replicated in England; in the main this was not the case although differences 
did occur in the use of secondary care services. The potential data linkages also make 
investigating the outcomes of some of these factors and conditions possible. There are 
also some data collected in HSE that are not collected in other sources profiled in this 
report; this includes limited information on over-the-counter medications in use by the 
population; for an example on statins see 220. 
Sensitivity: Distinguishing co-morbidities from complications is challenging due to the 
study design. However, researchers have used the breadth of HSE data to distinguish 
comorbid conditions as baseline in linked data projects see 221. 
Understanding or reporting of selection/sample composition: Some potential limitations 
around the sample are outlined earlier in the description provided on representativeness. 
These are outlined in full in the study documentation, along with information as to how 
analysts can work to mitigate some of these. An additional selection effect could also 
potentially occur when using linked data as not all respondents consent for their data to 
be linked to other records.  
Uniformity in data collection procedures: Procedures for data collection in HSE mirror 
those of other large population studies; there is potential for comparison between HSE 
data and Scottish Health Survey data see 221 for an example. 
Steps taken to minimise common forms of bias:  
Due to the cross-sectional study design of HSE, forms of bias discussed elsewhere, such as 
protopathic bias of confounding by indication are, in part, less relevant considerations as 
the study design would usually preclude carrying out the types of ‘effectiveness studies’ 
where these forms of bias would be most pertinent. 
Some forms of respondent level bias have been outlined earlier, such as social desirability 
bias where parents were completing overestimating the amount of exercise undertaken by 
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their children 210; this form of bias may also be a factor in adult self-reports of physical 
exercise 222. While some of these effects are inevitable in carrying out survey-based 
research, the extensive detail around methodology and the high number of studies 
critically investigating and utilising the data does mean that analysts can at least be well 
informed as to potentially compromising features of the data. 
Scope and flexibility in research design: In the absence of data linkage, these data are 
mainly suited to cross-sectional and repeated cross-sectional/time-series designs.  
Granularity of treatment/disease data: Detailed information is collected on variety of 
domains that allow for distinguishing different diseases and conditions but also allow for a 
very high level of detail in terms of data on social determinants of health and lifestyle 
factors; for example in terms of examining the impact of shift work on health status, 
analysts are able to compare the impact of a total of eight different categories of shift 
work 223. 
Other considerations/access information: Raw data are available free of charge to 
registered users of the UK Data Archive. Additional permissions and charges are applicable 
for non-standard or early release data and dependent on the request, these are obtained 
from NatCen or the HSCIC.     
CPRD in numbers: Extent of sweeps: 1991-present; Sample size variations – adults 
interviewed: 4,645 (2009) – 16,443 (1996); since 2010 the number of adults interviewed 
has been around 8,500 with around 2,000 interviews carried out with children living in the 
same household. 
Summary and utility for NICE: HSE was suggested in the context of monitoring 
epidemiological trends. However, the 2013 sweep contained a focus on social care and the 
survey is a multipurpose survey that can be used to gain an understanding of trends over 
time in terms of resource utilisation, epidemiological trends, trends in social care needs 
and usage, trends in lifestyles and social determinants of health, and some trends in 
prescribing and attitudes to health. The survey data may have great utility for NICE in 
gathering contextual information critical in the assessing feasibility of different forms of 
guidance aimed at public health and social care challenges. The data also have the added 
advantage of being relatively easy to obtain for further secondary data analysis and are 
free of charge. 
Key References:  
Boodhna, G., S. Bridges, et al. (2014). (Vol 1): Health, social care and lifestyles. Health 
Survey for England 2013. R. Craig and J. Mindell. Leeds, Health and Social Care 
Information Centre. 
Boodhna, G., S. Bridges, et al. (2014). (Vol 2): Methods and documentation. Health Survey 
for England 2013. R. Craig and J. Mindell. Leeds, Health and Social Care 
Information Centre. 
Mindell, J., J. P. Biddulph, et al. (2012). "Cohort profile: the health survey for England." 
International journal of epidemiology 41(6): 1585-1593. 
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Desire use by NICE Potential suitability48 
Research the effectiveness 
of interventions or 
practice in real-world (UK) 
settings 
There is scope to implement repeated cross-sectional 
designs with (unlinked) HSE data, although this type of 
study will only give limited insight into the effectiveness of 
interventions or practice. HSE data that are linked with 
other sources may offer greater utility and the possibility 
of implementing a longitudinal design. 
 
Example study and abridged abstract: 
“Fruit and vegetable consumption and all-cause, cancer 
and CVD mortality: analysis of Health Survey for 
England data: Governments worldwide recommend daily 
consumption of fruit and vegetables. We examine whether 
this benefits health in the general population of England. 
Methods: Cox regression was used to estimate HRs and 95% 
CI for an association between fruit and vegetable 
consumption and all-cause, cancer and cardiovascular 
mortality, adjusting for age, sex, social class, education, 
BMI, alcohol consumption and physical activity, in 65 226 
participants aged 35+ years in the 2001–2008 Health 
Surveys for England, annual surveys of nationally 
representative random samples of the non-institutionalised 
population of England linked to mortality data. 
Results: Fruit and vegetable consumption was associated 
with decreased all-cause mortality (adjusted HR for 7+ 
portions 0.67 (95% CI 0.58 to 0.78), reference category <1 
portion). Conclusions: A robust inverse association exists 
between fruit and vegetable consumption and mortality, 
with benefits seen in up to 7+ portions daily. Further 
investigations into the effects of different types of fruit 
and vegetables are warranted. 
Audit the implementation 
of guidance.  
 
There is scope for auditing the implementation of guidance 
through examining change in practice at a population 
level; one of the strengths of HSE data in doing so is the 
ability to examine social or medical inequalities in the 
implementation of guidance.  
 
Example study and abridged abstract: 
                                            
48 Potential suitability here is something of a subjective construct in the absence of a clear research 
question to be addressed. However,  
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“Are Current UK National Institute for Health and 
Clinical Excellence (NICE) Obesity Risk Guidelines 
Useful? Cross-Sectional Associations with 
Cardiovascular Disease Risk Factors in a Large, 
Representative English Population: The National Institute 
for Health and Clinical Excellence (NICE) has recently 
released obesity guidelines for health risk. For the first 
time in the UK, we estimate the utility of these guidelines 
by relating them to the established cardiovascular disease 
(CVD) risk factors. Health Survey for England (HSE) 2006, a 
population-based cross-sectional study in England was used 
with a sample size of 7225 men and women aged >= 35 
years (age range: 35-97 years). The following CVD risk 
factor outcomes were used: hypertension, diabetes, total 
and high density lipoprotein cholesterol, glycated 
haemoglobin, fibrinogen, C-reactive protein and 
Framingham risk score. Four NICE categories of obesity 
were created based on body mass index (BMI) and waist 
circumference (WC): no risk (up to normal BMI and 
low/high WC); increased risk (normal BMI & very high WC, 
or obese & low WC); high risk (overweight & very high WC, 
or obese & high WC); and very high risk (obese I & very 
high WC or obese II/III with any levels of WC. Men and 
women in the very high risk category had the highest odds 
ratios (OR) of having unfavourable CVD risk factors 
compared to those in the no risk category. For example, 
the OR of having hypertension for those in the very high 
risk category of the NICE obesity groupings was 2.57 (95% 
confidence interval 2.06 to 3.21) in men, and 2.15 (1.75 to 
2.64) in women. Moreover, a dose-response association 
between the adiposity groups and most of the CVD risk 
factors was observed except total cholesterol in men and 
low HDL in women. Similar results were apparent when the 
Framingham risk score was the outcome of interest. In 
conclusion, the current NICE definitions of obesity show 
utility for a range of CVD risk factors and CVD risk in both 
men and women 224. 
 
Provide information on 
resource use and evaluate 
the potential impact of 
guidance in changing 
resource use 
 
There is some scope for undertaking studies around 
resource use and how this varies by certain patient/service 
user characteristics. However, all resource use studies (in 
the absence of establishing data linkages) will be based on 
self reported data and therefore may lack sufficient depth 
for some research questions. 
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Example study and abridged abstract: 
“Inequity and inequality in the use of health care in 
England: an empirical investigation: Achieving equity in 
healthcare, in the form of equal use for equal need, is an 
objective of many healthcare systems. The evaluation of 
equity requires value judgements as well as analysis of 
data. Previous studies are limited in the range of health 
and supply variables considered but show a pro-poor 
distribution of general practitioner consultations and 
inpatient services and a pro-rich distribution of outpatient 
visits. We investigate inequality and inequity in the use of 
general practitioner consultations, outpatient visits, day 
cases and inpatient stays in England with a unique linked 
data set that combines rich information on the health of 
individuals and their socio-economic circumstances with 
information on local supply factors. The data are for the 
period 1998–2000, just prior to the introduction of a set of 
National Health Service (NHS) reforms with potential 
equity implications. We find inequalities in utilisation with 
respect to income, ethnicity, employment status and 
education. Low-income individuals and ethnic minorities 
have lower use of secondary care despite having higher use 
of primary care. Ward level supply factors affect utilisation 
and are important for investigating health care inequality. 
Our results show some evidence of inequity prior to the 
reforms and provide a baseline against which the effects of 
the new NHS can be assessed 225. 
 
Provide information on 
epidemiological trends 
 
HSE data were suggested as being useful to NICE in being 
able to monitor epidemiological trends, particularly around 
the social determinants of health. There are several 
examples across the literature of HSE data being used for 
these purposes; the example below demonstrates the 
breadth of HSE in collecting detailed measurements from 
both adults and children including the collection of salivary 
data.  
 
Example study and abridged abstract: 
“Recent trends in children's exposure to second-hand 
smoke in England: cotinine evidence from the Health 
Survey for England: Aims: To examine changes in 
children's exposure to second-hand tobacco smoke in 
England since 1998. Design: Repeated cross-sectional 
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surveys of the general population in England. The Health 
Survey for England. A total of 37  038 children participating 
in surveys from 1998 to 2012, 13  327 of whom were aged 
4–15  years, had available cotinine and were confirmed 
non-smokers. 
A total of 68.6% (95% CI  =  64.3–72.6%) of children had 
undetectable cotinine in 2012, up from 14.3% (95% 
CI  =  12.7–16.0%) in 1998. There was a highly significant 
linear trend across years (with a small but significant 
quadratic term) to declining geometric mean cotinine in all 
children from 0.52  ng/ml (95% CI  =  0.48–0.57) in 1998 to 
0.11  ng/ml (95% CI  =  0.10–0.12) in 2012. Children from 
routine/manual backgrounds were more exposed, but 
experienced similar gains across years to those from non-
manual backgrounds. 
Conclusions: In England, children's exposure to second-
hand smoke has declined by 79% since 1998, with 
continuing progress since smoke-free legislation in 2007. 
An emerging social norm in England has led to the adoption 
of smoke-free homes not only when parents are non-
smokers, but also when they smoke. 
Provide information on 
current practice to inform 
the development of NICE 
quality standards 
 
Some HSE information may be suitable in providing 
information for the development of NICE quality standards. 
These data may be particularly useful where the standard 
is based on meeting a certain level of patient satisfaction 
or experience, and perhaps less so in providing detailed 
information on the experience. 
 
 
Adult Social Care Survey 
Aims and description: The Adult Social Care Survey (ASCS) is an annual survey that takes 
place in England of adult (18+) service user of Local Authority (LA) with Adult Social 
Services Responsibilities (CASSRS) 49. The aim of the survey is to collect opinions and 
experiences of service users on a range of different topics including users’ satisfaction 
with services they received, general health and quality of life and well-being. The survey 
also allows service users to quality assess the social care provision in their Local Authority. 
The survey is completed either by the service user or someone who has consented on their 
behalf (carer, family member).  
 
                                            
49 http://www.hscic.gov.uk/socialcarecollections2015 
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Background, history and study design: 
The ASCS survey is a cross-sectional study developed by the Social Services User Survey 
Group (SSUSG). This group is a collection of representatives from the Department of 
Health (DH), the Health and Social Care Information Centre (HSCIC), CASSRs, the Care 
Quality Commission (CQC), the Association of Directors of Adult Social Services (ADASS) 
and the Personal Social Services Research Unit (PSSRU). The survey was initially piloted by 
PSSRU in 2010 and the first survey was conducted during 2010 - 2011.  
The survey is tailored for two types of users: residential care or nursing care residents and 
those receiving community-based services. The sample includes people with a variety of 
disabilities and problems and receiving a range of services including people with sensory 
and physical disabilities, learning disabilities (or intellectual impairments), and mental 
health problems. Services include residential services (e.g. personal care only homes and 
nursing care homes) as well as community-based services, such as home care and day 
centres, and other forms of low level or one-off support, such as equipment, transport and 
meals226. The questionnaire is available in a range of different accessible formats (large 
print, translated, as interview script for face-to-face/phone in addition to a postal 
survey). The format is generic but each individual LA can include questions that reflect 
their research needs50 ; key topics of the survey focus include: satisfaction with services, 
quality of life, feelings of control, levels and satisfaction with personal care, food and diet 
provided, accommodation, personal safety, social life, occupation and feelings of dignity.  
Validity of measures (e.g. construct, content, criterion validity) and case definitions: 
The constructs measured in the survey draw on other survey work and development 
projects by the SSUSG. Questions included in the survey support ASCOF framework (Adult 
Social Care Outcome Framework) consisting of seven questions around satisfaction with 
the quality of care, perceptions of support to maintain independence, understanding of 
the care system and entitlements, feelings of being in control, feelings of safety and 
security, and satisfaction with social contact 227. The survey also includes measures of 
social care related quality of life using the ASCOT measure, which has been rigorously 
tested in cognitive interviews 228. Other measures that have been incorporated into the 
survey include characteristics of age friendly environments identified by the World Health 
Organisation 58.  The questionnaire and survey methodology are usually piloted with 
volunteer LAs before being rolled out nationally 229. 
Representative of populations and settings  
Individual LAs are requested to send questionnaires to a stratified sample of service users. 
Respondents receive one reminder, although in residential settings the manager also 
receives a letter/reminder of completion226. Initially the survey was only completed by 
service users who were receiving complete or partial funding from social services in the 
same year the survey was carried out; although in 2014-15 the survey was also completed 
by those whose care needs are assessed and supported through LAs 230. Data are collected 
over a defined period across all LAs and a stratified sample approach is used across 
defined sub-populations; four strata were defined in each LA in 2013/14: all service users 
                                            
50 Ibid.p13 
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with a disability, all other service users aged 18-64, all service users aged 65+ in 
residential care, and all service users aged 65+ who are resident in the community 229. Due 
to the sampling strategy imposed, the results are weighted to ensure that the returned 
questionnaires are representative of the eligible population. With this scope of research, 
councils are able to over-sample to produce more robust results based on a specific strata 
(topic of interest).  
While a large number of social care recipients were included in the 2013/14 survey 
(73,925); the response rate stood at 38 per cent, introducing potential large selection 
effects in the type of responding user 231. The weighting strategy accounts only for 
compositional effects by strata within Local Authorities and does not adjust for the 
potential impact of non-response. Completion of the survey is now mandatory for LAs 
providing social care51, although no additional funding is provided. This means that there 
is little incentive for investing in improving response rates.  
There are concerns around the underrepresentation of certain groups such as adults who 
have cognitive or memory impairments such as dementia and are likely to be excluded 
from sampling frames, or when included, are unable to respond 226. The survey design does 
not allow for understanding of the full adult social care landscape in England as it either 
underrepresents or excludes many privately funded service users and those who receive 
direct payments and purchase their care directly.  
Representativeness of different disease stages: While it may be possible to ascertain 
levels of care needs in the population (as opposed to different disease stages per se), it is 
not possible to monitor change in needs at an individual level (also see note on consent 
below).  
Clear ethical frameworks: Ethical approval of ASCS has been given by the Social Care 
Research Ethics Committee; those without capacity to consent to the survey are removed 
from the sampling frame.  
Dynamic and adaptable: The cross-sectional nature of the data does mean that the 
potential for different epidemiological study designs to be implemented is limited. The 
survey has adapted to include greater breadth in the eligible population the survey has 
included changes to its content; there is also scope for LAs to adapt the survey to enable 
it to better suit their needs.  
Data Linkages: There are no clear direct data linkages between ASCS and other data 
sources.  
Collection of data reflective of real-world conditions (scope):  The ASCS collects a broad 
scope of data on user experiences and perceptions. However, there is less scope for 
understanding how these experiences vary by the intrinsic characteristics of the 
respondent.  
Sensitivity: N/A          
                                            
51 Each Local Authority must have an eligible population of 150 or more service users to make it a 
requirement to participate in the survey, if they have less than 150 users they are not required to 
participate. 
Section 4: Selected in-depth data profiles - Adult Social Care Survey 
123 
 
Uniformity in data collection procedures: There is a high degree of uniformity in the 
surveys in the overall approach. However, there is potential for differences to occur 
through different policies around fielding surveys in different formats and through LAs 
having the capacity to insert questions of interest into the survey. These additional 
questions are submitted to the HSCIC for approval.52 
Steps taken to minimise common forms of bias: Potential bias could occur through the 
high levels of non-response to the survey. Forms of bias could also occur in terms of 
different respondents completing the survey compared to the intended respondents, or 
respondents receiving assistance to complete the survey 231;  72% reported receiving 
assistance in completing the survey. However, allowing proxy respondents to complete or 
aid completion of the survey enables the responses to better reflect the spectrum of social 
care clients. Around one-in-ten (9%) intended survey respondents were not involved in 
completing the survey at all, although this is thought to have minimal impact on the 
results 231. As the surveys are conducted by LAs (either directly or contracted out to other 
agencies) there is scope for deviation to occur in the method of administration; such 
deviations usually result in the data for some LAs being excluded.  
Granularity of treatment/disease data: There is some scope for understanding service 
users’ experiences by their social care needs, measured by the Activities of Daily Living.  
Other considerations/information: 
More information is needed on the characteristics of eligible populations and a greater 
understanding is required around the factors that influence non-response rate and how 
surveys were conducted in each Local Authority 231. While the results of the survey are 
published by HSCIC, access to the individual level data may be restricted and the data 
have not been published on archives such as the UK Data Archive. 
Summary and Utility for NICE 
ASCS is a survey of users’ satisfaction with the care that they receive. Such data can be 
instrumental in forming guidance that is based on user experience and patient reported 
outcomes. A disadvantage of the data is that, unlike other surveys of patient or service 
user experiences, the data are not freely available through sources such as the UK data 
archive. As such there may be limited scope for undertaking secondary analysis of the 
individual service user data. Nevertheless, the detailed reports and tables produced still 
allow for gaining a good level of understanding of aspects of service user satisfaction with 
their care and broader aspects of wellbeing.  
Key References:  
HSCIC. Personal Social Services Adult Social Care Survey, England 2013-14, Final release. 
Leeds: Health and Social Care Information Centre, 2014. 
  
                                            
52 http://www.hscic.gov.uk/article/4793/User-survey-guidance---2014-15, p13 
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Desired use by NICE Potential suitability53 
Research the effectiveness 
of interventions or 
practice in real-world (UK) 
settings 
This is a cross-sectional survey of user experiences of social 
care. While it may be possible to undertake repeated 
cross-sectional studies and examine the impact of changing 
practice on user experiences, fully assessing the 
effectiveness of interventions through measuring 
longitudinal changes at a service-user level will be 
challenging with these data. 
 
Audit the implementation 
of guidance.  
 
It may be possible to assess whether guidance is being 
implemented, particularly around service user satisfaction 
or service user reported experiences, through analysing 
change at a LA level. While the example below does not 
directly do this, the excerpt highlights that such a study 
could be possible through examining change over time in 
reports of being treated with dignity.   
 
Example and excerpts from descriptive report: 
A common dictionary definition is “a state or quality or 
manner worthy of esteem or respect; and (by extension) 
self-respect.” while the online practice guide for dignity 
in care developed in partnership by the Department of 
Health with the Social Care Institute for Excellence 
(SCIE) and the Care Services Improvement Partnership 
(CSIP)17 offers the following definition “dignity consists 
of many overlapping aspects, involving respect, privacy, 
autonomy and self-worth. The provisional meaning of 
dignity used in the practice guide is: ‘a state, quality or 
manner worthy of esteem or respect; and (by extension) 
self-respect’”. 60 per cent of respondents had a positive 
reaction to how the way they were helped and treated 
made them think and feel about themselves in 2013-14 
(one percentage point higher than in 2011-12 and 2012-
13 and three percentage points higher than in 2010-11). 
31 per cent of respondents said the way they were 
helped and treated did not affect the way they thought 
and felt about themselves – unchanged from the 
previous year and down one percentage point from 
2010-11 and 2011-12. Eight per cent said it sometimes 
                                            
53 Potential suitability here is something of a subjective construct in the absence of a clear research 
question to be addressed. However,  
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undermined the way they thought and felt about 
themselves and one per cent said it completely 
undermined them – both of which have remained the 
same since 2011-12 231. 
Provide information on 
resource use and evaluate 
the potential impact of 
guidance in changing 
resource use 
 
The data can potentially provide a snapshot of resource 
use based on service users’ reports; repeat cross-sectional 
studies may provide information on the impact of changing 
guidance on resource use 
 
 
Provide information on 
epidemiological trends 
 
The study provides a snapshot of social care needs but 
among a population who are receiving LA assistance for 
these health needs. Given that eligibility for LA provided 
social care is changing and varies between LAs, there may 
be some caveats accompanying the results of studies that 
aim to provide information on how trends vary over time. 
Nevertheless, there is scope for the information to be used 
to understand inequalities in health status, wellbeing, or as 
in the excerpt below, quality of life.  
 
Example study and extracts from abstract: 
What can local authorities do to improve the social 
care-related quality of life of older adults living at 
home? Evidence from the Adult Social Care Survey. This 
study aims to examine the associations between social 
care-related quality of life (SCRQoL) in older adults and 
three potential policy targets for local authorities: (i) 
accessibility of information and advice, (ii) design of the 
home and (iii) accessibility of the local area. We used 
cross-sectional data from the English national Adult Social 
Care Survey (ASCS) 2010/2011 on service users aged 65 
years and older and living at home (N=29,935). To examine 
the association between SCRQoL, as measured by the 
ASCOT, and three single-item questions about accessibility 
of information, design of the home and accessibility of the 
local area, we estimate linear and quantile regression 
models. After adjusting for physical and mental health 
factors and other confounders our findings indicate that 
SCRQoL is significantly lower for older adults who find it 
more difficult to find information and advice, for those 
who report that their home design is inappropriate for 
their needs and for those who find it more difficult to get 
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around their local area. In addition, these three variables 
are as strongly associated with SCRQoL as physical and 
mental health factors. We conclude that in seeking to find 
ways to maintain and improve the quality of life of social 
care users living at home, local authorities could look more 
broadly across their responsibilities. Further research is 
required to explore the cost-effectiveness of these options 
compared to standard social care services 58. 
 
Provide information on 
current practice to inform 
the development of NICE 
quality standards 
 
There may be scope for the data to be used to form quality 
standards around social care experiences and trajectories – 
for example around information advice and guidance 
received by older people in accessing care. These data may 
be particularly valuable in providing information to support 
quality standards aimed at improving people’s feelings of 
dignity when receiving social care 
 
 
Care.data 
Aims and description: Care.data is an initiative which aims to implement a system for GP 
records data to be shared nationally with the Health and Social Care Information Centre 
(HSCIC) securely, and for these data then to be linked with other sources in order to 
create data that can help track patient journeys across the entire continuum of care. In 
2013, the HSCIC has described the aims of care.data as being six-fold including: (i) 
supporting patients’ choice; (ii) advance customer service; (iii) promote greater 
transparency; (iv) improve outcomes; (v) increase accountability; (vi) drive economic 
growth  232. If successfully implemented, care.data would make a substantial contribution 
to the data needs of NICE and other organisations. The research possibilities of such rich 
data would likely meet many of NICE’s needs with respect to real-world data, and would 
allow for establishing the long-term effectiveness of interventions through the capacity to 
track patient journeys through primary and into secondary care as standard, something 
that rarely occurs in real-world data projects and sources. Uniquely, it could also 
potentially, allow for insight into patterns of social care and their relationship clinical and 
public health data.  
The scheme is being developed first using four Clinical Commissioning Group areas 
(Blackburn with Darwen, Somerset, West Hampshire and Leeds North, West and South and 
East) as a test-bed in a pilot (pathfinder) stage. However, at the time of writing, the 
project progress has faltered; it has been met with widespread concern; and very recently 
the government’s own body on the implementation of major projects voiced concerns 
about the feasibility of the project 27. As care.data has not yet been fully implemented at 
the time of writing, this data source profile does not attempt to recreate a fuller profile 
provided for other sources of data; instead we focus further on the aims and some of the 
concerns surrounding the project.  
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Background, history and study design: The Health and Social Care Act 2012 changed the 
statutory designation of the Health and Social Care Information Centre (HSCIC) and its 
roles, responsibilities and powers. One of the changes included that HSCIC can under 
certain circumstances, including on mandatory request from statutory bodies (NICE being 
one of the bodies) or when directed by NHS England or the Secretary of State for Health, 
require individual patient data from GP practices without obtaining explicit additional 
consent from patients. One of the first examples of this occurring was the request to share 
data for the care.data project. 
Implementation of the care.data project is expected to bring several benefits. Health 
benefits include improved monitoring of performance and outcomes through linkage 
between primary and secondary care; earlier diagnoses of illness; predictive modelling of 
risk and improved decision-making; improved data for evaluation of interventions; and 
exploration of patient pathways 233. However, several times an economic argument was 
also espoused around the commercial value of the data which proved to be unpopular and 
overlooked the complexities of the debate 234.  
The first phases of the scheme were intended to be launched in March 2014. In January 
2014, the Guardian newspaper claimed that health data collected under the auspices of 
care.data would be made available to commercial firms 235; shortly afterwards HSCIC 
issued a statement denying that ‘data will be made available for the purposes of selling or 
administering any kind of insurance and that the NHS and the HSCIC never profit from 
providing data to outside organisations’ 54. However this was later partly refuted as it was 
revealed that individual patient data (HES data) had been shared with insurance bodies in 
the past 236.  In the run up to the planned launch and amidst the public controversy, up to 
700,000 formally objected to having their data shared with a third party and essentially 
opted-out. Such a high level of ‘non-response’ in future impedes the ability of the data to 
represent a ‘census’ of NHS records and may mean that weighting strategies may need to 
be implemented to adjust for differing levels of non-response across groups. It also 
recently emerged that there are issues in processing this volume of objections and there 
are technical issues in ensuring that the care of those who raised an objection was not 
compromised through losing access to services such as screening services55.  
Representativeness (populations and settings; different disease stages):   
One of the priority goals of the care.data initiative is to link GP records with other sources 
of data. Hospital Episodes Statistics (HES) data would become Care Episodes Statistics 
(CES) data as they would allow for tracing of patient journeys across care settings 233. 
Therefore in many ways care.data has the potential to become representative of several 
different disease stages and to be able to monitor change in disease stage or care need 
stage in order to facilitate understanding of the effectiveness of care interventions of 
different forms. However, the status of the 700,000 who have already opted out of 
care.data is unclear, and therefore an understanding of how the care.data ‘population’ 
differs from the wider population is scarce in the literature.  
                                            
54 http://www.hscic.gov.uk/article/3869/Response-to-Guardian-article-about-NHS-data-200114  
55 http://data.parliament.uk/writtenevidence/committeeevidence.svc/evidencedocument/health-
committee/handling-of-nhs-patient-data/written/18661.html 
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The technical specification for the extract of patient data from GP surgeries specified that 
the following patient-level fields would be included in the data: NHS number (the key 
linking field); date of birth, gender, postcode, ethnicity, registration details, details of 
events (e.g. appointments); referral dates and details; information on prescribed 
medication; information on diagnosis of a range of different conditions (non-
communicable diseases); background information on health status (e.g. cholesterol level, 
smoking status, lung functioning, Q-Risk values); vaccination status; care plans and 
reviews for different conditions; exception reporting (e.g. where patients had declined 
advice or treatment). Some data were to be specifically excluded from the extract 
including HIV status, STI history, abortion history, IVF treatment details, marital status, 
complaints, convictions, and history of abuse by others 233. It had been anticipated that 
care.data would join with other NHS projects including the 100k Genome Project, allowing 
phenotypic data to be linked with genomic data and enabling advances in precision 
medicine 28. 
Ethical concerns and concerns about anonymity:  
In 2014 the project was put on hold, although in 2015 it was announced that the 
pathfinder scheme would restart, beginning with Blackburn and Darwen. A major factor in 
the difficulties experienced was a perceived lack of communication with the public about 
plans to use their health records for medical research. Although NHS England had 
disseminated an information leaflet through 99% of households, two-thirds of householders 
did not recall receiving any information about the scheme 237. This meant that some of the 
ethical safeguards around informed consent had essentially failed, and some are sceptical 
about whether this issue has been fully resolved 234. As discussed earlier, there have also 
been issues in terms of processing objections and ensuring that these objections are 
recognised without impacting upon access to services such as screening services.  
In their study of care.data, Carter and colleagues identify three main reasons why the lack 
of social legitimacy of the initiative overruled any legal authority granted in the Health 
and Social Care Act 238. Firstly, they identify that there existed defects in the warrants of 
trust provided for care.data – to this end the levels of awareness were so low that that 
they rendered the legitimate means of opting out of care.data meaningless. Secondly, 
care.data ruptured the traditional role and expectations of general practitioners. Thirdly, 
there emerged widespread uncertainty about the status of care.data as a public good. This 
was particularly centred on the potential commercialisation of the public’s private 
medical records.  
Some have expressed concerns that some of the processes considered for anonymising the 
data collected (specifically pseudoanonymisation at the source as opposed to at HSCIC) 
will lead to errors in the data linkage which cannot be rectified centrally. Such 
inaccuracies are not only likely to increase the risk of clinical error, but will also be 
detrimental for research and decision-making 239. However, another concern is around so 
called ‘jigsaw attacks’ where data users are able to use the (linked) data released to 
deliberately identify individuals56; while such use of the data is forbidden, there remain 
concerns that the broad scope of potential users – including academic, public sector, 
                                            
56 http://www.england.nhs.uk/wp-content/uploads/2014/01/pia-care-data.pdf 
Section 4: Selected in-depth data profiles - Care.data 
129 
 
voluntary sector, commercial users in the UK and elsewhere – could equate to weak 
enforcement of rules of use.  
Current status: The Major Projects Authority expressed low confidence in the capacity to 
deliver care.data and gave the project a red rating in June 2015. A red rating indicates 
that: “Successful delivery of the project appears to be unachievable. There are major 
issues on project definition, schedule, budget, quality and/or benefits delivery, which at 
this stage do not appear to be manageable or resolvable. The project may need re-scoping 
and/or its overall viability reassessed”57. The initiative remains at the ‘pathfinder’ (pilot) 
stage and the project is still gathering data on the best ways to support GP practices in 
terms of the technicalities of sharing data but more importantly in ways that GP surgeries 
can support patients to make informed choices around their data and its use. It should be 
noted that this pilot stage does not include piloting the extraction systems themselves or 
any of the proposed data linkages that would subsequently need to occur to realise the 
ambitions of the project. Furthermore, the project was not given an end data (one of 
eight out of 188 major government projects) 27. A number of actions have been identified 
that can improve confidence in the implementation of the project; some actions are also 
reported to have been completed. However, the Major Projects Authority identified that a 
different rating would be applied when the assurance and approval processes were 
confirmed, pathfinder stage had been completed and approval for national rollout had 
been obtained, and the rollout for a nationally linked dataset had been approved; 
unusually the report also suggested that parts of the business case were still being 
developed 27. NHS England have responded that the rating was not current (based on data 
from September 2014) and that further actions have been completed to the extent that 
the rating should be downgraded to a less severe category 240. 
The Department of Health have also created a National Information Board and have 
appointed Dame Fiona Caldicott as a national data guardian in efforts to address concerns 
around confidentiality of data. However, there remain ongoing concerns among academic 
experts as to the response of bodies responsible for care.data to critiques around the 
sharing of data with commercial companies 234. Due to purdah (over spring/summer 2015), 
there have been few communications around care.data, although work has continued and, 
subject to approval, extraction of GP records may take place in September 2015 in 
pathfinder areas only 241. Should the project be implemented successfully, there are likely 
to be several opportunities made available to NICE with regards to real-world data usage. 
However, the degree to which care.data has served to erode public trust in medical 
research, and particularly medical research involving real-world data, should not be 
underestimated and may be a factor to consider when exploring suitable sources of real-
world data. 
It is unfortunate that the controversy surrounding care.data has overshadowed the many 
potential benefits of seeing the initiative to fruition, which in its full capacity could 
revolutionise our understanding of patient trajectories, needs and outcomes across the 
spectrum of care settings that form the mosaic of the health and social care system in the 
UK. The impact of the negative publicity has served to erode public trust in the use of 
electronic health records for medical research, while other forms of big data, from store 
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card spending patterns to apps and social network usage, continue to flourish. It has also 
sparked debate about the very purpose of medical research and widened the perceived 
gulf between commercial and non-profit research. Nevertheless, it does serve as a 
reminder that while the technological advances are increasingly permissive towards the 
incorporation of real-world in health decision-making, there remains a need to 
understand, maintain and prioritise the ethical frameworks surrounding this real world 
data collection.  
Salford Integrated Record 
Aims and description: The Salford Integrated Record (SIR) is an electronic health record 
that combines patients’ primary and secondary health records into a single system. At its 
core is an aim to ensure that patient records are available to all stakeholders involved in a 
patient’s care, including the patient themselves. The establishment of the record should 
improve the clinical outcomes of patients through ensuring that clinicians are able to 
access all relevant patient information in a timely fashion regardless of whether they are 
treating the patient in primary or secondary care settings 58. An anonymised research data 
repository has also been established 242.  
Background, history and study design:  
The Salford Integrated Record was established in 2001 243, although information uploaded 
in the system may pre-date this. Data are updated every 24 hours on patients’ GP 
consultations, hospital episodes, referrals, clinical attendances, as well as on background 
and selected lifestyle characteristics collected in clinical practice. The SIR also links 
individual patient prescription information with these primary and secondary data 243. The 
SIR was originally focussed on sharing information between providers on four key 
conditions: diabetes, coronary heart disease, chronic kidney disease and stroke 244.  
Validity of measures (e.g. construct, content, criterion validity) and case definitions:  
In common with other clinical databases, read codes are used as the basis of data entry. In 
some cases, read codes can lead to inaccurate estimates of the prevalence of conditions 
with sets of symptoms that overlap with other conditions. One study used SIR data as the 
basis of a validation study of the read codes of Irritable Bowel Disease (IBS), finding that 
levels of IBS were much lower than expected and hypothesised that this was due to a 
preference for using symptom codes as opposed to disease read codes 245. The limitation 
around read code usage is likely to be shared across primary care databases, although the 
advantage of the SIR is the routine data linkage which could facilitate validation.  
Validation studies of coverage have also suggested that SIR is highly concordant with 
patient information stored on other systems (for COPD and asthma patients), suggesting 
that SIR offers good levels of valid case definition 97. 
Representative of populations and settings: The SIR contains data for GP practices in 
Salford, Greater Manchester. Fifty-three practices are included and the data are linked 
with the Salford Royal Hospital. The records of approximately 220,000 residents are 
                                            
58 http://www.salfordccg.nhs.uk/download.cfm?doc=docm93jijm4n524.pdf&ver=680 
Section 4: Selected in-depth data profiles - Salford Integrated Record 
131 
 
included 246; all but one GP practice upload their data to the SIR. The data are estimated 
to account for 97% of Salford’s population 96. 
Representativeness of different disease stages: The integration of primary and 
secondary care data allows for research tracking patient outcomes across care providers 
(through examining Integrated Care Pathways (ICP)). One initiative using the data in this 
way is the Collaborative Online Care Pathway Investigation Tool, which is being used to 
examine missed opportunities in patient care – that is where primary prevention 
opportunities were missed which could lead to adverse health outcomes. This initiative is 
focussed on modelling the circumstances and frequency of variance between idealised ICP 
and the actual care provided 16.  
Clear ethical frameworks: Each patient has received information on the existence of the 
record and was given the option of requesting to opt-out of the record (through contacting 
their GP). Each time the record is accessed by healthcare staff, the permission of the 
patient needs to be asked before use. The information within the record can be used for 
medical research purposes, where patient identifiers are removed and medical research 
ethics committee permission has been granted. The NHS in Salford also advises that 
research companies may on occasion request patients’ personal details, but these are only 
shared with the express permission of the patient.   
Dynamic and adaptable: Several projects are underway that use data from SIR59. The 
potential for longitudinal analysis of patient trajectories allows for a large number of 
epidemiological study types to be implemented. The data have also been considered for 
calculations and selection of appropriate outcomes in RCTs and pragmatic trials 246.  
Additional patient reported outcomes can also be linked to the data. In the CLASSIC 
(Comprehensive Longitudinal Assessment of Salford Integrated Care) study for example, 
older people’s (65+) experiences and satisfaction with accessing integrated care will be 
assessed through a series of questionnaires that are linked to SIR data 60.  
Data Linkages:  
At its core, the Salford Integrated Record is a data linkage project that links primary and 
secondary care records to improve patients’ clinical outcomes. Linkages are made 
between local GP practices and the Salford Royal Hospital. Further linkages have been 
made including with Hospital Episodes Statistics, ONS mortality statistics and the NHS 
Exeter system (which allows for sharing of data including some screening information, GP 
payments data and NHS organ donation data) 246. Pharmacy data have also been linked into 
the SIR 243. 
Collection of data reflective of real-world conditions (scope): The breadth of data 
collected in the SIR has meant that the data have already been used in effectiveness 
studies using a pragmatic RCT design 243. The data have also been used for research 
questions that can only be addressed using real-world data, such as medication prescribing 
risks occurring in general practice 247.  
                                            
59 http://www.herc.ac.uk/research-development/ 
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Other considerations/access information: The research potential of the data is being 
explored by NorthWest e-Health group (NWeH; see http://www.nweh.org.uk/). The 
availability of the data for researchers and the procedures and costs around accessing the 
data are unclear from online documentation.  
Salford Integrated Record in numbers: 53 GP practices and Salford Royal Hospital; close 
to 200,000 patient records 
Summary and utility for NICE: SIR was suggested as a source of data that may have the 
potential to overcome the limitations of other data source and examine patients’ 
integrated care pathways. The potential of the data for research purposes are likely to be 
in the process of being realised and there are comparatively few publications using these 
data in the literature; the data may have been used primarily to facilitate clinical 
decision-making and performance management initially. Perhaps one of the most 
appealing characteristics of the data, given the current climate around the use and ethics 
of electronic health records in medical research, is the high degree of patient involvement 
and the ability of patients to access their own records.   
 
Key References:  
New JP, Bakerly ND, Leather D, Woodcock A. Obtaining real-world evidence: the Salford 
Lung Study. Thorax 2014:thoraxjnl-2014-205259. 
Akbarov A, Kontopantelis E, Sperrin M, Stocks SJ, Williams R, Rodgers S, et al. Primary 
Care Medication Safety Surveillance with Integrated Primary and Secondary Care 
Electronic Health Records: A Cross-Sectional Study. Drug safety 2015:1-12. 
Prescribing Observatory for Mental Health 
Aims and description: The Prescribing Observatory for Mental Health (POMH-UK) is a 
quality improvement programme that is run by the Royal College of Psychiatrists. The aim 
of the POMH-UK is to work with specialist mental health trusts to improve their prescribing 
practices. The POMH-UK works with member organisations to identify suitable topics for 
audit-based quality improvement programmes, the costs of which are borne through 
subscription costs of member organisations61.  
Background, history and study design: 
The POMH-UK was established in 2005 and has been housed at the Centre for Quality 
Improvement in the Royal College of Psychiatrists since inception 248. Each quality 
improvement audit tends focuses on a new topic around prescribing practice in mental 
health care, although topics tend to be repeated across years. Several audits take place 
within a year, with different rates of participation among contributing NHS trusts, 
reflective of the degree of specialism of the given audit. Between June 2006 and October 
2013, twelve different topics had been included and thirty-five different audit reports 
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produced. The programme tends to start with a baseline audit of practice against 
evidence-based standards, followed by interventions that aim to change practice and 
improve adherence to guidance, followed by a re-audit 12-18 months later 249.  
Topics covered over this period included: (i) prescribing high dose and combined 
antipsychotics on adult acute and psychiatric intensive care wards; (ii) screening for 
metabolic side effects of antipsychotic drugs; (iii) prescribing high dose and combined 
antipsychotics on forensic wards; (iv) prescribing high dose and combined antipsychotics in 
cases of acute/PICU, rehabilitation/complex needs, and for forensic psychiatric services; 
(v) prescribing anti-dementia drugs; (vi) assessment of side effects of depot antipsychotic 
medication; (vii) monitoring of patients prescribed lithium; (viii) medicines reconciliation; 
(ix) antipsychotic prescribing in people with learning disabilities; (x) prescribing 
antipsychotics for children and adolescents; (xi) prescribing antipsychotics in people with 
dementia; (xii) prescribing for people with personality disorder; and (xiii) prescribing for 
ADHD in children, adolescents and adults62. Topics are chosen on the basis that they meet 
eight criteria including: that they are relevant to the implementation of particular NICE 
guidelines; are seen as a clinical priority; where there is likely to be variation at a trust 
level; and where it is practical and feasible to collect the data63. Between 2006 and 2013, 
the number of cases included in an audit has varied between 1,035 (screening for 
metabolic side effects of drugs) to 12,790 (prescribing anti-psychotics for people with 
dementia). The maximum number of participating trusts recorded over this period was 57, 
with as few as 12 participating in more specialist audits.  
In addition to clinical information some additional patient characteristics are collected 
including the age, gender and ethnicity of the patient 249. Clinical teams in NHS Mental 
Health Trusts selected their own audit samples using a variety of methods and can enter 
as many case histories as they wish 249. Within trusts, the performance of different clinical 
teams can be compared. 
In recent years, the POMH-UK audits have moved progressively from solely being reliant on 
case and record submission to audit methods where clinical teams are asked directly about 
the actions they have taken 250. 
Validity of measures (e.g. construct, content, criterion validity) and case definitions: 
The criteria used in the audit are expected to be evidence-based and clinical credible 
(which are not always synonymous 251). 
Representative of populations and settings  
Since inception, the number of participating trusts has risen and in addition to NHS trusts, 
charitable and private organisations also participate in POMH-UK 248. The results of POMH-
UK are generally regarded as generalisable to practice across NHS Mental Health Trusts. 
While NHS trusts are able to submit as many cases as they want to into the audit, some 
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like South London and Maudsley NHS Trust have submitted all cases that fit within the 
population of interest in previous audits 252.  
Representativeness of different disease stages: The data are focussed on different topics 
at each audit. There may be a greater depth of data collected on disease stage 
(dependent on the audit) compared to either non-specific databases or databases set up 
for administrative as opposed to quality assurance purposes 249.  
Clear ethical frameworks: Participating trusts are encouraged to contact service users 
about their involvement in the POMH-UK. Specific patient identifiers such as names and 
addressed are not shared with POMH-UK. 
Data Linkages: There are studies that have used linked NHS trust level data on geographic 
and healthcare attributes in order to attempt to measure bias in submitted records 251.  
Collection of data reflective of real-world conditions (scope):  The POMH-UK collects 
records and case notes from patients. In addition, where necessary, further information 
reflective of real-world conditions and practice are collected through surveys 253.  
Sensitivity: Sensitivity has been used in earlier profiles to denote the ability to distinguish 
complications from comorbidities. These audit data have been used to understand the 
emergence of, or more precisely steps taken to prevent and screen for, iatrogenic disease 
– for example the impact of lithium intake on renal function. However, sensitivity could 
also indicate the degree to which the data can be used to successfully monitor change, 
and those working closely with the POMH-UK suggest it can take up to three years to 
observe a change at a national level in practice, and that any changes are likely to be 
modest in nature 251.    
Uniformity in data collection procedures: While there is a high degree of uniformity in 
the tools used to conduct audits, there are differences between the way participating 
trusts select samples.  
Steps taken to minimise common forms of bias: Allowing NHS trusts to select their own 
cases for inclusion into the audit could introduce selection bias in that those cases known 
to be adhering to the clinical standard of interest are more likely to be included. This 
form of bias has been examined in studies using the data through analysing linked data 
based on trust socio-demographic characteristics and its CQC quality ratings to assess 
whether the submitted samples were over-representative of any group or section of 
performance 251. There was little evidence of systematic bias in this assessment. 
Furthermore, given that participation in the audit is voluntary, creating deliberately 
biased samples for inclusion in the audit defeats the purpose of participation.  
Some of the findings of the audit may reflect poor documentation standards or poor 
quality of case notes as opposed to actual failure to adhere to guidelines, although the 
extent of this potential bias is relatively unknown 17.  
In the analysis of findings, the central POMH-UK analysts are blinded as to the identity of 
teams within trusts, and analysis files include codes for trusts, as opposed to names or 
other identifiers 253.  
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Granularity of treatment/disease data: ICD-10 disease codes are used to categorise 
mental health conditions, although the specialist nature of the observatory allows for 
greater granularity of psychiatric morbidity 249.  
Summary and utility for NICE 
One of the key criteria for choosing a topic focus of the POMH-UK is that the topics are 
relevant for monitoring the implementation of NICE guidelines. This has direct relevance 
to one of the intended uses of real-world data by NICE. An example of study directly 
assessing the implementation of NICE guidance can be found in a study of renal and 
thyroid functioning among patients who are prescribed lithium 17.  
However, these audit data are very much focussed on comparing practice against pre-
defined standards; therefore as emphasised by Paton and Barnes 251, the utility of the data 
for other more research-focused or evaluative activities, for example in assessing the 
effectiveness of interventions or monitoring epidemiological trends, may consequently be 
limited. The data are not widely used in the literature and it is not clear the extent to 
which these data are available for re-analysis of individual patient data, reflecting their 
primary function as a quality improvement tool. Nevertheless, there are several important 
questions that could be addressed for NICE as there may be potential to understand not 
only whether practice/outputs changed over time but also the processes that led to these 
changes, as highlighted in Mace and Taylor’s account of change in one NHS Trust 252. 
Key References:  
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Section 5: Summary of in-depth profiles of data and organisational 
case study 
 
Section 4 includes detailed profiles of 11 data sources that were primarily named in 
interviews as being useful for NICE. Here we include a summary of these sources and we 
also provide information collected from an organisation with a similar profile to NICE on 
the way in which real-world data contributes to their practice. 
Selection of findings 
Primary care databases 
 Three primary care databases are included in the in-depth data profiles: THIN, 
QResearch and CPRD. All three differ slightly in coverage and include between 587-
950 GP practices, and achieve a level of coverage of between 6-9 per cent (THIN 
being the smallest and QResearch the largest). There has been little work to try to 
understand the similarities or differences of these data in the literature. Each data 
source has a similar approach in that they are reliant on using the information 
inputted into GP systems as part of clinical care for research purposes; no 
additional data is routinely collected/inputted (although other that may be linked) 
apart from the data that is inputted as a result of GP consultations, vaccinations, 
blood tests and similar data (for example data from registration questionnaires). 
There may be provision for collecting additional data, however. THIN and CPRD are 
most closely structured in terms of the underlying databases, and have similar 
access procedures. They also have overlapping GP surgeries – the same GP surgery 
can appear in both datasets. QResearch is the largest of the databases but uses 
different software to input the data. All three databases are reliant on the 
voluntary cooperation of GPs (as well as of patients who can drop out of the data) 
although validation studies suggest that all three are broadly representative with 
some minor variances.  
 All three have identical systems of recording information (read codes) and there is 
a substantial degree of uniformity in this respect. However, none of the data 
sources is infallible to problems of misclassification. There are also shared 
weaknesses with respect to data quality and breadth of sociodemographic and 
socioeconomic data. Some minor differences are present. QResearch data will not 
include free-text data whereas CPRD and THIN do; THIN and CPRD also explicitly 
state that additional data – e.g. patient reported outcomes – can be collected 
although this is not explicit/a feature in QResearch documentation.  
 All three datasets have been used to conduct sophisticated analyses and could be 
used to implement studies that meet all five of NICE’s needs of real world data. 
However, QResearch, being the newest of the three sources, appears less 
frequently in the literature. It may also be less advanced in terms of data linkages, 
although this is changing very rapidly. CPRD is notable in having rebranded to 
reflect the intention to link primary care data with hospital episodes and other 
data. Studies that use linked data for any of the three main primary care datasets 
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are in the minority and are comparatively rare. CPRD data appears more frequently 
in the literature, either as CPRD or its forerunner the GPRD. THIN and CPRD have 
markedly different access policies to QResearch; data in QResearch is only 
available to research consortiums where the PI is based in a UK university; THIN 
and CPRD access policies are less bounded. All three have a cost affixed to 
accessing the data that varies by the size, breadth and complexity of the data 
needed and the type of provider. 
Table 3: UK Primary Care databases in numbers 
 Number of GP 
practices 
Number of patient 
records 
Number of active 
patients 
CPRD 685 13.7 million 4.4 million 
QResearch 950 13 million ~5.1 million64 
THIN 587 12.4 million 3.7 million 
 
Data on resource use and quality – utilising service user reports 
 Two of the datasets profiled in section 5 – the Adult Social Care Survey and the 
Community Mental Health Survey - highlight a relatively untapped resource around 
monitoring the way in which guidelines, and particularly those aimed at improving 
patient experiences, can be used to monitor changes at a population level before 
and after implementation. One of the issues with these specific data is that 
changes in the population included or in the questions asked means that 
comparability across recent sweeps has been impeded. Nevertheless, these data do 
offer a potential resource to monitor such changes in future. 
 A number of survey data sources including those above as well as the Health Survey 
for England and the English Longitudinal Study for Ageing allow for monitoring 
changes in resource use through patient/service user reports. While the data may 
only be suitable for providing headline trends and may lack some of the detail 
required for assessing resource use, they may nevertheless present useful sources 
of data, particularly given the breadth of other data on the characteristics of 
patients/service users. Furthermore the latter data source allows for assessing 
patterns of longitudinal change among individuals as well as population level 
change.   
Data linkage studies remain underrepresented and under-utilised at a national level 
 Some real-world data sources are purposefully either set-up or re-developed to 
enhance their data linkages and to examine the presence/absence of integrated 
patient care. This is a key area for real world data if it is to meet the evidence 
needs of decision-makers and clinicians and to keep pace with policy 
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developments. However, those that are designed to enable the monitoring of care 
across providers, or at least have the capability to do so at a national level, have 
been utilised relatively rarely for this purpose. Furthermore, none of the data 
sources we have profiled have been used in studies that have examined transitions 
between clinical and social care, despite the increasing recognition of the 
interdependency between these sectors. One of our interviewees did however 
consider the most likely candidate where this type of data would occur was in 
either local data sources, such as the Salford Integrated Record or in registry or 
audit data. In the latter case the more focussed nature of the research questions 
being considered may necessitate these data to be linked and for integrated care 
pathways across the continuum of care to become a data attribute. On a national 
level, care.data may provide a catalyst for this type of data to become available 
for health researchers, although there are several milestones to reach before this 
becomes a viable possibility.    
Using survey data to understand the feasibility and impact of guidance (and potential 
support needs) 
 Among the data sources we examined in the in-depth data profiles, it was clear 
that no one data source represented a panacea for NICE’s real world data needs. 
Where some data sources would give detailed information on the nature of the 
clinical or social care episode, there was less information available on the 
characteristics of the patient or service users. Similarly, where there was detailed 
information on the socio-demographic and lifestyle characteristics of patients or 
service users, the information on clinical or social care interactions would be less 
granular. This does highlight the merits and importance of data linkage projects 
succeeding although as discussed above, these types of studies are generally 
underrepresented. The findings from the in-depth profiles are suggestive of a need 
to triangulate evidence across different data, particularly in order to understand 
the feasibility and impact of guidance. For example, while detailed granular 
information from large clinical databases may be useful for setting standards and 
developing guidance around GP consultations (for example), information from 
surveys can help to reveal the feasibility of this guidance on a patient level and 
illuminate where inequalities may lie in simple measures of GP access. We 
highlighted earlier that survey data was generally underutilised within NICE; these 
in-depth profiles illuminate the large number of different study designs and 
research questions that can be addressed using these data. 
Using clinical and administrative data for medical research 
 These in-depth profiles of data sources highlight that the research potential of 
some is yet to be fully realised. For example, many of the data sources focussed on 
service user experiences and those focussed on auditing practice rarely appear in 
the peer-reviewed literature. However, this does not diminish either their 
robustness of the data or their future potential. NICE’s own intended uses of real-
world data cover a spectrum of needs from addressing in-depth research questions 
around the effectiveness and variance in the effectiveness of interventions to more 
audit purposes. A broad brushed approach to considering different forms of real-
world data is likely to yield substantial benefits. 
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Addressing concerns around data quality and bias 
 The findings highlight that researchers have used a variety of methods to 
investigate and address potential sources of bias in the data. These include various 
sensitivity analyses and analytical techniques to investigate and limit the impact of 
sources of bias including confounding by indication and selection bias. Other forms 
of bias around measurement have been addressed through implementing rigorous 
quality assurance processes and fielding instruments that have been rigorously 
tested across other data sources. Similarly, the sensitivity of some of the sources 
have been exploited to examine the occurrence of iatrogenic diseases over a long 
exposure time, and even to detect changes in practice following the issuing of NICE 
guidelines. A good deal of familiarity with the data source is likely to be required 
to understand the extent of potential bias and implement techniques that may help 
to address these. Nevertheless, all the sources profiled in-depth all show a 
substantial degree of potential to address the real world data needs of NICE where 
the appropriate analytical technique is employed. Furthermore, should a similar 
profile have been developed for all the named data sources in section 2, we expect 
that the same conclusions would have been drawn. 
Addressing gaps in coverage 
 The in-depth profiles revealed that some data sources – notably the CPRD and THIN 
– hold the potential for additional data to be collected, particularly around Patient 
Reported Outcomes. Furthermore, some of the data sources were specifically 
focussed on understanding patients’ experiences and satisfaction with services, 
while others collected in-depth measures of patients’ mental wellbeing which 
could be associated with their health state (although do not fall within the remit of 
‘patient reported outcomes’ strictly in terms of outcomes following clinical or care 
interventions). These in-depth profiles offer ideas of how patient and service user 
input could be incorporated to a greater extent into NICE’s work. Some of the gaps 
identified earlier (section 2) do remain, even after creating the in-depth data 
profiles. These include obtaining data on care home or extra care housing residents 
who are privately funded as well as data on service user experience of public 
health services, for example user experiences and characteristics in sexual health 
programmes or smoking cessation programmes. There may also be gaps in the 
covering different disease stages; for example end of life/palliative care was not a 
focus in this review but some sources, for example the 2013 sweep of the Health 
Survey for England, have included modules covering this issue.  
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Focus on the potential utility of different datasets for NICE 
All the profiled data sources are likely to have some utility to NICE dependent on the 
research question and making a specific recommendation around use is challenging as 
this is very much dependent on the context and the focus of the research question. The 
following section summarises the utility of the different sources for NICE.  
 
English Longitudinal Study of Ageing (ELSA) 
 ELSA has been used to establish the effectiveness of interventions at a population 
level using observational methods, for example in a cost-benefit analysis of cataract 
surgery among ELSA respondents 4. ELSA may be less suitable for establishing the 
effectiveness of more specialist interventions/practice, or establishing how 
interventions/practice vary among minority groups.  
 ELSA can be used to determine the implementation of guidance through examining 
broad population-level temporal changes in the receipt of common interventions or 
practice. For example ELSA data were used to examine shortfalls in care for chronic 
conditions using set quality indicators 5. Without further linkages, ELSA data may be 
less suitable for explaining the underlying mechanisms around the implementation of 
guidance, beyond patient/service-user characteristics. 
 ELSA data can be used to provide information on some aspects of resource use for 
example how many people receive common interventions and can be used to 
establish how access may vary by individual patient characteristics.  
 ELSA data can be used to establish self-reported levels and determinants of many 
age related conditions and non-communicable diseases and more broadly 
information on lifestyle behaviours and attitudes among older people.  
 ELSA data may be less suitable for establishing the incidence/prevalence/outcomes 
of very uncommon diseases/conditions/interventions. 
Community Mental Health Survey 
 The CMHS data have been used to monitor the implementation of guidance, for 
example in monitoring the implementation of guidance aiming to strengthen support 
for service users during times of turnover in staffing 6.  The data have also been used 
to draw together guidance around expected standards of care 7. There may also be 
potential to use the data to monitor different aspects of resource usage.  
 The focus of the survey is on service user experiences and there is less information 
on outcomes following receipt of different forms of care, limiting the utility of the 
data with respect to establishing the effectiveness of interventions. The data are 
less suitable as a tool for monitoring epidemiological patterns in mental health. 
Clinical Practice Research Datalink (CPRD) 
 CPRD data have utility for NICE through the flexibility in being able to collect 
additional fields. CPRD data are also available to medical researchers based outside 
UK universities potentially expanding the pool of potential partners with which NICE 
could work in using the dataset. The long established nature of CPRD (based on 
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GPRD) means that several retrospective studies could also be potentially conducted 
using these data.  
 There are numerous examples where CPRD (and GPRD) data have been used in 
studies that cover all of NICE’s intended uses of real-world data. For example, CPRD 
have been used to evaluate changes in cancer diagnostic intervals following the 
introduction of NICE guidance 8. Given the potential to draw large samples, studies 
could be implemented that examine the epidemiology/outcomes/implementation of 
rare or less common conditions and procedures. Unlike survey-based sources, for 
example ELSA and HSE, and in the absence of further data collection, there is 
potential to examine only a limited range of patient-level intrinsic factors, although 
these may be sufficient for many studies.  
 Data linkages will expand the utility of CPRD data for NICE; current linkages include 
those with MINAP data, National Cancer Intelligence Network data and HES data. 
Area level data are also available including Index of Multiple Deprivation data and 
Townsend deprivation scores 9. Further data linkages are planned. 
QResearch 
 QResearch is of interest to NICE for many of the real world data uses identified by 
NICE, but access appears to be restricted to research consortiums led by academic 
institutions. Nevertheless, given the substantial potential of these data, NICE could 
consider ways of developing research projects based on QResearch data led by 
universities. 
 There is potential for QResearch data to be used in studies that cover all of NICE’s 
intended uses of real-world data. The use of QResearch data in developing risk 
prediction scores may also be of interest to NICE, potentially around forecasting and 
modelling future disease burden.  
 Given the potential to draw large samples, studies can be implemented that 
examine the epidemiology/outcomes/implementation of rare or less common 
conditions and procedures. One example is a study of peanut allergy, where a 
prevalence rate of 0.51 per 1000 patients in the UK was estimated 10. 
 The study depositors state that QResearch data are suitable for case control studies 
designed to examine risk factors for onset of disease, cross sectional surveys, cohort 
studies and sample size calculations (for non-observational studies) 11. 
 As is the case for all three large primary care databases, there is potential to 
examine only a limited range of patient-level intrinsic factors, although these may 
be sufficient for many studies. 
The Health Improvement Network (THIN) 
 There are numerous examples where THIN data have been used in studies that cover 
all of NICE’s intended uses of real-world data. For example, THIN data have been 
used to examine equity in access to cancer screening among people with Intellectual 
Disabilities compared to those without across different types of cancer  12. 
 Data linkages expand the utility of THIN, and THIN data have been linked with 
Hospital Episodes Statistics (HES) data, providing potential for studying continuity in 
care between primary and secondary care. A number of patient postcode-based 
socioeconomic, ethnicity and environmental indicators are available to researchers 
including Townsend deprivation quintile scores.  
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 Overall there is a wide scope for analysing data reflecting outcomes and experiences 
of morbidity and mortality at primary care level, as well as trends in the care and 
treatment provided. These data can also be linked to HES data allowing for potential 
tracking of patient journeys between primary and secondary care. As is the case for 
all three large primary care databases, there is potential to examine only a limited 
range of patient-level intrinsic factors, although these may be sufficient for many 
studies. 
 THIN data have utility for NICE through the flexibility in being able to collect 
additional fields and the potential to conduct research based on free-text fields. 
THIN data are also available to medical researchers based outside UK universities 
potentially expanding the pool of potential partners with which NICE could work 
with in utilising real world data.  
National Minimum Data Set for Social Care (NMDS-SC) 
 NMDS-SC is a specialist dataset suitable for monitoring trends in the social care 
workforce. This data can potentially help NICE to understand workforce capabilities 
and undertake preliminary work to understand the feasibility of implementing new 
standards and guidance in social care settings.  
 The data may be suitable to examine changes following the implementation of NICE 
guidance at a workforce level in terms of indicators such as pay, training or 
necessary skills. They may also be useful in helping to set benchmarks and develop 
quality standards around workforce capacity and skills. The data have also been 
incorporated into calculations of resource use in the literature 13. While the data do 
not provide insight into epidemiological trends per se, they do provide insight into 
the workforce preparedness for responding to epidemiological challenges, such as 
dementia 14. 
 As social care outcomes are not collected in NMDS-SC, it is unlikely that these data 
are suitable for researching the effectiveness of interventions and practice. 
Health Survey for England (HSE) 
 HSE was suggested in the context of monitoring epidemiological trends although the 
potential usage extends beyond this purpose alone and potentially HSE data can be 
used to gain an understanding of trends over time in terms of resource utilisation, 
trends in social care needs and usage, trends in lifestyles and social determinants of 
health, and some trends in prescribing, service usage and attitudes to health. With 
regards to researching the effectiveness of interventions, in the absence of data 
linkages, there may be more limited potential to measure the effectiveness of 
interventions or changes in practice. Examples where data have been linked to 
explore later outcomes include an examination of fruit and vegetable intake and 
mortality 15. 
 The survey data may be of great utility for NICE in gathering contextual information 
critical in the assessing feasibility of different forms of guidance aimed at public 
health and social care challenges. The data also have the added advantage of being 
relatively easy to obtain for further secondary data analysis and are free to use. 
 There is scope for auditing the implementation of guidance through examining 
change in practice at a population level; one of the strengths of HSE data in doing so 
is the ability to examine social or medical inequalities in the implementation of 
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guidance. Some HSE information may be suitable in providing information for the 
development of NICE quality standards and these data may be particularly useful 
where the standard is based on meeting a certain level of patient satisfaction or 
experience. 
Adult Social Care Survey 
 ASCS is a survey of users’ satisfaction with the care that they receive. Such data can 
be used in forming guidance that is based on user experience and patient reported 
outcomes. There may be limited scope for undertaking secondary analysis of the 
individual service user data without further permissions being sought. Nevertheless, 
the detailed reports and tables produced may allow for gaining a good level of 
understanding of aspects of service user satisfaction with their care and broader 
aspects of wellbeing.  
 With regards to measuring the effectiveness of practice, while it may be possible to 
undertake repeated cross-sectional studies and examine the impact of changing 
practice on user experiences, fully assessing the effectiveness of interventions 
through measuring longitudinal changes at a service-user level will be challenging 
with these data. However, it may be possible to assess whether guidance is being 
implemented, particularly around service user satisfaction or service user reported 
experiences, through analysing change (for example at a Local Authority level). 
 With regards to using the data as an epidemiological tool, the study provides a 
snapshot of general health trends and social care needs but among a population who 
are receiving LA assistance for these health needs (the sample design represents a 
caveat around the applicability of the data). There may be scope for the data to be 
used to form quality standards around social care experiences and trajectories – for 
example around information advice and guidance received by older people in 
accessing care.  
Salford Integrated Record 
 SIR was suggested as a source of data that may have the potential to overcome the 
limitations of other data source and examine patients’ integrated care pathways. 
The potential of the data for research purposes are likely to be in the process of 
being realised and there are comparatively few publications using these data in the 
literature; the data may have been used initially to mainly facilitate clinical 
decision-making and performance management. Perhaps one of the most appealing 
characteristics of the data, given the current climate around the use and ethics of 
electronic health records in medical research, is the high degree of patient 
involvement and the ability of patients to access their own records.   
 The data hold substantial potential for improving patient care. The integration of 
primary and secondary care data allows for research tracking patient outcomes 
across care providers (through examining Integrated Care Pathways (ICP)). One 
initiative using the data in this way is the Collaborative Online Care Pathway 
Investigation Tool that is being used to examine missed opportunities in patient care 
– that is where primary prevention opportunities were missed which could lead to 
adverse health outcomes. This initiative is focussed on modelling the circumstances 
and frequency of variance between idealised ICP and the actual care provided 16.   
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Prescribing Observatory for Mental Health 
 One of the key criteria for choosing a topic focus of the POMH-UK is that the topics 
are relevant for monitoring the implementation of NICE guidelines. This has direct 
relevance to one of the intended uses of real-world data by NICE. An example of 
study directly assessing the implementation of NICE guidance can be found in a study 
of renal and thyroid functioning among patients who are prescribed lithium 17.  
 The utility of the data for other more research-focused or evaluative activities, for 
example in assessing the effectiveness of interventions or monitoring 
epidemiological trends, may be more limited. The data are not widely used in the 
literature and it is unclear the extent to which these data are made available for re-
analysis, reflecting their primary function as a quality improvement tool. 
Nevertheless, there are several important questions that could be addressed for 
NICE as there may be potential to understand whether practice/outputs have 
changed over time. In addition, this source represents one of the few specialist 
sources of real-world data on mental health encountered. 
Care.data 
 If successfully implemented, care.data would make a substantial contribution to the 
real-world data needs of NICE and other organisations. The data could allow for 
establishing the long-term effectiveness of interventions through the capacity to 
track patient journeys through primary and into secondary care as standard, 
something that rarely occurs as standard in real-world data projects and sources. 
Uniquely, it could also potentially, allow for insight into patterns of social care and 
their relationship clinical and public health data.  
 At the time of writing it is too early to tell the extent to which care.data has been 
able to overcome the challenges encountered, particularly around consent and 
conditions around data usage. The results of the pathfinder exercise will offer 
further insight into the viability of the whole project; the majority of testing in 
pathfinder areas is due to begin later this year. 
 
 
 
Using real-world data in Healthcare Technology Assessment: experiences from the 
Swedish Council on Healthcare Technology Assessment (SBU) 
Background  
Interviewees were asked for their input to help identify organisations with a similar remit 
to NICE who were using real-world data in an extensive and effective way. One of the 
criteria for selecting an organisation for a case study was that the organisation’s 
experience of real-world data should be primarily as a user of real-world data and not as a 
producer. Some suggestions were received, although most promising in terms of 
comparability were suggestions of examining the way in which the extensive sources of 
real-world data in Sweden were used by organisations with a similar remit to NICE.  
Section 5: Summary of in-depth profiles of data and organisational case study - Using real-
world data in Healthcare Technology Assessment: experiences from the Swedish Council 
on Healthcare Technology Assessment (SBU) 
145 
 
Context of Real-world data in Sweden 
Sweden has an extensive framework of central government funded registers which 
encompass aspects of clinical healthcare, public health and social care. These are often 
characterised by having extensive coverage, scope, are available for medical research, 
and are operated on a non-commercial basis. One example is the National Patient 
Register, a complete census of all inpatient events since 1987 and a census of inpatient 
and outpatient events across private and public hospitals (including psychiatric hospitals) 
since 200665. Another is the Swedish Pharmaceuticals Registry, which provides information 
on prescribed medications and is compulsory for all pharmacies operating in the country66. 
In addition to national, centrally funded registries, there is also an extensive network of 
more localised or more focused registers that cover specific diseases/conditions. A recent 
review by  Emilsson and colleagues assessed 103 of these active registers (known as 
Quality Registries) 254. These registers are intended to improve the delivery of patient 
outcomes by monitoring quality standards and adherence to guidelines, investigating 
disparities in healthcare by geographic and social characteristics, and comparing the 
effectiveness of different interventions. This network of specialist registers complements 
the coverage of national registers through providing the depth of information not found in 
more generic national clinical databases. It is this breadth of potential sources of real-
world data that makes Sweden an interesting context for examining real-world data use. 
  
Context of SBU [and TLV; TBC] 
SBU is one of the oldest Health Technology Assessment (HTA) organisations in the world, 
established in 1987. SBU take a broad approach to assessing interventions and consider the 
clinical, social, economic and ethical dimensions of interventions. The organisation 
primarily relies on systematic reviews as its prime research methodology and has made 
methodological contributions in the systematic review field67. Unlike NICE, it has a 
narrower remit in terms of its decision-making functions. Its prime function is to present 
comprehensive, rigorous and impartial summaries of the evidence around interventions 
and to present these findings to decision-making authorities such as the National Board of 
Health and Welfare, the Medical Products Agency and the Dental and Pharmaceutical 
Benefits Agency. Therefore, an assessment of the use of real-world data in HTA needs to 
incorporate the experience of both SBU and another decision-making authority. This case 
study focuses on the experiences and viewpoints of SBU and TLV (Dental and 
Pharmaceutical Benefits Agency [TBC]) in real-world data against a context of a rich 
landscape of real-world data sources.  
SBU experience of using real-world data 
SBU currently use real-world data primarily to understand the use of the evidence it 
produces. Of NICE’s intended data usages; this corresponds closely with the aim of 
auditing the implementation of guidance.  
Most of the organisation’s current data usage is based on evidence from RCTs (and in some 
cases evidence from observational studies), used as part of systematic reviews. This is 
                                            
65 http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish  
66 http://www.jpi-dataproject.eu/Home/Database/388?topicId=1  
67 http://www.sbu.se/en/About-SBU/  
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rarely accessed in the form of granular individual patient data. Where real world data is 
used is around the assessment of whether SBU’s reports and conclusions are used in 
healthcare decision-making, as opposed to using real-world data to create these reports. 
However, the organisation is planning to incorporate real-world data within more aspects 
of its work and there is substantial appetite and interest within the organisation to do so. 
SBU has been developing relationships in order to realise these ambitions. 
The specific aspects of interest for SBU in using real-world data are around establishing 
the generalisability of evidence from RCT studies and examining the effectiveness of 
interventions using the extensive registry data collected in Sweden. SBU is currently 
discussing with partner organisations how to develop methods to understand the utility of 
these data.  
Currently, registry data is rarely used in SBU’s work, although summaries of evidence of 
register-based studies are likely to feature in the systematic reviews it collects. The most 
common form of real-world data in use are based on surveys of practitioners and decision-
makers where SBU aims to assess the degree to which its findings are influencing clinical 
practice. The surveys are administered in-house and usually receive a remarkably high 
response rate (>90%). The questions are usually limited to assessing the impact of findings, 
and the results are used to understand how to better improve the production and 
dissemination of SBU’s findings, and the results are published on the organisation’s 
website and in discussion and debate papers. Unlike NICE’s intended use of real-world 
data, SBU has not yet used real-world data at any point in making definitive 
recommendations, primarily because the remit of the organisation differs from that of 
NICE.  
Nevertheless, there is recognition that there is potential for much greater usage and 
particularly in incorporating the wealth of new data sources established locally in the past 
decade. While SBU has been able to present evidence on the safety of interventions, the 
use of real-world data in future will be able to help it present evidence around the 
effectiveness of interventions, and there is particular interest in sources of real-world 
data that allow for the administration of pragmatic trials. While the organisation is at an 
early stage in expanding its profile of real-world data use, one of the important 
considerations that will feature in its quality assurance assessments of real-world data 
sources is the population coverage. Many of Sweden’s national registers have over 90 per 
cent population coverage, allowing for understanding of local patterns of healthcare 
delivery. As much of Sweden’s healthcare system is devolved at the municipal level, a 
data source that allows for understanding of municipal level trends will be an important 
consideration in appraising sources of real-world data. As the trend in the English NHS is 
also following suit, this may be an increasingly important shared criteria in assessing 
sources of real-world data.    
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Key Findings and Recommendations 
Key Findings 
 The real-world data landscape remains complex and heterogeneous and 
composed of sources with different purposes, structures and collection methods. 
This heterogeneity may increase with opportunities stemming from the 
incorporation of new technologies in data collection (current quality assured 
sources are limited in number) 
 Some real-world data sources are purposefully either set-up or re-developed to 
enhance their data linkages and to examine the presence/absence/effectiveness 
of integrated patient care; however, such sources are in the minority. 
Furthermore, the small number that are designed to enable the monitoring of 
care across providers, or at least have the capability to do so at a national level, 
have been utilised infrequently for this purpose in the literature. 
 Data that offer the capacity to monitor transitions between health and social 
care do not currently exist at a national level, despite the increasing recognition 
of the interdependency between these sectors.  
 Among the data sources we included, it was clear that no one data source 
represented a panacea for NICE’s real world data needs. This does highlight the 
merits and importance of data linkage projects and is suggestive of a need to 
triangulate evidence across different data, particularly in order to understand 
the feasibility and impact of guidance.  
Key Overall Recommendation 
 There exists no overall catalogue or repository of real-world data sources for 
health, public health and social care, and previous initiatives aimed at creating 
such a resource have not been maintained. As much as there is a need for 
enhanced usage of the data, there is also a need for taking stock, integration, 
standardisation, and quality assurance of different sources. This research 
highlights a pressing need for a systematic approach to creating an inventory of 
sources with detailed meta-data and the funding to maintain this resource. This 
would represent an essential first step to support future initiatives aimed at 
enhancing the use of real-world data. 
Key Recommendations for NICE 
Increased utilisation of existing sources beyond clinical databases: 
 Making recommendations is difficult around the use of specific data sources. 
However, NICE’s current use of real-world data differs substantially from the 
landscape with respect to its low utilisation of clinical audit, disease registry and 
survey data. Several of the datasets profiled in-depth highlight the potential of 
different sources of survey, clinical database and audit data.  
 We also recommend that NICE further review its use of disease registry and audit 
data and engage in dialogue with collectors and depositors of these data to 
explore the utility of these types of data. Sources, such as those available from 
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the National Cancer Data Repository, are currently underutilised or entirely 
overlooked during the production of guidance or technology assessments.  
Investment in capacity and partnership building 
 Use of real-world data requires substantial investment of resource that allows for 
the organisation to develop an in-depth understanding and experience of using 
different real-world sources. The extent of this undertaking should not be 
underestimated; any commitments and real-world data usage strategies should 
be matched by resources that allow for developing expertise in-house and in 
developing partnerships with study depositors and academic experts. 
 Many of the data sources profiled either have active user groups or hold regular 
consultative exercises. NICE should further investigate these opportunities and 
capitalise on these. 
Strategy and influence 
 NICE has the potential to influence the availability of real-world data sources 
and good practice around the collection and utilisation of real-world data. This 
influence could be used to develop good practice around aspects such as 
obtaining informed consent from patients or obtaining investment around the 
creation of data linkages. NICE should develop and publish an outward-facing 
policy around its use of real-world data which includes transparent means of 
influencing the state of the landscape, in order to ensure that sources continue 
to meet its organisational needs. Exerting such influence could not only lead to 
benefits to NICE, but will have broader positive impacts across other 
stakeholders more widely, and could lead to improved patient and service user 
outcomes. This influence could also extend to developing quality standards 
around the way in which data are collected that can be shared across the sector. 
 Care.data represents an initiative that could potentially meet many of NICE’s 
real-world data needs. NICE should engage in discussions with HSCIC to better 
understand and prepare for potentially using these data, while continuing to 
monitor whether and how the initiative overcomes challenges identified in 
earlier stages.  
Understanding implementation 
 Finally, while NICE is potentially able to monitor the implementation of 
guidelines using several sources, it may still lack information on the underlying 
mechanisms as to how or why guidelines succeed or fail in implementation. 
Starting its own programme of real-world data collection in the form of surveys 
of practitioners may be a way of understanding the mechanisms of un/successful 
implementation. Such an approach has been adopted elsewhere, for example by 
the Swedish Council on Healthcare Technology Assessment (SBU). 
Green shoots 
There are three key factors as to why the state of the real world data landscape should 
be regarded with some optimism for NICE and more generally. 
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1. Firstly, while data linkage and the capacity to research patient journeys is not at the 
point where many would desire, there are several examples where these efforts have 
been met with success and some of these have been met with a high degree of public 
acceptance. On a national level, the care.data initiative has restarted after a pause, 
and if these efforts succeed, they could meet many of NICE’s real-world data 
requirements. 
2. Secondly, while we have been critical in the study about the representation of 
sources of patient reported outcomes, there are examples featured in the main report 
where patients have become more involved and have become gatekeepers to their own 
data (e.g. Salford Integrated Record), providing a possible model for the future. In 
addition, the ubiquity of smartphone technology and apps mean that ways of patients 
providing and managing their own information are increasing at pace. 
3. Thirdly, methodological advances in the design and analysis of studies continue to 
ensure that real-world data becomes of greater utility for organisations, such as NICE, 
who wish to understand the implications of their decisions in real-world settings. These 
advances include the development of pragmatic trials using electronic health data 
which offer a balance between the methodological rigour of RCTs and the 
generalisability of observational studies. Several UK based organisations and teams – 
some of which are represented among the expert stakeholders involved in the present 
study – are involved in driving these advances and it is likely that future studies will 
feature the results of these undertakings extensively in their findings. 
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Glossary 
Real-world data 
The definition of real-world data can be contentious and different stakeholders have 
different views as to what constitutes ‘real-world’ data. Real world data is defined in this 
report through two key tenets: 
a. The collection of real world data reflects the usual care or treatment provided to 
populations of patients, service users or the public. This therefore excludes 
conventional Randomised Controlled Trials (RCT(s)) but could include other forms 
of RCT design, namely pragmatic RCTs.  
b. Real world data provides enough depth to assess trends around everyday practice, 
service usage, or assess outcomes. 
Clinical databases 
Clinical databases usually collect data from a particular form of service or a set of 
services. They have undefined/multiple entry points and less well-defined criteria around 
case definitions than is the case for registry data (and consequently have no defined 
denominator68). Due to the breadth of data collected, they can be used to address a 
variety of research questions although they do vary in their quality and value in addressing 
some questions (e.g. some forms of epidemiological surveillance). Multicentre databases 
are particularly useful tools for monitoring/assessing population health. Clinical databases 
may be particularly useful for monitoring conditions that may be difficult to diagnose or 
where there are no definitive clinical tests but where diagnoses are made through 
observing symptomology (using a structured checklist) and/or response to medication; 
they may be less useful for monitoring very rare conditions. 
Disease/case registries 
Disease registers are effectively a census of all cases of a particular disease or health 
condition 3 105, and can additionally include much more detailed accounts of treatment 
regimes. Disease registries can be population based, hospital based or clinical based; or 
can reflect some other form of community boundary. Detailed case histories can lend 
disease registry data particularly suitable for some forms of research (for example 
pharmaco-epidemiological studies and resource use studies). Disease registries are viewed 
as important tools in improving (i) patient care; (ii) public health; (iii) technology 
assessment and (iv) information provision 105. Disease registers are most useful in 
situations where disease or risk factor status does not tend to change over time; the 
diagnosis of disease needs to be consistent, and based on a robust diagnostic test. 
Furthermore, a register is of use when there is a requirement for ongoing health care, for 
example, retinal screening among patients with diabetes 2. 
                                            
68 Although clinical databases are often intended to be representative of a specific population with 
a denominator in mind 
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Workforce registers/case registers 
Workforce or case registers are another form of real-world data. They can include data on 
qualifications, training and continuous professional development, specialism, and socio-
demographic information, and provide indicative evidence around resource use and skill 
surpluses and deficits. They can be collected by public health authorities as well as 
representative bodies who may require staff to be registered in order to practice.    
Healthcare technology/surgical registers 
Surgical/technology registers are similar in design to disease registers in that they 
effectively comprise a census of all specific surgical procedures or technological 
implementation and the outcomes of these procedures. Pharmacoepdiemiological 
registers/databases comprise another form of register, although are rarely confined to a 
single drug and are more akin to clinical databases in having a broader case definition. 
Surveys 
Data provided by surveys can help identify specific problems in the delivery of healthcare 
services or the health status of individuals. Surveys can provide a much deeper 
understanding of the lifestyles and antecedent factors surrounding contact with health or 
social care providers; longitudinal (e.g. panel or cohort studies) provide an opportunity to 
develop models of causal inference. Surveys can also be useful for determining patients’ 
views about the care that they receive as well as other factors surrounding patients and 
service users including their mental health and quality of life outcomes. There can exist 
methodological issues in the design of surveys with how patients are sampled, non-
response and missing data which can compromise the generalisability of results 2. In 
addition, sample size can be a substantial limitation in general purpose surveys where the 
number of observed contacts with service providers and/or observed episodes of ill health 
or care needs can be relatively low. 
Clinical audits 
A clinical audit is a process that has been defined by NICE as "a quality improvement 
process that seeks to improve patient care and outcomes through systematic review of 
care against explicit criteria and the implementation of change” 255. In many ways the 
distinction between clinical audits and disease registries may be fuzzy in terms of design, 
although the remit of disease registries can be broader in that they can be focussed upon 
predetermined scientific (research) purposes as well as clinical and policy purposes; 
clinical audits are arguably more focused on performance against standards. Generally, it 
is accepted that there are few distinguishing features between clinical audits and 
registries set-up for research purposes 256, although in practice some differences may arise 
in terms of the scale of collection, structure and establishment and funding of data, and 
some of these differences have, on occasion, limited the use (or dissemination) of clinical 
audit data for research purposes 257. 
Population registries and censuses    
Another common form of real-world data are population registries and censuses. The 
census has included questions on self-rated health and caring, and a proportion of census 
respondents are also monitored more closely in some studies (e.g the LS study; see 
Appendix 2). Included in this category are those registers that capture vital events such as 
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fertility and mortality; the universal coverage of vital statistics registers mean that they 
comprise censuses of births and death for large geographic areas. 
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Appendix 1: List of expert stakeholders 
Professor Nick Black London School of Hygiene and Tropical Medicine 
Professor Joanna Chataway Open University/RAND Europe 
Dr José-Luis Fernández London School of Economics 
 Colin Flynn Public Health England 
Dr Shereen Hussein Kings College London 
Professor Martin Knapp London School of Economics 
Professor Jan Liliemark SBU - Swedish Council on Health Technology Assessment 
Dr Owen Nicholas University College London 
Dr Miriam O’Hare Micron Group 
Dr Louise Parmenter Quintiles 
 Paul Ross Social Care Institute of Excellence 
Professor Tjeerd van Staa University of Manchester 
 John Varlow Health and Social Care Information Centre 
 Raphael Wittenberg London School of Economics 
 
*An additional two interviews were carried out with real world data experts based at a 
regulatory body and a public sector organisation. 
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Appendix 2: List of sources uncovered 
It was also acknowledged that the HSCIC website held a great number of sources that could also be potentially 
profiled – future exercises could include a more detailed inventory of the HSCIC datasets. 
 
Source name Type 
Disease/Condition 
/Setting 
Population 
(characteristi
c) Geographic 
Continuing 
or Defunct 
All Wales Injury Surveillance 
System Clinical database Trauma All Wales Subsumed 
Assessment of Stomach and 
Oesophageal Cancer Disease registry Cancer All Unknown 
Discontinue
d 
British Association of Surgical 
Oncology—Breast Unit 
Database Disease registry Cancer All Unknown 
Discontinue
d 
British Isles Network of 
Congenital Anomaly Registers 
(BINOCAR) Disease registry 
Congential 
Abnormalities Children 
Wales, 
Ireland (NI), 
50% of 
England Continuing 
Carers and Users Expectations 
of Mental Health Services Clinical database Mental Health All Unknown 
Discontinue
d 
Chronic Obstructive Pulmonary 
Disease Audits Clinical audit Respiratory All 
England and 
Wales Continuing 
Mothers and Babies: Reducing 
Risk through Audits and 
Confidential Enquiries; Centre 
for Maternal and Child 
Enquiries (CMACE) Clinical audit Maternal health 
Mothers and 
Children UK Continuing 
East Midlands and South 
Yorkshire (EMSYCAR) Disease registry 
Congential 
Abnormalities Children Midlands  Continuing 
Functional Analysis of Care 
Environments 
Not a primary real 
world datasource Mental Health Unknown Unknown Unknown 
General Practice Research 
Database Clinical database GP experiences All GB Subsumed 
Glasgow Register of Congenital 
Anomalies Disease registry 
Congential 
Abnormalities Children Scotland Continuing 
Hospital Episode Statistics Clinical database Hospital admissions All England Continuing 
Intensive Care National Audit 
and Research Centre—Case Mix 
Program Database Clinical database Trauma All UK Continuing 
Manchester Children’s Tumour 
Registry (MCTR); Manchester 
Children’s Cancer registry Disease registry Cancer Children 
North 
England Continuing 
MRC National Survey of Health 
and Development (1946 cohort) Survey Health (general) 
Lifecourse; 
cohort GB Continuing 
Myocardial Infarction National 
Audit Programme (MINAP) Clinical audit Cardiovascular Adults 
England and 
Wales Continuing 
National Adult Cardiac Surgery 
Audit  Clinical audit Cardiovascular Adults 
England and 
Wales 
Contiuning 
(2012) 
National Drug Treatment 
Monitoring System Clinical audit Substance Abuse All England Continuing 
National Pacemaker Database 
Surgery/technology 
register Cardiovascular All UK Subsumed 
National Paediatric Diabetes 
Audit Clinical audit Diabetes Children 
England and 
Wales Continuing 
National Prospective 
Monitoring Scheme on HIV Disease registry HIV All Unknown 
Discontinue
d 
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National Registry of Childhood 
Tumours Disease registry Cancer Children GB Continuing 
National Sentinel Audit of 
Stroke Clinical audit Cardiovascular All 
England, 
Wales, 
Northern 
Ireland Continuing 
North east and North Cumbria 
(NorCAS) Disease registry 
Congential 
Abnormalities Children 
North 
England Continuing 
North of England Collaborative 
Cerebral Palsy Survey (NECCPS) Disease registry Cerebal Palsy Children 
North 
England Continuing 
North West Hip Arthroplasty 
Register 
Surgery/technology 
register 
General/Technology 
Assessment All 
North West 
England 
Discontinue
d 
North West Cancer Registry Disease registry Cancer All 
North West 
England Continuing 
Northern Ireland Cancer 
Registry Disease registry Cancer All 
Northern 
Ireland  Continuing 
Northern Region Haematology 
Register Disease registry Cancer All 
North 
England 
Discontinue
d 
Northern Region Young Persons 
Malignant Disease Registry 
(NRYPMDR) Disease registry Cancer Children 
North 
England Continuing 
Nosocomial Infection National 
Surveillance Scheme Survey 
Other Infectious 
Disease All UK 
Discontinue
d 
4Child register; Oxford Register 
of Early Childhood Impairments Disease registry Cerebal Palsy All South East 
Discontinue
d 
Oxfordshire, Berkshire and 
Buckinghamshire (CAROBB) Disease registry 
Congential 
Abnormalities Children South East Continuing 
Quality Indicators in Diabetes 
Service 
Not a primary real 
world datasource Diabetes Unknown Unknown Unknown 
Scotland and Newcastle 
Lymphoma Group Database Disease registry Cancer Unknown Unknown 
Discontinue
d 
Scottish Asthma Management 
Initiative 
Not a primary real 
world datasource Respiratory Unknown Scotland Continuing 
Scottish Motor Neurone 
Disease Register Disease registry 
Motor Neurone 
Disease All Scotland 
Continuing 
(2010) 
South West  Congenital 
Anomaly Register (SWCAR) Disease registry 
Congential 
Abnormalities Children South West Continuing 
St Mary’s Maternity 
Information System Clinical database Maternal health Women London 
Discontinue
d 
North East Paediatric Diabetes 
Network (NEPDN) Database Disease registry Diabetes Children 
North 
England Continuing 
Trauma Audit and Research 
Network Clinical audit Trauma All UK Continuing 
UK Cystic Fibrosis Database Disease registry Genetic disease All UK Continuing 
National Diabetes Audit Clinical audit Diabetes All 
England and 
Wales Continuing 
UK Hydrocephalus Shunt 
Registry Disease registry Surgery All UK Continuing 
UK Registry for Rare Kidney 
Diseases  Disease registry Renal All UK Continuing 
UK National Renal Registry Disease registry Renal All UK Continuing 
UK Register of HIV 
Seroconverters Disease registry HIV All UK Continuing 
Wessex Antenatally Detected 
Anomalies (WANDA) Disease registry 
Congential 
Abnormalities Children South East Continuing 
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West Midlands Congenital 
Anomaly Register (WMCAR) Disease registry 
Congential 
Abnormalities Children Midlands  Continuing 
West Midlands Regional 
Children’s Tumour Registry 
(WMRCTR) Disease registry Cancer Children Midlands  Continuing 
Yorkshire and Humber 
Congenital Anomaly Register 
(YHCAR) Disease registry 
Congential 
Abnormalities Children 
North 
England Continuing 
Yorkshire Specialist Register of 
Cancer in Children and Young 
People (YSRCCYP) Disease registry Cancer Children 
North 
England Continuing 
Tayside Medicines Monitoring 
Unit (MeMo) Clinical database 
Pharmacoepidemiolo
gy All Tayside Continuing 
Oxford Record Linkage Study 
(ORLS) Clinical database Hospital admissions All 
Oxfordshire 
and 
Berkshire 
Discontinue
d 
Human Fertilisation and 
Embryology Authority Database Disease registry Fertility All UK Continuing 
Central Cardiac Audit Database 
(9 individual audits; listed 
separately) Disease registry Cardiovascular All UK Continuing 
Yorkshire Register of Diabetes 
in Children and Young People Disease registry Diabetes Children Yorkshire Continuing 
Leicestershire Diabetes Register Disease registry Diabetes All 
Leicestershir
e 
Discontinue
d 
Breast Implant Register 
Surgery/technology 
register 
General/Technology 
Assessment Women Unknown 
In 
developme
nt 
UKHVR: United Kingdom Heart 
Valve Register 
Surgery/technology 
register Cardiovascular All UK 
Discontinue
d 
National Transplant Database Donation registry Organ donation All UK Continuing 
NHS Organ Register Donation registry Organ donation All UK Continuing 
UK Database of Uncertainties 
about the Effects of Treatments 
Not a primary real 
world datasource Health (general) Unknown Unknown Continuing 
Sample of Anonymised Records 
(SAR) Census Health (general) All  UK Continuing 
Census - Longitudinal Study (LS) Census Health (general) All  UK Continuing 
British Household Panel Study Survey Health (general) Adults GB Subsumed 
Understanding Society Survey Health (general) Adults GB Continuing 
Health Survey for England Survey Health (general) Adults England Continuing 
ELSA (English Longitudinal Study 
of Ageing) Survey 
Health 
(general)/Social Care Older adults England Continuing 
Life Opportunities Survey Survey Disability Adults GB Continuing 
Adult Social Care Survey (ASCS) Survey Social Care Adults England Continuing 
Count me in census Census Mental health Adults 
England and 
Wales 
Discontinue
d 
Children in need census (Looked 
After Children Stats) Social care database Social Care Children England Continuing 
National Minimum Data Set for 
Social Care (NMDS-SC) Workforce registry Social Care Workforce England Continuing 
The Health Improvement 
Network (THIN) Clinical database GP experiences All UK Continuing 
Dr Foster 
Not a primary real 
world datasource Health (general) Unknown Unknown Continuing 
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British Thoracic Society National 
Pleural Procedures Audit Clinical audit Respiratory All UK Continuing 
British Thoracic Society National 
Paediatric Bronchiectasis Audit Clinical audit Respiratory Children UK Continuing 
British Thoracic Society National 
Paediatric Pneumonia Audit Clinical audit Respiratory Children UK Continuing 
British Thoracic Society National 
Adult NIV Audit Clinical audit Respiratory Adults UK Continuing 
British Thoracic Society National 
Adult Asthma Audit Clinical audit Respiratory Adults UK Continuing 
British Thoracic Society National 
Paediatric Asthma Audit Clinical audit Respiratory Children UK Continuing 
British Thoracic Society National 
Adult Bronchiectasis Audit  Clinical audit Respiratory Adults UK Continuing 
British Thoracic Society National 
Emergency Oxygen Audit Clinical audit Respiratory All UK Continuing 
British Thoracic Society National 
Adult Community Acquired 
Pneumonia Audit Clinical audit Respiratory Adults UK Continuing 
British Thoracic Society Lung 
Disease Registry Disease registry Respiratory All UK Continuing 
British Thoracic Society Difficult 
Asthma Registry Disease registry Respiratory All UK Continuing 
The British Society of 
Urogynaecology (BSUG) Audit 
Database Clinical audit Genitourinary All GB Continuing 
National Reporting and 
Learning System Incident registry 
General/Technology 
Assessment All England Continuing 
National Database for Primary 
Care Groups and Trusts GP Population List Health (general) All England 
Discontinue
d 
General Household Survey 
(General Lifestyle Survey) Survey Health (general) Adults GB 
Discontinue
d 
Fourth Morbidity Survey in 
General Practice (MSGP4) Survey Health (general) All Unknown 
Discontinue
d 
Primary Care Information 
Services (PRIMIS) Clinical database GP experiences All England  Continuing 
General and Personal Medical 
Services Data Workforce registry Workforce GPs England  
Continuing 
(2013) 
RCGP RSC National Monitoring 
Network Clinical database GP experiences All 
England and 
Wales Continuing 
Morbidity, Information Query 
and Export Syntax (MIQUEST) 
Not a primary real 
world datasource GP experiences All N/A Continuing 
Primary Care Networks: Trent 
Focus 
Not a primary real 
world datasource GP experiences All Trent Unknown 
Prescribing Analysis and Cost 
(PACT) data 
Pharmacoepidemiologic
al database 
Pharmacoepidemiolo
gy All England Continuing 
Quality Management and 
Analysis System (QMAS) Clinical database GP experiences All England 
Discontinue
d 
Quality Prevalence and 
Indicators Database (QPID) Clinical database Health (general) All England Subsumed 
Qresearch Clinical database GP experiences All UK  Continuing 
UK Biobank Precision medicine Biomarkers Older adults UK Continuing 
Suicide Information Base Cymru Mortality registry Death All Wales Continuing 
Welsh Cancer Intelligence & 
Surveillance Unit (WCISU) Disease registry Cancer All Wales Continuing 
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Welsh Demographic Service 
(WDS) Census Population  All Wales Continuing 
Primary Care GP dataset Clinical database GP experiences All Wales Continuing 
National Community Child 
Health Database (NCCHD) Screening register Health (general) Children Wales Continuing 
Congenital Anomaly Register 
and Information Service (CARIS) Disease registry 
Congential 
Abnormalities Children Wales Continuing 
Cervical Screening Wales (CSW) Screening register Cancer Women Wales Continuing 
Annual District Birth Extract 
(ADBE) Birth register Births Children Wales Continuing 
Bowel Screening Wales (BSW) Screening register Gastroenterology All Wales Continuing 
Scottish Suicide Information 
Database Mortality registry Death All Scotland Continuing 
ONS Mortality Dataset Mortality registry Death All 
England and 
Wales Continuing 
Annual District Deaths Extract Mortality registry Death All Wales Continuing 
Patient Episode Database for 
Wales Clinical database Hospital admissions All Wales Continuing 
Outpatient Dataset (OPD) Clinical database Hospital admissions All Wales Continuing 
Emergency Department Data 
Set (EDDS) Clinical database Trauma All Wales Continuing 
Health & Social Care (HSCIC) 
National provider of 
data          
ASCOT (The Anglo Scandinavian 
Cardiac Outcomes Trial) 
Not a primary real 
world datasource Cardiovascular Unknown Unknown Unknown 
Projecting Older People 
Population Information (poppi) Population data Health (general) Older adults England Continuing 
Born in Bradford Study Survey Health (general) Children Bradford Continuing 
National Child Measurement 
Programme Survey Obesity Children England Continuing 
Patients Like Me 
Patient reported 
outcome database Health (general) All 
UK and 
Internationa
l Continuing 
Hospital Pharmacy Audit Index 
Pharmacoepidemiologic
al database 
Pharmacoepidemiolo
gy All England Continuing 
Electronic Prescribing Analysis 
and Cost Tool (ePACT) 
Pharmacoepidemiologic
al database 
Pharmacoepidemiolo
gy All England Continuing 
IMS Disease Analyser Clinical database GP experiences All UK Continuing 
UK Nursing Dataset 
Not a primary real 
world datasource Nursing Adults Unknown Unknown 
General Medical Services (GMS) 
Data Warehouse  GP Population List GP experiences All Scotland Continuing 
Quality Outcomes Framework 
Clinical database/ 
Disease registry Health (general) All England Continuing 
National Adult Social Care 
Intelligence Service (NASCIS)  Social care database Social Care All England Continuing 
Transcatether aortic valve 
intervention (TAVI) Registry 
Surgery/technology 
register Cardiovascular All UK Continuing 
Quality Outcome Framework 
(QOF) - Dementia Register Disease registry Dementia All England Continuing 
Prescription Pricing Authority 
database 
Pharmacoepidemiologic
al database 
Pharmacoepidemiolo
gy All England Continuing 
IMS Health databases (Medical 
Data Index) Clinical database 
Pharmacoepidemiolo
gy All UK Continuing 
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172 
 
IMS Health databases (MIDAS 
Prescribing Insights) 
Pharmacoepidemiologic
al database 
Pharmacoepidemiolo
gy All UK Continuing 
Yellow card scheme Disease registry 
Adverse 
reaction/iatrogenic 
disease All UK Continuing 
Smoking Toolkit Study Survey Smoking All England 
Continuing 
(2014) 
Scottish Health Survey Survey Health (general) Adults Scotland Continuing 
Case Mix Programme (CMP) Clinical audit Intensive Care All 
England, 
Wales, 
Northern 
Ireland Continuing 
Scottish Hepatitis-C Virus 
Clinical database Disease Registry 
Other Infectious 
Disease All Scotland Continuing 
Integrated Household Survey Survey Health (general) All UK Continuing 
South East London Community 
Health (SELCoH) Survey Mental health Adults London 
Discontinue
d 
English Adult Psychiatric 
Morbidity Study (APMS) Survey Mental health Adults England 
Discontinue
d 
West of Scotland Twenty-07 
prospective cohort study Survey Health (general) 
Lifecourse; 
cohort Glasgow Continuing 
National Clinical Audit of Falls 
and Bone Health Clinical audit Falls Older adults 
England, 
Wales, 
Northern 
Ireland 
Discontinue
d 
The Health and Occupation 
Reporting network (THOR) Disease registry Workforce All UK Continuing 
South Yorkshire Cohort health 
and weight study 
Not a primary real 
world datasource Obesity Unknown Unknown Unknown 
Perineal Assessment and Repair 
Longitudinal Study (PEARLS) 
Not a primary real 
world datasource Maternal health Unknown Unknown Unknown 
EPIC-Norfolk (European 
Prospective Investigation of 
Cancer-Norfolk) Disease registry Cancer All Norfolk Continuing 
Scottish Morbidity Records Clinical database Hospital admissions All Scotland Continuing 
Computerised Radiology 
Information System (CRIS) 
reports 
Not a primary real 
world datasource 
General/Technology 
Assessment Unknown Unknown Unknown 
UK Obstetric Surveillance 
System Disease registry Maternal health All UK Continuing 
Prescribing Observatory for 
Mental Health 
Pharmacoepidemiologic
al database 
Pharmacoepidemiolo
gy (Mental health) All UK Continuing 
British Society of Rheumatology 
Biologics Register (BSRBR) 
Pharmacoepidemiologic
al database 
Pharmacoepidemiolo
gy (Rheumatology) All GB Continuing 
National Bowel Cancer Audit Clinical audit Cancer All 
England and 
Wales Continuing 
National Audit of Continence 
Care for Older People Clinical audit Incontinence Older adults 
England, 
Wales, 
Northern 
Ireland 
Continuing 
(2010) 
National Cardiac Arrest Audit 
(NCAA) Clinical audit Cardiovascular All UK Continuing 
Paediatric Intensive Care Audit 
Network Clinical audit Intensive Care Children UK Continuing 
British HIV Association (BHIVA) 
audit Clinical audit HIV All GB Continuing 
Scottish Diabetes Survey Survey Diabetes All Scotland Continuing 
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Association of Coloproctology 
of Great Britain and Ireland 
(ACPGBI) colorectal cancer 
database Clinical audit Cancer All UK Subsumed 
European Clinical Database Clinical database Health (general) All Europe 
Discontinue
d 
Sample of Anonymised Records Census Health (general) All UK Continuing 
Doctors Independent Network 
clinical database Clinical database GP experiences All Unknown 
Discontinue
d 
National Child Health Computer 
System Clinical database Health (general) Children Wales 
Discontinue
d 
Community Mental Health User 
Survey Survey Mental Health Adults England Continuing 
Survey of Adult Carers in 
England (SACE); Carers' 
Experience Survey (CES) Survey Social Care Adults England Continuing 
National Child Development 
Study Survey Health (general) 
Lifecourse; 
cohort GB Continuing 
British Association of Paediatric 
Surgeons Congenital Anomalies 
Surveillance System Disease registry 
Congential 
Abnormalities Children UK Continuing 
Hospice Clinical Administration 
System Disease registry Acute care All Local Continuing 
Involve to Evolve  Disease registry Acute care All 
West 
Midlands Continuing 
Liverpool Orthognathic 
Database 
Surgery/technology 
register Surgery All Local Continuing 
National InPatient Pain Study Disease registry Acute care All 
England, 
Wales, 
Northern 
Ireland Continuing 
North Devon Abdominal Aortic 
Aneurysm (AAA) Surveillance 
Register Disease registry Acute care All Local Continuing 
Podiatric Audit in Surgery and 
Clinical Outcome Measurement 
Tool  Disease registry Podiatry All UK Continuing 
Poole Enhanced Recovery 
Database 
Surgery/technology 
register Surgery All Local Continuing 
Thoracic Surgical Database  
Surgery/technology 
register Surgery All GB Continuing 
UK Fatal Anaphylaxis Register Disease registry Acute care All 
England and 
Scotland  Continuing 
UK National HALO Patient 
Registry 
Surgery/technology 
register Surgery All   Continuing 
UK Rehabilitation Outcomes 
Collaborative Database.  
Surgery/technology 
register Surgery All England Continuing 
Databases in Histocompatibility 
and Immunogenetics  Disease registry Blood disorder All GB Continuing 
Databases in Red Cell 
Immunohematology Disease registry Blood disorder All GB Continuing 
National Haemoglobinopathy 
Registry Disease registry Blood disorder All GB Continuing 
Association of Breast Surgery 
Breast Screening Audit 
Database Screening register Cancer All GB Continuing 
BAUS Cancer Registry (BCR) 
Complex Operations Audit 
Surgery/technology 
register Cancer All GB Continuing 
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Breast Cancer Clinical Outcome 
Measures Project Disease registry Cancer All GB Continuing 
British Association of Urological 
Surgeons Cancer Registry Disease registry Cancer All GB 
Discontinue
d 
Eastern Cancer Registration and 
Information Centre Disease registry Cancer All GB Continuing 
Family History of Bowel Cancer 
Clinic Database Disease registry Cancer All GB Continuing 
KC65 Screening register Cancer All Local Continuing 
Liverpool Head and Neck 
Cancer Disease registry Cancer All Local Continuing 
National Botulinum Toxin 
Therapy Audit Disease registry Cancer All GB Continuing 
Sloane Project Disease registry Cancer All GB Continuing 
Thames Cancer Registry Disease registry Cancer All South East Continuing 
Upper Urinary Tract Transitional 
Cell Carcinoma Audit Disease registry Cancer All GB Continuing 
Welsh Cancer Intelligence and 
Surveillance Unit Disease registry Cancer All Wales Continuing 
National Cancer Intelligence 
Network (various data) Disease registry Cancer All GB Continuing 
Lipoprotein Apheresis Register Disease registry Cardiovascular All GB Continuing 
Sudden Arrhythmic Death 
Syndrome Database Disease registry Cardiovascular All GB Continuing 
International Gastrointestinal 
Neuromuscular Disease 
Database Disease registry Gastroenterology All England Continuing 
Alström Syndrome UK Clinical 
Research Database Disease registry Genetic disease All GB Continuing 
Clinical and Laboratory Online 
Patient- and Research Database 
for Primary Immunodeficiencies  Disease registry Immunodeficiencies All GB Continuing 
Database of Alkaptonuria 
Patients Disease registry Genetic disease All GB Continuing 
Diabetes Specialist Workforce 
Audits  Workforce registry Workforce Workforce GB Continuing 
DiabetesE Service audit Workforce Workforce England Continuing 
Early Rheumatoid Arthritis 
Study Disease registry Rheumatology All Local Continuing 
East Kent Carpal Tunnel 
Syndrome Database Disease registry Other All South East Continuing 
East Kent Movement Disorders 
Database Disease registry Other All South East Continuing 
Hepatology Database Disease registry Liver disease All Local Continuing 
HIV and AIDS New Diagnoses 
Database Disease registry HIV All GB Continuing 
IBD database (Infoflex) Disease registry Gastroenterology All Local Continuing 
IBD Registry (Dendrite) Disease registry Gastroenterology All England Continuing 
Inflammatory Bowel Disease 
Database Disease registry Gastroenterology All North East Continuing 
National Congenital Rubella 
Surveillance Programme Disease registry 
Congential 
Abnormalities All UK Continuing 
National Haemophilia Database Disease registry Blood disorder All UK Continuing 
References - Appendix 2: List of sources uncovered 
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National New Patient 
Registration of Patients with 
Bisphosphonate Related 
Osteonecrotic Jaw in England, 
Wales, Scotland & N Ireland Disease registry Other All UK 
Discontinue
d 
Sarcoidosis Registry Disease registry Immunodeficiencies All UK Continuing 
Survey of Prevalent HIV 
Infections Diagnosed Disease registry HIV All UK Continuing 
UK Collaborative HIV Cohort 
Study  Survey HIV All 
London and 
Scotland Continuing 
UK HIV Drug Resistance 
Database 
Pharmacoepidemiologic
al database 
Pharmacoepidemiolo
gy (HIV) All UK Continuing 
UK National Neuromuscular 
Database Disease registry Other All GB Continuing 
Unique Database Disease registry Genetic disease All GB Continuing 
National Ophthalmology 
Database Disease registry Opthalmology All GB Continuing 
Non Arthroplasty Hip Register Disease registry Surgery All UK Continuing 
Temporomandibular joint 
prosthesis national registration Disease registry Other All UK Continuing 
All Wales Perinatal Survey Mortality registry Death Children Wales Continuing 
CRANE Database Disease registry 
Congential 
Abnormalities Children 
England, 
Wales, 
Northern 
Ireland Continuing 
National Study of HIV in 
Pregnancy and Childhood Disease registry HIV Children UK Continuing 
Northern Survey of Diabetes in 
Pregnancy  Disease registry Diabetes Children 
North East 
England and 
North 
Cumbria Continuing 
Northern Survey of Twins and 
Multiple Pregnancy Mortality registry Death Children 
North East 
England and 
North 
Cumbria Continuing 
Perinatal Mortality and 
Morbidity Survey  Mortality registry Death Children 
North East 
England and 
North 
Cumbria Continuing 
National Neonatal Research 
Database Clinical database Health (general) Children 
England and 
Wales Continuing 
Hip Fracture Perioperative 
Network Clinical database Bone, Joint, Muscle All UK Continuing 
International Burn Injury 
Database Clinical database Trauma All 
England and 
Wales Continuing 
Clinical Database for Cluster 
Headache Disease registry Other All UK Continuing 
British Society of Interventional 
Radiology (BSIR) Inferior Vena 
Cava (IVC) Filter Registry 
Surgery/technology 
register Surgery All UK Continuing 
Bowel cancer audit Clinical audit Cancer All GB Continuing 
Cardiac arrhythmia audit Clinical audit Cardiovascular All GB Continuing 
Chronic Kidney Disease in 
primary care audit Clinical audit Renal All GB Continuing 
Congenital heart disease 
(Paediatric cardiac surgery) Clinical audit Cardiovascular Children GB Continuing 
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Coronary angioplasty / 
purcutaneous coronary 
interventions Clinical audit Cardiovascular All GB Continuing 
Diabetes Audit (Adult)  Clinical audit Diabetes Adults GB Continuing 
Diabetes Audit (Paediatric)  Clinical audit Diabetes Children GB Continuing 
Falls and Fragility Fractures 
Audit Programme (includes the 
hip fracture database) Clinical audit Falls All GB Continuing 
Head and Neck Oncology Audit Clinical audit Cancer All GB Continuing 
Inflammatory Bowel Disease 
Audit Clinical audit Gastroenterology All GB Continuing 
National Emergency 
Laparotomy Audit  Clinical audit Surgery All GB Continuing 
National Joint Registry  Clinical audit Bone, Joint, Muscle All GB Continuing 
National Vascular Registry  Clinical audit Cardiovascular   GB Continuing 
Neonatal intensive and special 
care Audit Clinical audit Trauma Children GB Continuing 
Oesophago-gastric cancer Audit Clinical audit Cancer   GB Continuing 
Ophthalmology Audit Clinical audit Opthalmology Men GB Continuing 
Prostate cancer Clinical audit Cancer All GB Continuing 
Rheumatoid and early 
inflammatory arthritis Audit Clinical audit Rheumatology All GB Continuing 
End of Life Care Audit Clinical audit Palliative Care All GB Continuing 
Cohort for Skeletal Health in 
Bristol and Avon (COSHIBA) Cohort study Musculoskeletal  Women SW England Continuing 
UK 10K Rare Genetic Variants in 
Health and Disease Research database Precision medicine Unknown Various Continuing 
Twins UK Cohort Cohort study Precision medicine Adults UK Continuing 
National Safety Thermometer Survey Patient safety Adults UK Continuing 
Mental Health & Learning 
Disabilites Data Set (MHLDDS) Clincal Audit Mental Health Adults England Continuing 
Learning Disability Census Clincal Audit Learning Disability Adults England Continuing 
Maternity Service Dataset Clinical Audit Maternal health 
Women and 
child England Continuing 
Child Dental Health Survey Survey Dental care Children 
England, 
Wales, 
Northern 
Ireland Continuing 
Patient Experience of Diabetes 
(PEDS) Survey Diabetes All 
England and 
Wales Continuing 
Critical Care Minimum Data Set 
(CCMDS) Clinical audit 
Critical/emergency 
care Adults England Continuing 
National InPatient Diabetes 
Audit (NaDIA) Clinical audit Diabetes All England Continuing 
NHS Dental Statistics for 
England Service audit Dental care Adults England Continuing 
The National Audit of 
Pulmonary Hypertension 
(NAPH) Clinical audit Respiratory Adults 
England, 
Scotland, 
Wales, 
Northern 
Ireland, the 
Channel 
Islands, Continuing 
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Gibraltar 
and the Isle 
of Man 
The Improving Access to 
Psychological Therapies (IAPT) 
Dataset Service audit Mental Health Adults England Continuing 
The Adult Psychiatric Morbidity 
Survey (APMS) Survey Mental Health Adults England Continuing 
GP Practice Prescribing 
Presentation-level Data Clinical database Medical prescriptions All England Continuing 
Cardiovascular disease profile/ 
National Cardiovascular 
Intelligence Network (NCVIN) Disease registry Cardiovascular All England Continuing 
Diabetes Community Health 
Profile Disease registry Diabetes Adults England Continuing 
Interactive Health Atlas of Lung 
Conditions in England (INHALE)  Disease registry Respiratory All England Continuing 
General Lifestyles Survey Survey Public Health Adults GB 
Discontinue
d 
National Centre for Smoking 
Cessation and Training Statistics Clinical database Smoking All England Continuing 
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Appendix 3: Semi-structured interview schedules 
Social care example 
 Thank you for time 
 Introduce – Researcher; EPPI-Centre 
 Working on a number of projects looking at the way evidence is used on decision-making, including this one for NICE 
 Overall we’re seeing the number of RW datasources expand but also the analytical capability is also 
 We know that there are many sources – but they’re also fragmented and of varying quality  
 But it is of value in assessing practice and trends in real world settings – and in many ways the diversity may be highly positive; – 
NICE would like to use more in its work 
 NICE want to use the data in the following ways: 
(f) Research the effectiveness of interventions or practice in real-world (UK) settings (e.g. through monitoring outcomes or proxy 
outcomes).  E.g. NICE has a choice between two drugs for migraine and wants to know about adverse complications in routine 
settings. 
(g) Audit the implementation of guidance. For example, to assess the equity of implementation across different groups (including 
socioeconomic, geographic, demographic and groups differentiated by different diseases/health conditions) 
(h) Provide information on resource use and evaluate the potential impact of guidance. 
(i) Provide epidemiologic information. For example prevalence/incidence of diseases, natural history, co-morbidities and information 
on current practice. 
(j) Provide information on current practice to inform the development of NICE quality standards – e.g. what works best, so for 
example minimum staffing levels 
 Interview will take approximately 45-1 hr but can be shorter if have other commitments 
 Being recorded – check if okay 
 Check if okay with information and consent sheet 
 Going to be talking about RW data – and we’ll be asking about definition – but for now referring to it as data collected outside RCT 
 Most questions open about experiences of using different sources, in what way, and thinking about how assessing strengths and 
weaknesses 
Questions to ask: 
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 Construct Question Probes (if needed) 
1 Opening Can you tell me a little about your experience or interest in using RW 
data? 
Maybe a little bit about any studies 
using RW data that you’ve been 
involved with in the past couple of 
years 
 
2 Suitability of real-
world data for 
social care 
RW data tends to refer to routinely collected administrative data that 
is collected outside laboratory or experimental conditions. A 
fundamental principle of real-world data is that no 
‘treatment’/’technology’ or in this case social care package would be 
changed on account of the collection of the real-world data itself. Is 
this a workable principle for social care real world data? 
Should a different definition of RW 
data be considered for social care 
RW data as opposed to data from 
other fields? 
3 Types of real world 
data coverage (i) 
RW data covers a broad taxonomy of different sources and forms. 
Some of the different forms include: 
- Administrative data 
- Routinely collected data (e.g. based on LA returns) 
- Needs/care registries 
- Workforce registries 
How well represented are the different forms in terms of social care 
real world data sources? 
Is social care RW data more reliant on survey based methods? 
Are there some forms of real-world 
data that are better represented 
than others in terms of data from 
social care settings? 
4 Types of real world 
data coverage (ii) 
Are there some groups in receipt of social care that are better or 
worse represented than others in terms of RW data? For example are 
Are there some population groups in 
terms of social care where more 
should be done to collect data? 
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data lacking on the breadth of older people in receipt of social care, 
but are data on adults with learning difficulties better represented?  
5 Types of real world 
data coverage (iii) 
Are there some settings where there is greater representation in 
terms of RW settings but some setting where there is 
underrepresentation? For example are there problems with getting 
private sector data? 
Given that many social care settings 
actually represent private provider 
settings, are there initiatives out 
there to encourage collection from 
these? 
6 Types of real world 
data – suitability 
for social care 
Are there some forms of RW data that are better suited for collection 
in social care settings? For example are surveys a more appropriate 
tool in social care settings? 
 
7 Experience – go to 
sources for 
different purposes 
I want to move on to some questions about your own experience of 
using RW data.  
 
Firstly would you be able to let me know what might be your first port 
of call in terms of RW data when it comes to assessing practice for a 
particular group – e.g. older people. So these might be data which 
include depth around the characteristics of older people, the service 
they receive, and their outcomes (almost like a gold standard)?  
 
How would you appraise the quality of this data?  
Aggregate data 
8 Experience – go to 
sources for 
different purposes 
Suppose NICE were to recommend a particular care pathway (e.g. for 
older people) and you were interested in examining the extent to 
which care providers were adhering to this recommendations – where 
Best practice; Safeguarding adults 
database 
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might be your first port of call in terms of RW data when it comes to 
assessing this type of problem?  
 
How would you appraise the quality of this data?  
9 Experience – go to 
sources for 
different purposes 
Suppose NICE were interested in examining resource use – e.g. staff 
time and costs (e.g. for older people) – where might be your first port 
of call in terms of RW data when it comes to assessing this type of 
problem?  
 
How would you appraise the quality of this data?  
 
10 Experience – go to 
sources for 
different purposes 
Suppose NICE were interested in examining the prevalence of care 
needs – e.g. through ADLs– where might be your first port of call in 
terms of RW data when it comes to assessing this type of problem?  
 
How would you appraise the quality of this data?  
  
11 Challenges How might you summarise the main challenges of working with RW 
based on your experiences? 
Particular challenges around real 
world data 
12 Ways of 
overcoming 
challenges 
Which new sources of data do you see helping to overcome some of 
the challenges you mentioned earlier [repeat challenge back] 
 
13 Closing Is there anything we haven’t covered which you think we should 
consider in our study? 
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Appendix 4: Current real-world data usage by NICE 
Grey cells indicate where the data are not in use; green cells are those that do not constitute real-world data or are incorrectly specified 
NICE team 
Organ-
isation 
Title of dataset or 
database 
Licence/subscription 
holder arrangements 
Costs (for 
subscription/usage) 
What the data is used 
for 
Limitations/Comments 
Costing and 
Commissioni
ng, Health & 
Social Care 
HSCIC 
Primary Care - IMS 
disease analyser. 
Secondary Care (HES) - 
Admitted care, 
outpatients, maternity, 
A&E, Adult critical care.  
Licence £xk per user; 6/7 users 
Costing of guidance and 
QS; Impact & evaulation 
  
Costing and 
Commissioni
ng, Health & 
Social Care 
NHS 
Prescriptio
n Services 
ePACT - Prescribing data - 
Primary & community. 
Also includes non NHS 
pharmacists located on 
NHS premises 
Agreement None 
Drug prescribing 
information 
  
Costing and 
Commissioni
ng, Health & 
Social Care 
IMS Health 
HPIA - hospital dispensed 
prescribing data 
Agreement None 
Drug prescribing 
information 
  
Impact & 
Evaluation 
NHS 
Business 
Services 
Authority 
Electronic prescribing 
analysis and cost tool 
system (EPACT) 
The I&E data analysts can 
access ePACT data via a 
network connection. 
None 
To inform medicines 
metrics work, monitoring 
the uptake of NICE 
guidance. Ad hoc 
enquiries from other 
teams within NICE. 
ePACT data do not link to 
patient information.  
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Impact & 
Evaluation 
IMS (via 
HSCIC) 
IMS HEALTH Hospital 
Pharmacy Audit Index 
(IMS HPAI) 
The I&E data analysts  
request data from the 
Health and Social Care 
Information Centre 
(HSCIC). 
None 
To inform medicines 
metrics work, monitoring 
the uptake of NICE 
guidance. Ad hoc 
enquiries from other 
teams within NICE. 
The data do not link to 
patient information. 
Impact & 
Evaluation 
Access via 
HSCIC 
The Health Improvement 
Network (THIN) database  
The I&E data analysts  
request data from the 
Health and Social Care 
Information Centre 
(HSCIC). 
None 
To inform medicines 
metrics work, monitoring 
the uptake of NICE 
guidance. Ad hoc 
enquiries from other 
teams within NICE. 
Vision software is patient 
management and not 
medical research; data 
reflects events deemed 
to be relevant to the 
patient’s care only. 
 
Impact & 
Evaluation 
Access via 
HSCIC 
IMS Disease analyser 
The I&E data analysts  
request data from the 
Health and Social Care 
Information Centre 
(HSCIC). 
None 
To inform medicines 
metrics work, monitoring 
the uptake of NICE 
guidance. Ad hoc 
enquiries from other 
teams within NICE.  
  
Impact & 
Evaluation 
HSCIC 
Quality Outcomes 
Framework 
QOF results are pubically 
available as such the 
analysts have access to 
the data via HSCIC 
website. 
None 
To inform medicines 
metrics work, monitoring 
the uptake of NICE 
guidance. Ad hoc 
enquiries from other 
teams within NICE.  
  
Impact & 
Evaluation 
HSCIC 
Hospital Episode 
Statistics (HES) 
The data analysts have 
been trained to query 
the database using SAS 
Enterprise guide, to 
produce bespoke queries 
and NICE has purchased 
licenses to access the 
database.  
The cost of the primary 
license holder/user for a 
new organisation is 
£xxxx. All additional 
license holders/users 
within the same 
organisation cost £xxxx 
per license 
To inform medicines 
metrics work, monitoring 
the uptake of NICE 
guidance. Ad hoc 
enquiries from other 
teams within NICE.  
Also used by 
Interventional 
procedures 
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Safe Staffing 
(and 
contractors) 
HSCIC  
Health Episode Statistics 
(HES) 
Contractor request via 
official application for 
data on website 
Variable (approximately 
£xxxx) 
To inform safe staffing 
evidence review, 
economic analysis and 
modelling.  
Estimating relationship 
between staffing 
numbers, and skill mix to 
patient outcomes using 
multilevel, multivariate 
regression analysis.  
Data requires careful 
cleaning and filtering.  
NICE already have access 
as members of the I&E 
team are trained to 
extract data from HES 
and we have direct 
access to it. Any team 
can request data from 
I&E within NICE. 
Impact & 
Evaluation 
  ONS   None 
To inform medicines 
metrics work, monitoring 
the uptake of NICE 
guidance. Ad hoc 
enquiries from other 
teams within NICE. 
The analysts use ONS 
data for population and 
epidemiology data. 
Also used by 
Interventional 
procedures 
Impact & 
Evaluation 
  National audits   None     
Impact & 
Evaluation 
  Uptake collection / ERNIE   None 
To inform medicines 
metrics work, monitoring 
the uptake of NICE 
guidance. Ad hoc 
enquiries from other 
teams within NICE.  
Summary of other data 
sources. 
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Safe Staffing 
(and 
contractors), 
Costing and 
Commissioni
ng 
HSCIC Workforce data / ESR 
NICE: analysts request 
data from the Health and 
Social Care Information 
Centre (HSCIC). 
Contractors via official 
application for data on 
website 
None 
To inform safe staffing 
economic analysis and 
modelling. Informs for 
costing commentary on 
safe staffing guidelines.  
Contains baseline 
registered nurses, 
healthcare assistants, 
and other professional 
baseline numbers per 
organisation. 
Speciality of ward-type 
information at a very 
high-level.  
Safe Staffing 
(and 
contractors) 
  
UK Nursing database 
(Keith Hurst dataset) 
Direct request via email 
Variable (approximately  
£xxxx) 
Workforce (nursing) data 
and outcomes. 
To inform safe staffing 
evidence review, 
economic analysis and 
modelling.  
Estimating relationship 
between staffing 
numbers, and skill mix to 
patient outcomes using 
multivariate regression 
analysis.  
Data collected at 
irregular intervals at 
some hospitals. Requires 
substantial cleaning 
before statistical analysis. 
Quality of data highly 
variable.  
Social care HSCIC 
Social care activity, social 
care expenditure 
Accessed from HSCIC 
website direct 
None 
To inform the writing of 
scopes. For example 
HSCIC has a national data 
collection that reports 
information on the 
numbers of people 
accessing home care by 
local authority and 
expenditure on home 
care by local authority.   
Nationally reported 
datasets do not always 
provide data in the detail 
that can be obtained 
from bespoke data 
requests from the HSCIC. 
Lacking in particular is 
details on people 
purchasing their own 
care  
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Guidance 
producing 
/supporting 
teams 
NHSE 
Systemic Anti Cancer 
Therapy (SACT) dataset 
Under discussion TBD 
To inform on the uptake 
of cancer medicines. 
We are currently in 
discussion with NHSE, 
who manage the SACT 
dataset, about how we 
can access this and what 
we can use it for.  
Internal 
Clinical 
Guidelines 
(CCP) 
HSCIC 
The Health Improvement 
Network (THIN) database  
Directly request data 
from the Health and 
Social Care Information 
Centre (HSCIC). 
None 
Health economic 
modelling (e.g. defining 
baseline characteristics 
of population of interest) 
No ethnicity data 
Internal 
Clinical 
Guidelines 
(CCP) 
HSCIC 
Hospital Episode 
Statistics (HES) 
see I&E arrangements see I&E arrangements 
Health economic 
modelling (e.g. 
estimating resource use 
associated with 
particular types of 
hospital admission) 
 
Internal 
Clinical 
Guidelines 
(CCP) 
HSCIC 
Health Survey for 
England 
n/a n/a 
Health economic 
modelling (can be good 
for quality of life data; 
have used to plug the 
ethnicity hole left by 
THIN) 
 
Internal 
Clinical 
Guidelines 
(CCP) 
DH NHS reference costs n/a n/a 
Health economic 
modelling (mainly costs, 
obviously, but also some 
useful data on frequency 
of hospital contacts and 
duration of admissions) 
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Internal 
Clinical 
Guidelines 
(CCP) 
NHS 
Prescriptio
n Services 
Prescription Cost Analysis 
(PCA) Data 
n/a n/a 
Health economic 
modelling and other cost 
analyses 
 
Internal 
Clinical 
Guidelines 
(CCP) 
NHS 
Prescriptio
n Services 
NHS drug tariff n/a n/a 
Drug costs for health 
economic modelling and 
other cost analyses 
Not all medications 
covered 
Internal 
Clinical 
Guidelines 
(CCP) 
eMC 
Dictionary of Medicines 
and Devices 
n/a n/a 
Drug costs for health 
economic modelling and 
other cost analyses 
(especially in instances 
where products are not 
listed in NHS drug tariff) 
 
Internal 
Clinical 
Guidelines 
(CCP) 
ONS National Life Tables n/a n/a 
Health economic 
modelling 
 
Internal 
Clinical 
Guidelines 
(CCP) 
ONS 
Cancer Registration 
Statistics 
n/a n/a 
Health economic 
modelling 
 
National 
Collaboratin
g Centre - 
Mental 
Health 
HSCIC  
Health Episode Statistics 
(HES) 
none at the moment  N/A 
to inform guideline 
models 
  
National 
Collaboratin
g Centre - 
Mental 
Health NHS NHS reference costs 
freely available None 
Health economic 
modelling 
rough coding of MH 
services on some 
occasions (not always 
disorder-specific) 
National 
Clinical 
Guideline 
Centre 
DH 
NHS reference costs 
Data are freely available 
on website 
None 
Health economic 
modelling 
https://www.gov.uk/gov
ernment/publications/nh
s-reference-costs-2013-
to-2014  
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National 
Clinical 
Guideline 
Centre 
HSCIC 
Health Episode Statistics 
(HES) 
Data are freely available 
on website 
None 
Health economic 
modelling 
 
National 
Clinical 
Guideline 
Centre 
PSSRU 
Unit costs of health and 
social care 
Data are freely available 
on website 
None 
Health economic 
modelling 
http://www.pssru.ac.uk/
project-pages/unit-costs/  
National 
Clinical 
Guideline 
Centre 
NHSBSA 
Drug tariff 
Data are freely available 
on website 
None 
Health economic 
modelling 
http://www.nhsbsa.nhs.
uk/PrescriptionServices/
4940.aspx  
National 
Clinical 
Guideline 
Centre 
NICE BNF 
Data are freely available 
on website 
None 
Health economic 
modelling 
 
National 
Clinical 
Guideline 
Centre 
NHSBSA 
Prescription Cost Analysis 
(PCA) Data 
Data are freely available 
on website 
None 
Health economic 
modelling 
http://www.nhsbsa.nhs.
uk/PrescriptionServices/
3494.aspx  
National 
Clinical 
Guideline 
Centre 
DH CMU 
EMIT 
Data are freely available 
on website 
None 
Health economic 
modelling 
https://www.gov.uk/gov
ernment/publications/dr
ugs-and-pharmaceutical-
electronic-market-
information-emit  
National 
Clinical 
Guideline 
Centre 
OECD 
Purchasing power 
parities 
Data are freely available 
on website 
None 
to convert the results of 
overseas economic 
evaluations to £ 
http://stats.oecd.org/Ind
ex.aspx?datasetcode=SN
A_TABLE4  
National 
Clinical 
Guideline 
Centre 
ONS 
National Life Tables & 
mortality data 
Data are freely available 
on website 
None 
Health economic 
modelling 
http://www.ons.gov.uk/o
ns/taxonomy/index.html
?nscl=Interim+Life+Table
s#tab-data-tables  
NCC-Cancer Quality 
Health 
National Cancer Patient 
Experience Survey Data supplied via e-mail None 
People's experience of  
cancer diagnosis and  
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treatment- according to  
ICD-10 code. 
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